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1
iNTroducTioN
In 2002, our research group started investigating 
various aspects of Prader-Willi syndrome (PWS) 
and the effects of growth hormone (GH) treat-
ment in children with PWS. Since then the knowl-
edge about PWS has markedly increased, which 
also improved the quality of life of the children 
and their families. This is the sixth thesis of our 
research group including new studies in children 
and young adults with PWS.
The first patient with PWS was presented by Sir 
Langdon-Down in 18871. He described an adoles-
cent girl with short stature, obesity, hypogonad-
ism and cognitive impairment (Figure 1). Seventy 
years later, in 1956, three Swiss endocrinologists 
Andrea Prader, Alexis Labhart and Heinrich Willi 
reported a series of patients with similar phe-
notypes2. The common characteristics included 
small hands and feet, abnormal growth and body 
composition with a very low lean body mass and early-onset obesity, hypotonia at birth, 
insatiable hunger and intellectual disability. Knowledge about different aspects of PWS 
markedly increased since these reports, but raised new questions as well. Studies are 
needed to unravel the challenges of PWS and to improve the quality of life of this patient 
group.
This chapter describes the genetic basis of PWS, the clinical characteristics of children 
and young adults with PWS in different stages of life, hypothalamic dysfunction and our 
studies regarding GH treatment in children with PWS. Subsequently, the clinical topics 
that needed to be further investigated are defined. Finally, the objectives of the studies 
described in the various chapters are presented.
1.1 Prader-Willi SyNdrome
Prader-Willi syndrome is a rare neurogenetic disorder resulting from the absence of 
expression of the paternally inherited genes located on chromosome 15 at the locus 
q11.2-133, 4. PWS is considered the most common cause of genetic obesity and equally 
affects boys and girls, without association with race or social-economic status5. The 
incidence of PWS is estimated at 1 in every 12,000-15,000 live births5-7. Hypothalamic 
figure 1. Young girl from the 17th century, 
believed to have had PWS.
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dysfunction seems to be the underlying cause for most symptoms of PWS, although the 
phenotype of PWS is very variable8.
1.2 GeNeTic cauSe
History
For a long time, the diagnosis of PWS was exclusively based on a combination of clinical 
signs and symptoms, described as the Holm’s criteria9. In 1976, it was for the first time 
reported that a clinically diagnosed patient with PWS had an abnormal karyotype with a 
15/15 Robertsonian translocation10. In the 80s, it became clear that also deletions of the 
long arm of chromosome 15 at region q11-13 resulted in PWS11, and that it specifically 
concerned the paternally inherited chromosome 1512. In 1991, a third subtype was re-
ported, a maternal uniparental disomy (mUPD), leading to lack of a paternally inherited 
chromosome 1513. To date, it is known that PWS is caused by a lack of expression of the 
paternally inherited genes located on chromosome 15, on the locus 15q11-13, which is 
called the ‘Prader-Willi region’. Lack of expression of the genes in the PWS region is lost 
due to either a deletion, an mUPD, an imprinting center defect (ICD) or a translocation4, 14.
Genomic imprinting
Genes are regions of DNA encoding information for functional proteins. Genes are 
located on chromosomes and vary in size from a few hundred DNA base pairs to more 
than 2 million (Figure 2). Humans have 23 pairs of chromosomes in the nucleus of each 
cell in the body. Children inherit 23 chromosomes from their father and 23 chromo-
somes from their mother, which result in 23 pairs in each cell. One of these 23 pairs is 
chromosome 15.
Genomic imprinting is an epigenetic phenomenon by which certain genes are 
expressed in a parent-of-origin specific manner without changing the DNA structure 
or base pair sequence15. During gametogenesis, genes are imprinted or silenced and 
only a small percentage of genes is active. In healthy subjects, the PWS region on the 
paternally inherited chromosome 15 is expressed, while this region on the maternally 
inherited chromosome 15 is silenced by imprinting. An abnormal or absent expression 
of the paternally inherited genes on the PWS region results in PWS.
The PWS region contains multiple imprinted genes and the loss of these genes con-
tributes to the complete phenotype of PWS16 (Figure 3). The exact function of each gene 
on the PWS region remains to be elucidated and in humans no single gene mutation has 
been found that will explain all the features of PWS.
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figure 2. Cell with nucleus, chromosomes and DNA.
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figure 3. PWS region on chromosome 15. Order of genes on 15q11-q13 region, and patterns of expression.
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Genetic subtypes and phenotype
The lack of expression of the genes in the PWS region on the paternally derived chromo-
some 15q11-q13 can be caused by 4 different mechanisms, namely a deletion, an mUPD, 
an ICD or a translocation4, 14, 16, 17 (Figure 4). The two proximal breakpoints (BP1 and BP2) and 
the distal breakpoint (BP3) appear to predispose to the typical deletion seen in PWS16, 18. The 
larger type I deletion involves BP1 to BP3, while type II deletion involves BP2 to BP3 (Figure 
3). Besides the most common deletions, the second most frequent cause of PWS is an 
mUPD. In an mUPD, both chromosomes 15 are inherited from the mother, due to a gamete 
completion by the union of a nullisomic and a disomic gamete, or at trisomic conception 
followed by a trisomy rescue in early pregnancy and loss of the paternal chromosome 1519.
An imprinting defect explains less than 5% of PWS cases14. Patients have apparently 
normal chromosomes 15 of biparental inheritance, but a mutation in the imprinting 
control region results in a maternal imprint, which leads to a complete loss of the pater-
nally expressed genes of the PWS region. Less than 1% of the patients with PWS have a 
Robertsonian translocation, in which a part of the paternally inherited chromosome 15 
has moved to another chromosome4, 20.
Worldwide, a paternal deletion occurs in approximately 70% of people with PWS, an 
mUPD in 25%, and the rest is caused by an imprinting defect or translocation in the 
PWS region16. However, in the last decade, West-European studies demonstrate a shift 
towards equal rates of the genetic subtypes deletion and mUPD, most probably due to 
an increasing maternal age21-23. According to the literature, patients with a deletion have 
more typical facial characteristics and hypopigmentation, while those with an mUPD 
often have higher verbal IQ scores, but are also more at risk for psychiatric problems, like 
psychosis and autistic behaviour18, 24-26.
Recurrence risk is typically very low in families with a person with a deletion or an 
mUPD, but if the father carries a translocation or if PWS is caused by an imprinting 
center mutation, the recurrence risk would be considerably higher, up to 50%16. Prenatal 
diagnosis for PWS is available16.
figure 4. Schematic overview of the genetic abnormalities causing PWS. P=paternally inherited chromo-
some 15, M=maternally inherited chromosome 15, mUPD=maternal uniparental disomy.
General introduction and aims of the thesis 15
1
1.3 Prader-Willi SyNdrome iN differeNT PHaSeS of life
Various clinical features of PWS change during the different stages of life, but the most 
obvious change is the one in eating behaviour, from feeding problems to hyperphagia9, 27. 
It was traditionally described as ‘the switch’ in eating behaviour28, although it is a gradual 
and complex process. Nowadays the clinical symptoms and signs are usually subdivided 
in nutritional phases27 (Table 1). In the early phase after birth, severe hypotonia with 
poor feeding and failure to thrive are prominent, followed by a period of appropriate 
growth without feeding problems. Subsequently, generally between 18 and 36 months 
of age, body weight starts to increase without an increase in calorie intake or interest in 
food. Then in early childhood, interest in food and appetite increase abnormally and the 
child becomes overweight when leaving unattended. Thereafter, hyperphagia develops 
with impaired satiety leading to obesity and food seeking behaviour9, 27. In some adults, 
hyperphagia diminishes and appetite is no longer insatiable13, 14.
Prenatal period and birth
Around 85% of the mothers report decreased fetal movements during their pregnancy 
of a child with PWS27. The incidence of polyhydramnios and breech presentation are 
increased, and delivery by caesarian section is more common16. The latter two could be 
related to the hypotonia of the fetus, but it might also be due to hypothalamic dysfunc-
tion8. Babies with PWS are on average born at a gestational age of 38.2 weeks, but both 
preterm and post-term deliveries are more often seen27. Birth weight, length and BMI are 
generally about 15-20% lower in babies with PWS than in their siblings, even in full-term 
pregnancies3, 27, 29.
Table 1. Nutritional phases
Phases median ages clinical characteristics
0 Prenatal to birth Decreased fetal movements and lower birth weight than sibs
1a Birth to 9 months Hypotonia with difficulty feeding and decreased appetite
1b 9 to 25 months Improved feeding and appetite and growing appropriately
2a 2.1 to 4.5 years Weight increasing without appetite increase or excess calories
2b 4.5 to 8 years Increased appetite and caloric intake, but can feel full
3 8 years to adulthood Hyperphagic, rarely feels full
4 Adulthood Appetite is no longer insatiable (described in some adults)
Modified from Am J Med Gen A27
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Newborn period
In the early phase after birth, severe hypotonia with poor feeding and failure to thrive 
are prominent. The marked central hypotonia causes decreased movements, a severe 
head leg, lethargy with decreased arousal, weak or absent cry and diminished reflexes, 
including a poor suck. Practically every newborn with PWS has feeding problems in the 
first period after birth and requires some kind of feeding assistance such as a nasogastric 
tube. The severe hypotonia is partly responsible for the feeding problems, but also the 
concomitant lack of appetite plays a role27, 30. Neonates with PWS show no evidence of 
being hungry and do not get excited at feeding time9, 13. If feeding would only occur 
when the neonate cries for milk, severe failure to thrive would develop. Most babies with 
PWS need a nasogastric tube until the age of 3 to 9 months (Figure 5).
The abnormal body composition is already present at birth. Even if the newborn 
has no failure to thrive and a normal body weight, an increased fat mass percentage 
and decreased lean body mass (LBM) can be found by skin fold measurements or dual 
energy-x-ray absorptiometry (DXA)31, 32. Other typical dysmorphic features include a 
narrow bifrontal diameter, almond-shaped eyes, a narrow nasal bridge and a thin upper 
vermillion with down-turned corners of the mouth. These may be present at birth, but 
become more pronounced during infancy and slowly evolve over time16. Other abnor-
malities include hypogonadism with genital hypoplasia, hip dysplasia and thermoregu-
lation and breathing problems. Testing for PWS should be performed in all neonates 
with otherwise unexplained hypotonia with poor suck33. Nowadays, the diagnosis PWS 
can be genetically confirmed in the neonatal period3.
figure 5. Young infant with PWS. Photo is depicted with permission from parents.
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infancy
After the newborn period with severe hypotonia and feeding problems, the eating 
behaviour gradually changes into approximately normal with appropriate growth16. 
Although the severe hypotonia considerably improves in the first year, there will always 
remain a decreased LBM and muscle strength which result in a delayed motor develop-
ment34, 35. The mental development and speech and language development are delayed 
as well and milestones are on average reached at double the normal age34-36. Physical 
training and speech therapy are important to stimulate the development of the infant36. 
During the first years of life, children with PWS are friendly, easy going and affectionate37 
(Figure 6a-c).
Toddlers age
Usually between 18 and 36 months of age, body weight starts to increase without an 
increase in calorie intake or interest in food27. The growth chart of weight for height 
will not parallel the reference charts anymore, but starts to increase and crosses the 
lines. The energy expenditure of a child with PWS decreases with age to 50% lower than 
normal, mainly due to the abnormal body composition and in particular the decreased 
LBM32, 38. A reduction of the energy intake with a well-balanced diet, in combination with 
enough physical exercise, is necessary to prevent the development of obesity 38, 39.
early childhood
In early childhood, rather soon after phase 2a, interest in food and appetite increases 
abnormally and the child becomes overweighed if there is no parental guiding. The 
preoccupation with food becomes more prominent and the child shows food-related 
behaviour, such as asking and talking about food, but also reading in cookbooks and 
acting like they work in a kitchen. The child is typically very concerned about the next 
meal and reminds others not to forget. If allowed, the child will eat more than peers 
and becomes obese. However, in this phase the child can be fairly easily redirected 
a b c
figure 6a-c. Young children with PWS. Photos are depicted with permission from parents.
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about food and can feel full27. The median age of onset of phase 2b is around 4.5 years, 
although a wide variation is seen.
In the majority of children with PWS, the gradual change in eating behaviour coin-
cide with a changing behavioural phenotype with more maladaptive behavioural and 
emotional disturbances. Most children with PWS have a psychomotor and cognitive 
impairment, resulting in a mild to moderate learning disability40-42. Mean total IQ scores 
are around 65 points, although there is a wide variation34, 42. They have a poor short-term 
memory and a deficit in sequential processing, but perform relatively well on visuospa-
tial skills and exceptionally well on jigsaw puzzles4.
Other signs and symptoms commonly seen during childhood are scoliosis43, strabis-
mus44, sleep-related breathing disorders including apneas45 and stress-induced central 
adrenal insufficiency46.
childhood and puberty
Hyperphagia is the main characteristic of phase 3, which typically starts around the age 
of 8 years27. The profound preoccupation with food makes that the child thinks about 
food all day long. While eating they can already ask when the next meal will come and 
the child will continue eating if portions are not limited, as the child will rarely feel full. 
Common additional features are food-seeking behaviour, stealing food, lying about 
food, eating inedible things and temper tantrums related to food, and the impact on the 
quality of life of the patients and their families is huge47. As children with PWS could eat 
without stop when leaving unattended and their energy expenditure is very low, they 
could easily develop extreme obesity with concomitant problems. Besides, they are at 
risk for overeating, resulting in an acute life-threatening gastric rupture48, 49. Therefore, 
parental guidance and supervision are crucial and children must be supported 24 hours 
per day. Locks on kitchen doors and fridges will help children not to take food away and 
also give them rest that they do not have to seek for food.
Simultaneously with the gradual change in eating behaviour, the majority of children 
with PWS start to show more maladaptive behavioural and emotional characteristics, 
like temper tantrums, skin picking, stubbornness, mood lability, impulsivity, argumenta-
tiveness, and inappropriate social behaviour50, 51. Obsessive-compulsive symptoms are 
frequently seen in children with PWS and one third of children with PWS score positive 
for Autism Spectrum Disorder with mainly aberrations on maladaptive behaviour52, 53. 
A child with PWS is impaired in feeling empathy for others and has difficulties in social 
reciprocity (Figure 7a).
Pubertal development starts often spontaneously, but progresses delayed or incom-
plete23, 54-56. In most adolescents with PWS, sex steroid replacement therapy is necessary 
to attain a complete pubertal development and to achieve an adequate bone mineral 
density in adulthood23.
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adulthood
Some adults with PWS who were previously in phase 3 do no longer have an insatiable 
appetite and could feel full. This phase was described as nutritional phase 4 and has only 
been observed in adulthood27. It is unknown whether all adults with PWS eventually end 
up in this phase.
The behavioural phenotype of adults with PWS includes temper tantrums, skin pick-
ing, impulsiveness, lability of mood, inactivity and repetitive speech57. For most adults 
with PWS, it is not feasible to live independently (Figure 7b). Psychosis may occur, in 
particular in those with an mUPD24.
The current generation of adults with PWS had a relatively late diagnosis and most 
did not receive growth hormone (GH) treatment. This resulted in a short adult height of 
145-150 cm in women and 155-160 cm in men29, 58. Obesity was often already present 
at diagnosis and complications such as diabetes mellitus type 2 (T2DM), cardiovascular 
disease (CVD) and respiratory insufficiency impair life expectancy59, 60. However, when 
severe obesity can be avoided, life expectancy is reasonable59.
Nutritional phases in clinical practice
The nutritional phases according to Miller et al.27 were used to score the feeding 
problems (Table 1), but in practice, the clinical presentation of children with PWS has 
significantly changed in today’s population. Nowadays, some children have less signs 
figure 7a-b. Child and young adult with PWS.
Photos are depicted with permission from patients 
and parents.
a b
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of classical hyperphagia without an increased weight or food-seeking behaviour. This 
might be due to an early diagnosis, improved health care, physiotherapy, diet regimen 
and the awareness of caregivers to limit the food intake. It could also be that GH treat-
ment itself is able to suppress the hyperphagia. This controlled hyperphagia makes it 
difficult to categorize the child according to the nutritional phases. Development of a 
better hyperphagia scale for today’s population is, therefore, warranted.
1.4 HyPoTHalamuS
The hypothalamus is a part of the brain that contains a number of small nuclei with a 
variety of functions. One of the most important is the link between the nervous system 
and the endocrine system via the pituitary gland.
The hypothalamus synthesizes and secretes the neurohormones growth hormone-
releasing hormone (GHRH), gonadotropin-releasing hormone (GnRH), corticotropin-
releasing hormone (CRH) and thyrotropin-releasing hormone (TRH). These hypotha-
lamic-releasing hormones are released to the blood stream and stimulate the anterior 
pituitary to secrete the following hormones: GH, gonadotropins (LH/FSH), corticotropin 
(ACTH), thyrotropin (TSH) and prolactin. Besides, the hypothalamus produces oxytocin, 
which is known to be involved in food intake, body weight and social skills.
Hypothalamic dysfunction seems to be the underlying cause for various signs and 
symptoms of PWS8. The hypothalamus acts as the control center for hunger and satiety, 
and seems to be involved in the regulation of appetite-regulating hormones, although 
there are still a lot of uncertainties. Other symptoms of PWS that have been related to 
dysregulation of the hypothalamus are temper tantrums, decreased activity level and 
energy expenditure, abnormal temperature control, excessive daytime sleepiness, ab-
normalities of sleep architecture, sleep-related breathing disorders, hypogonadotropic 
hypogonadism and hormonal insufficiencies such as a functional growth hormone 
deficiency and stress-related central adrenal insufficiency8, 46, 61, 62.
1.5 GroWTH HormoNe TreaTmeNT
Children with PWS show similarities with those with GH deficiency. They have a decreas-
ing growth velocity despite the onset of obesity, reduced lean body mass in the pres-
ence of adiposity, small hands and feet, and relatively low serum levels of insulin-like 
growth factor-I and low insulin62. However, most children do not fulfill the criteria for GH 
deficiency when they undergo a GH stimulation test63. This might argue for the presence 
of a functional GH deficiency, probably due to the hypothalamic dysfunction62. Without 
GH treatment, mean adult height in women is 145-150 cm and in men 155-160 cm29, 58.
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In the late 90s, the first positive effects of GH treatment on growth and body com-
position in children with PWS were reported64-66. In 2002, the Dutch national GH trial 
for children with PWS was started to investigate the effects on growth, body composi-
tion, activity level, psychological development and quality of life. It was started as a 
GH randomized controlled trial, lasting 1 year for infants and 2 years for prepubertal 
children, and children were subsequently followed during continuous GH treatment 
in the Dutch PWS Cohort Study until they attained adult height (for study designs see 
Appendix 1). Several long-term studies, including the Dutch PWS Studies, demonstrated 
that GH treatment is an effective and safe therapy for children with PWS23, 66-70. GH treat-
ment improves body composition, bone mineral density, psychomotor development, 
cognition, adaptive functioning, linear growth and adult height and has substantially 
changed the phenotype of children with PWS23, 34, 42, 70, 71. GH treatment, in combination 
with an early diagnosis with early care and treatment, has resulted in a new generation 
of children with PWS67, 70.
Nowadays, GH treatment is registered and reimbursed for children with PWS. Most 
Dutch infants start GH treatment soon after diagnosis and are followed in the Dutch 
PWS Cohort Study until adult height.
1.6 uNreSolved iSSueS
The hypothalamus seems to play an important role in various signs and symptoms in 
PWS. The underlying mechanism of hyperphagia is unknown, but appetite regulating 
hormones might be involved. There were only limited data about the appetite-regulat-
ing hormone ghrelin in PWS, and about the effects of glucose intake on this hormone. 
Therefore, these topics needed to be investigated. The effects of treatment with the 
hypothalamic neurohormone oxytocin on hyperphagia and social behaviour in children 
with PWS were unknown and were therefore investigated as well. Furthermore, an 
important clinical topic that needed to be investigated was the effect of GH treatment 
versus placebo in young adults with PWS who were GH-treated during childhood and 
had attained adult height, as there were no data about the effects of discontinuation 
or continuation of GH treatment on body composition, metabolic health profile and 
cognition.
appetite-regulating hormone ghrelin
As mentioned previously, the most striking symptom of PWS is hyperphagia, character-
ized by an excessive food intake and the lack of satiety. In the presence of a reduced 
metabolic rate and a decreased physical activity level, hyperphagia will often result in 
morbid obesity in children with PWS, when food intake is not restricted72. Remarkably, 
the complete opposite eating behaviour is present in the first period after birth with 
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feeding problems leading to severe failure to thrive when feeding assistance is not 
provided27.
The mechanisms for the switch in eating behaviour from impaired suckling and failure 
to thrive to excessive weight gain and hyperphagia with impaired satiety are currently 
unknown, but abnormalities in appetite-regulating hormones might be involved. It is 
crucial to obtain knowledge about the pathophysiology of the switch, since this might 
help to fi nd an appropriate treatment. One of the possibly involved hormones is ghrelin. 
Ghrelin is predominantly produced in the stomach and ghrelin cells are under the con-
trol of complicated mechanisms, which are still obscure73-75. It has an acylated (AG) and 
an unacylated (UAG) form in circulation73-75 (Figure 8). The presence of the acyl group is 
necessary for the binding to the growth hormone secretagogue receptor (GHSR-1a)74 
and for that reason, unacylated ghrelin (UAG) was considered to be inactive. Nowadays 
there is increasing evidence that UAG has also several actions78. Both AG and UAG can be 
determined in blood samples, but AG is unstable and rapidly deacylates to UAG76, 77. UAG 
acts as a functional inhibitor of AG, suggesting an important role for the ratio between 
AG and UAG levels78, 79. Immediate addition of an esterase inhibitor at time of blood col-
lection is therefore needed. In healthy individuals, AG and UAG levels are high in fasting 
state, while levels decline after food intake80. Furthermore, intravenous AG administra-
tion in healthy subjects increased food intake and appetite81.
Acylated ghrelin (AG)
Unacylated ghrelin (UAG)
Serine-specific protease 
removes n-Octanoyl group 
from AG
AEBSF binds to the active  
serine residue of the protease, 
thus inhibiting its activity
figure 8. Schematic overview of acylated and unacylated ghrelin.
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In patients with PWS, hyperghrelinemia has been reported82-87. As high AG levels 
are associated with increased food intake, they might explain part of hyperphagia in 
PWS, but these studies did not treat the samples with an esterase inhibitor to prevent 
deacylation82-87. Most studies described total ghrelin levels, thus did not distinguish be-
tween AG and UAG levels and did not report AG/UAG ratios. In addition, it was unknown 
whether there was a difference in ghrelin levels between patients in various nutritional 
phases. We therefore wanted to answer the question whether fasting ghrelin levels were 
abnormal in patients with PWS in comparison with obese and healthy controls.
Ghrelin after glucose intake
Hyperphagia, characterized by a combination of a preoccupation with food, an excessive 
food intake and the lack of satiety, has a major impact on the quality of life of patients 
with PWS and their surroundings. For a long time it was thought that patients experi-
enced chronic hunger, but studies also demonstrated a decreased satiation in patients 
with PWS compared to obese and healthy controls88. It was unknown why patients with 
PWS do not feel satiated after a meal, but hypothalamic dysfunction in combination 
with abnormal peripheral endocrine responses was one of the possible causes.
In contrast to most other appetite-regulating hormones, ghrelin levels in healthy 
humans are high in a fasting state, while they decrease after food intake. In PWS, fasting 
ghrelin levels are abnormally high, but the response of the ghrelin system to food intake 
could be abnormal as well. The appropriate response would be a decrease in levels of AG 
and UAG, and AG/UAG ratio after food intake, possibly mediated by the hypothalamus. 
However, prior to our study, it was unknown whether this would occur in patients with 
PWS as well. We wanted to answer the question whether the lack of satiety in PWS was 
caused by an abnormal response of the orexigenic ghrelin to food intake.
oxytocin treatment
Quality of life is hampered by temper tantrums and the preoccupation with food, which 
makes every day a challenge for many patients and their caregivers. Worldwide, there is 
ongoing research to find a solution for the main problems of patients with PWS. There is 
increasing interest in the hormone oxytocin, as oxytocin is involved in food intake, body 
weight and social skills, and these are seriously affected in patients with PWS.
Prader-Willi syndrome is caused by the lack of expression of the PWS region on chro-
mosome 15 and one of the genes in this region is MAGEL2. This means that MAGEL2 is not 
expressed in PWS. The exact link between MAGEL2 and oxytocin is not clear, but animal 
studies demonstrated a major reduction of oxytocin secretion in the hypothalamus of 
MAGEL2-deficient mice. These mice had an altered onset of suckling activity resulting in 
impaired feeding and 50% mortality89. Human neonates with PWS show similar suckling 
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problems. Oxytocin treatment to MAGEL2-deficient mouse pups normalized suckling 
and feeding behaviour and rescued all of them89.
In addition to the evidence in animal studies, there were clues that the oxytocin 
system is disturbed in humans with PWS. The number of oxytocin-expressing neurons 
in the hypothalamus of patients with PWS is significantly decreased by 42% and plasma 
levels of oxytocin are lower than in healthy controls8, 90. Thus, patients with PWS seem 
to have a deficiency of oxytocin and it was considered worth to investigate the effects 
of treating this deficiency with oxytocin. The oxytocin system is a promising target for 
therapeutic interventions, especially in obesity control and in aberrations in social func-
tion. A pilot study with intranasal oxytocin administration in adults with PWS showed 
positive effects on social behaviour91, but prior to our study, the effects of oxytocin in 
children were unknown. We wanted to answer the question whether oxytocin treatment 
has positive effects on social behaviour and eating behaviour in children with PWS.
body composition in early adulthood
In children with PWS, the benefits of GH treatment are nowadays well established and 
GH treatment is approved by EMA and FDA. GH treatment in children with PWS improves 
body composition, bone mineral density, psychomotor development, cognition, adap-
tive functioning, linear growth and adult height23, 34, 42, 70, 71. The most important reason 
for treating these children is to optimize their abnormal body composition67, 70. Without 
GH treatment, body composition tends to deteriorate over time, leading to a BMI of 35 
(+3.5 SDS) at the age of 18 years29, 58. A recent study showed that 8 years continuous 
GH treatment resulted in a healthy BMI around +1 SDS in adolescents with PWS, with a 
stable LBM and FM%70. This indicates that GH treatment is a potent force to counteract 
the clinical course of obesity in children with PWS70. GH treatment, in combination with 
an early diagnosis and care, has substantially changed the phenotype of these children 
and has resulted in a new generation of patients67. But it also brought new questions 
regarding those who reach adult height, as there is only a registration of GH treatment 
for PWS during linear growth. Although most adults with PWS are not GH deficient, it 
might be that they also need GH treatment for sustainment of their improved body com-
position like children with PWS do92-94. Should GH treatment thus be continued when a 
young adult with PWS has attained adult height? Prior to our study, there were no data 
on the effects of cessation or continuation of GH on body composition in young adults 
with PWS who were treated with GH during childhood and had attained adult height.
metabolic health profile in young adulthood
PWS patients have lower fasting insulin levels and higher insulin sensitivity than a 
weight-comparable group95-97. One of the suggested mechanisms for the higher insulin 
sensitivity in PWS is the reduced visceral adiposity compared to simple obesity98. Nev-
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ertheless, adults with PWS are predisposed to develop diabetes mellitus type 2 (T2DM), 
probably due to their extreme obesity99, and to cardiovascular disease (CVD) because 
risk factors for CVD such as hypertension and hyperlipidemia occur more often in PWS100.
Without GH treatment, body composition tends to deteriorate over time58, which is 
associated with an unfavourable metabolic health profile. On the other hand, GH treat-
ment is a potent force to increase LBM and decrease FM%70, which is associated with 
improved insulin sensitivity and metabolic health profile, but GH has also diabetogenic 
effects and treatment has been associated with decreased insulin sensitivity101, 102. Prior 
to our study, it was thus the question whether the benefits of GH treatment would out-
weigh the possibly unfavourable effects on glucose and insulin homeostasis in young 
adults. There were also no data on the effects of cessation or continuation of GH on 
metabolic health profile in these young adults.
cognition in young adulthood
In general, patients with PWS have a cognitive impairment with IQ scores between 50 
and 85 points42, 103. We have demonstrated that GH-untreated children with PWS show 
a deterioration of cognitive functioning over time, while GH treatment prevents dete-
rioration of certain cognitive skills on the short-term and significantly improves abstract 
reasoning and visuospatial skills during 4 years of GH treatment34, 42. The exact mecha-
nism by which GH exerts its beneficial effects on cognitive functioning is not elucidated. 
MRI studies in PWS suggest that lower cortical complexity partially underlies cognitive 
impairment and developmental delay104, and it might be that the brain tissue is affected 
by GH itself, or through the release of IGF-I. When young adults with PWS have attained 
adult height, they have to discontinue GH treatment. In untreated adults with PWS, 
lower IGF-I levels were correlated with poorer intellectual skills105, which might suggest 
that discontinuation of GH treatment, which decreases IGF-I, could be disadvantageous.
Prior to our study, the effects of cessation or continuation of GH on cognitive function-
ing in this new generation of patients with PWS were unknown and required further 
research.
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1.7 aimS of THe STudieS aNd ouTliNe of THe THeSiS
This thesis presents a detailed description of the studies, which were performed to 
increase the knowledge about PWS and to improve the care for patients with PWS. 
Serum levels of the appetite-regulating hormones acylated and unacylated ghrelin were 
measured in patients participating in the Dutch PWS Cohort Study, in collaboration 
with two French PWS centers. These hormone levels were also measured during oral 
glucose tolerance tests in participants of the Young Adult PWS Study. In the randomized, 
double-blinded, placebo-controlled PWS Oxytocin Study, the effects of 4 weeks of intra-
nasally administered oxytocin versus 4 weeks of placebo on social behaviour and eating 
behaviour were investigated in children with PWS. In the randomized, double-blinded, 
placebo-controlled GH study (PWS Transition Study), the study population consisted of 
young adults with PWS who were GH-treated during childhood and had attained adult 
height, and thus had to stop GH treatment. In this specific group, we evaluated the ef-
fects of 1 year of GH treatment versus 1 year of placebo on body composition, metabolic 
health profile and cognition. Study designs are described in Appendix 1.
chapter 1 gives an introduction in PWS and the topics described in this thesis.
chapter 2 presents the results of a study evaluating the serum levels of the appetite-
regulating hormones acylated and unacylated ghrelin in a large cohort of children 
and young adults with PWS, compared with age-matched obese subjects and healthy 
controls.
chapter 3 reports the response of the appetite-regulating hormones acylated and un-
acylated ghrelin to glucose intake during an oral glucose tolerance test in young adults 
with PWS.
chapter 4 describes the results of the randomized, double-blinded, placebo-controlled 
PWS Oxytocin Study, investigating the effects of 4 weeks of oxytocin versus 4 weeks of 
placebo on social behaviour and eating behaviour in children with PWS.
chapter 5 presents the PWS Transition Study, a 2-year randomized, double-blinded, 
placebo-controlled cross-over GH trial in young adults with PWS who were GH-treated 
during childhood and had attained adult height. This study investigated whether body 
composition deteriorated after cessation of GH treatment, and whether 1 year of GH 
treatment versus 1 year of placebo administration could maintain the improved body 
composition.
chapter 6 presents the effects on metabolic health profile in the PWS Transition Study, 
a 2-year randomized, double-blinded, placebo-controlled cross-over GH trial in young 
adults with PWS who were GH-treated during childhood and had attained adult height.
chapter 7 describes the effects on cognition in the PWS Transition Study, a 2-year ran-
domized, double-blinded, placebo-controlled cross-over GH trial in young adults with 
PWS who were GH-treated during childhood and had attained adult height.
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chapter 8 discusses the results and conclusions in the light of the current literature and 
presents clinical implications of our findings.
chapter 9 contains an English and Dutch summary of the results described in this thesis.
chapter 10 contains an overview of publications by PWS-team of Dutch Growth Re-
search Foundation.
chapter 11 contains lists of abbreviations, co-authors and affiliations, and publications, 
and the PhD portfolio, CV and acknowledgements.
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aPPeNdix 1: duTcH PWS STudieS
Project coordination
The Dutch Growth Research Foundation (Stichting Kind en Groei) is the initiator and co-
ordinator of the Dutch PWS studies. The PWS team consists of MD-researchers, research 
nurses and a psychologist.
Both the Dutch randomized controlled GH trial (Dutch GH RCT) and the multicenter 
follow-up study (Dutch PWS Cohort Study) are multicenter studies. Three-monthly, 14 
hospitals throughout The Netherlands are visited by the MD-researcher and the research 
nurse, where children are examined, in collaboration with the local pediatrician or pedi-
atric endocrinologist (Figure 9). Standardized measurements take place at the Erasmus 
University Medical Center - Sophia Children’s Hospital in Rotterdam, The Netherlands, 
at start, at 6 and 12 months and subsequently once a year. In the PWS Oxytocin Study, 
children visited the Sophia Children’s Hospital at baseline, after 4 weeks and after 8 
weeks. The PWS Transition Study was a single center study and young adults visited the 
Sophia Children’s Hospital in Rotterdam twice a year for standardized measurements.
General introduction and aims of the thesis 29
1
figure 9. Participating centers Dutch GH trial and PWS Cohort Study.
Rotterdam R.J. Kuppens, S.H. Donze, L. Damen, E. Mahabier, P.M.C.C. van Eekelen, L. Schafthuizen,
G.C.B. Bindels-de Heus, A.C.S. Hokken-Koelega
Previously: N.E. Bakker, S.T. Lo, E.P.C. Siemensma, R.F.A. Tummers-de Lind van Wijngaarden, 
D.A.M. Festen, A. Lukoshe, B. Kerkhof
Dutch Growth Research Foundation and Erasmus University Medical Center Rotterdam-Sophia 
Children’s Hospital (black dot)
Nijmegen A.A.E.M. van Alfen-van der Velden, Radboud University Medical Center-Amalia Children’s 
Hospital
From 2015: One accredited Dutch Prader-Willi Reference Center with 2 locations,
Dutch Growth Research Foundation in collaboration with Erasmus University Medical Center-Sophia Children’s 
Hospital, and Radboud University Medical Center-Amalia Children’s Hospital
Amsterdam J. Rotteveel, VU University Medical Center
Amsterdam N. Zwaveling-Soonawala, Academic Medical Center-Emma Children’s Hospital
Apeldoorn L. Lunshof, Gelre Hospitals
Den Bosch P.E. Jira, E.G.A.H. van Mil, Jeroen Bosch Medical Center
Den Haag E.C.A.M. Houdijk, Haga Hospitals-Juliana Children’s Hospital
Eindhoven R.J.H. Odink, V. van Tellingen, St. Catharina Hospital
Enschede M. Wegdam-Boer, Medical Center Twente
Groningen G. Bocca, University Medical Center Groningen-Beatrix Children’s Hospital
Harderwijk M. van Leeuwen, St. Jansdal Hospital
Leeuwarden E. van Pinxteren-Nagler, Medical Center Leeuwarden(2002-2014)
Leiden D.A.J.P. Haring, Alrijne Hospital
Leiden W. Oostdijk, Leiden University Medical Center-Willem-Alexander Children’s Hospital
Lelystad R. Lauwerijs, MC Zuiderzee (2002-2013)
Nijmegen C. Westerlaken, Canisius-Wilhelmina Hospital (2004-2011)
Utrecht J.J.G. Hoorweg-Nijman, H. van Wieringen, St. Antonius Hospital
Zwolle E.J. Schroor, Isala Hospital (2002-2014)
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dutch GH rcT and PWS cohort Study
Patients
Until July 2016, more than 185 Dutch children with PWS were included in the Dutch GH 
RCT and PWS Cohort Study, and nowadays, almost all Dutch infants are included in the 
PWS Cohort. For both studies, children had to meet the following criteria:
Inclusion criteria
- Genetically confirmed diagnosis of PWS;
- Age between 6 months and 16 years; (extended in 2016: between 0 months and 16 
years)
- Maximal bone age of less than 14 years in girls, or 16 years in boys.
Exclusion criteria
- Non-cooperative behaviour;
- Extremely low dietary intake of less than minimal required intake according to 
guidelines set by the World Health Organization;
- Medication to reduce weight (fat);
- In children above 3 years of age: height above 0 SDS, unless weight-for-height is 
above 2 SDS;
- Previous treatment with GH (not applicable for the Dutch PWS Cohort Study).
Design
From 2002 to 2008, 61 infants, 47 prepubertal children and 7 pubertal children were 
included in the RCT (Figure 10). Infants and prepubertal children were randomized into 
either a GH-treated group or a control group for respectively 1 or 2 years, and subse-
quently all were treated with GH 1 mg/m2 per day. All pubertal children were treated 
with GH, but were randomized to receive either 1 mg/m2 per day or 1.5 mg/m2 per day 
until adult height. All were prospectively followed and GH treated in the Dutch PWS Co-
hort Study in collaboration with pediatricians or pediatric endocrinologists throughout 
The Netherlands.
Since 2009, Dutch infants with PWS are directly included in the PWS Cohort Study for 
follow-up during long term GH treatment until attainment of adult height. All children 
are treated with GH 1 mg/m2 per day and are prospectively followed in the Dutch PWS 
Cohort Study in collaboration with pediatricians or pediatric endocrinologists through-
out The Netherlands (Figure 9).
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Pubertal children 
1 mg/m2∙day 
Prepubertal children 
PWS Cohort Study 
Control 
1 mg/m2∙day 
1.5 mg/m2∙day 
1 mg/m2∙day 
1 mg/m2∙day 
Control Control 
1 mg/m2∙day 1 mg/m2∙day 
1 mg/m2∙day 
1 mg/m2∙day 
From 12 or 24 months 
1.5 mg/m2∙day 
-3 months 
Diet and  
exercise 
Start to 12 or 24 months 
Dutch GH RCT 
Infants 
1 mg/m2∙day 
1 mg/m2∙day 
1.5 mg/m2∙day 
figure 10. Design of the multicenter randomized controlled GH trial and the Dutch PWS Cohort study.
GH dose 1.0 mg/m2∙day≈0.035 mg/kg∙day, GH dose 1.5 mg/m2∙day≈0.052 mg/kg∙day.
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PWS oxytocin Study
Patients
Between January and September 2015, 25 children with PWS were included in the PWS 
Oxytocin Study. Children had to meet the following criteria:
Inclusion criteria
- Genetically confirmed diagnosis of PWS;
- Age between 6 and 15 years;
- Social behavioural problems and/or a preoccupation with food;
- Naïve for oxytocin treatment at time of enrollment;
- Used GH treatment for at least 1 year and were still receiving it.
Exclusion criteria
- Severe psychiatric problems, serious illness or cardiac abnormalities;
- Allergic reactions or hypersensitivity to oxytocin;
- Medication to reduce weight (fat) other than GH;
- Non-cooperative behaviour.
Design
A randomized, double-blind, placebo-controlled, cross-over study was conducted to 
investigate the effects of intranasal oxytocin administration on social behaviour, food 
intake and satiety (Figure 11). Children received either oxytocin or placebo for 4 weeks, 
after which they crossed-over to the alternative treatment for a further 4 weeks. No 
wash-out period was implemented. The children were stratified according to gender 
and age (6-10 or 11-14 years) and then randomly and blindly assigned to receive intrana-
sal administration twice daily, before breakfast and dinner, of either oxytocin or identical 
appearing placebo. The dose was calculated according to body surface. Investigators 
were blinded for the allocation.
 Oxytocin
Oxytocin
 
Placebo 
Start 4 weeks 8 weeks
Placebo 
PWS Oxytocin Study
Oxytocin
figure 11. Design of the randomized, double-blinded, placebo-controlled cross-over PWS Oxytocin Study.
Oxytocin dose calculated according to body surface
General introduction and aims of the thesis 33
1
PWS Transition Study
Patients
Until January 2014, 28 Dutch young adults with PWS who were treated with GH during 
childhood and attained adult height, were included in the PWS Transition Study. Young 
adults had to meet the following criteria:
Inclusion criteria
- Genetically confirmed diagnosis of PWS;
- GH treatment during childhood for at least 2 years and being on GH at time of inclu-
sion;
- Adult height attainment, defined as a height velocity less than 0.5 cm per 6 months 
and a complete epiphyseal fusion.
Exclusion criteria
- Non-cooperative behaviour;
- Medication to reduce weight (fat).
Design
Two-year, randomized, double-blind, placebo-controlled, cross-over study investigating 
the effects of 1 year placebo versus 1 year GH on body composition, metabolic health 
profile and cognition (Figure 12). Young adults were stratified according to gender and 
BMI (below or above 25 kg/m2) and then randomly and blindly assigned to receive 1 
year of subcutaneous injections once daily at bedtime of either 0.67 mg/m2/day GH or 
1 year of identical appearing placebo, after which they crossed-over to the alternative 
treatment for another year. Investigators were blinded for the allocation.
 
0.67 mg/m2∙day 
Placebo 0.67 mg/m2∙day 
PWS Cohort Study
Start 12 months 24 months
Placebo 
PWS Transition Study
figure 12. Design of the 2-year randomized, double-blinded, placebo-controlled cross-over GH trial. GH 
dose 0.67 mg/m2∙day≈0.023 mg/kg∙day.
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abSTracT
context Prader-Willi syndrome (PWS) is characterized by a switch from failure to thrive 
to excessive weight gain and hyperphagia in early childhood. Hyperghrelinemia may be 
involved in the underlying mechanisms of the switch.
Purpose To evaluate acylated ghrelin (AG) and unacylated ghrelin (UAG) levels in PWS 
and investigate their associations with hyperphagia.
design Cross-sectional clinical study in three PWS expert centers in the Netherlands 
and France.
method Levels of AG and UAG and the AG/UAG ratio were determined in 138 patients 
with PWS (0.2-29.4 years) and compared with 50 age-matched obese subjects (4.3-16.9 
years) and 39 healthy controls (0.8-28.6 years). AEBSF was used to inhibit deacylation of 
AG.
results As a group, PWS patients had higher AG but similar UAG levels as healthy con-
trols (AG 129.1 vs 82.4 pg/ml, p=0.016; UAG 135.3 vs 157.3 pg/ml, resp.), resulting in 
a significantly higher AG/UAG ratio (1.00 vs 0.61, p=0.001, resp.). Obese subjects had 
significantly lower AG and UAG levels than PWS and controls (40.3 and 35.8 pg/ml, resp.), 
but also a high AG/UAG ratio (1.16). The reason for the higher AG/UAG ratio in PWS and 
obese was, however, completely different, as PWS had a high AG and obese a very low 
UAG.
PWS patients without weight gain or hyperphagia had a similar AG/UAG ratio as age-
matched controls, in contrast to those with weight gain and/or hyperphagia who had 
an elevated AG/UAG ratio.
conclusion The switch to excessive weight gain in PWS seems to coincide with an 
increase in the AG/UAG ratio, even prior to the start of hyperphagia.
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iNTroducTioN
Prader-Willi syndrome (PWS) is a neurogenetic disorder caused by the lack of expression 
of the paternally derived genes on chromosome 15 at locus q11-q131. Clinical findings 
change when children become older: infancy is characterized by poor feeding, failure to 
thrive and muscular hypotonia, while hyperphagia with impaired satiety, obesity, short 
stature, psychomotor delay and behavioural problems are prominent during childhood 
and adulthood2, 3. The mechanism behind the switch from failure to thrive to excessive 
weight gain and hyperphagia in early childhood is not yet known, but hyperghrelinemia 
might be involved4, 5.
Most children with PWS nowadays receive growth hormone (GH) treatment, which 
counteracts the clinical course of obesity and improves the metabolic profile, leading 
to better lipid levels, higher adiponectin levels and lower systolic blood pressure6, 7. 
However, GH treatment does not solve the problem of hyperphagia.
The appetite-stimulating hormone ghrelin has an acylated and an unacylated form in 
circulation8-10. Acylated ghrelin (AG) is known to be diabetogenic and has many actions 
such as stimulating appetite and inducing a positive energy balance, which can lead 
to weight gain11-14. Intravenous AG administration in healthy volunteers increased food 
intake and appetite15, suggesting that the hyperphagia in PWS might be associated with 
increased ghrelin levels. For a long time, unacylated ghrelin (UAG) was considered to 
be an inactive degradation product of AG. Currently, there is increasing evidence that 
UAG has also distinct actions16. It is reported that UAG has protective effects on beta 
cells, endothelial progenitor cells and muscle cells, and UAG seems to improve glycemic 
control14. In addition, UAG acts as a functional inhibitor of AG and it was reported to 
suppress ghrelin levels in humans16, 17. This suggests a crucial role for the ratio of AG and 
UAG levels (AG/UAG ratio) in maintaining weight balance.
Ghrelin can be determined in blood samples, but AG is unstable and is rapidly deacyl-
ated to UAG through the action of esterases18, 19. Thus, reliable ghrelin determination 
needs the immediate addition of an esterase inhibitor at the time of blood collection. In 
patients with PWS, hyperghrelinemia has been reported, but in these studies samples 
were not treated in this way4, 5, 20-23.
 We formulated three hypotheses. Children and young adults with PWS have (1) higher 
AG levels and lower UAG levels than healthy and obese controls; (2) increasing AG and 
decreasing UAG levels with the rise of the nutritional phases, resulting in increased AG/
UAG ratios in the higher nutritional phases; and (3) a higher AG/UAG ratio in the pres-
ence of weight gain and/or hyperphagia and a normal AG/UAG ratio in the absence of 
weight gain and/or hyperphagia, compared with age-matched healthy controls.
Therefore, a cross-sectional study was conducted in which we measured the plasma 
levels of AG and UAG in children and young adults with PWS and compared these levels 
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with those of obese and healthy controls. AEBSF, an inhibitor of deacylation of AG, was 
immediately added to all blood samples. In patients with PWS, we investigated the 
associations between AG and UAG ghrelin levels and the following factors: age, BMI, 
genotype, eating behaviour and food intake. In addition, we investigated whether the 
switch from failure to thrive to excessive weight gain and hyperphagia is associated with 
a change in the AG/UAG ratio.
SubjecTS aNd meTHodS
Subjects
The study group consisted of 138 children and young adults with PWS, either participat-
ing in the Dutch PWS studies coordinated by the Dutch Growth Research Foundation, 
or followed at the PWS reference center in Toulouse or Children’s Hospital in Lyon. PWS 
was genetically confirmed in all patients. One hundred and seven patients (77.5%) were 
treated with growth hormone (GH), the others had not yet started with GH or had reached 
final height without possibilities to continue GH treatment or the parents refused the 
GH treatment. Three patients with PWS had diabetes mellitus type 2 (T2DM) and all were 
treated with metformin. As their ghrelin levels were similar as in the total PWS group, we 
did not exclude them from analyses. None of the healthy or obese controls had T2DM.
Plasma ghrelin levels of subjects with PWS (PWS) were compared with 50 obese 
subjects (obese) and 39 healthy controls (controls). Obese and controls suffering from 
any systemic illness, growth disorder, syndrome or having dysmorphic features were 
excluded. Obese children had a BMI>+2 SDS and were regularly seen in the outpatient 
department of the pediatric endocrinology unit in Toulouse. Healthy controls were chil-
dren and young adults with a normal BMI, who underwent a minor surgical procedure 
at Erasmus Medical Center in Rotterdam. Normal BMI was defined as a BMI between -2 
SDS and +2 SDS24.
Standing height was measured with a calibrated Harpenden stadiometer or, when 
appropriate, supine length with a Harpenden infantometer (Holtain Ltd). Weight was 
determined on a calibrated scale (Servo Balance KA-20-150S; Servo Berkel Prior) and BMI 
was calculated. Height, weight and BMI were expressed as SDS, adjusted for age and sex. 
The Dutch reference data were used for the Dutch children and young adults24, 25 and the 
French reference data for height and weight and the Cole BMI reference data were used 
for the French patients26, 27. All SDS values were calculated with Growth Analyser (version 
4.0; www.growthanalyser.org).
The Medical Ethics Committees of the 3 participating centers approved the study. 
Written informed consent was obtained from parents of PWS. For obese and controls, 
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written informed consent was obtained from themselves and, if they were younger than 
18 years, also from their parents or custodians.
eating behaviour
The nutritional phases according to Miller were used to score the eating behaviour of 
the subjects with PWS3: 1a Hypotonia with difficulty feeding, 1b No difficulty feeding 
and growing appropriately on growth curve, 2a Weight increasing without an increase 
in appetite or excessive calories, 2b Weight increasing with an increase in appetite, 
3 Hyperphagia, feels rarely full, 4 Appetite no longer insatiable. For each subject with 
PWS, the nutritional phase was assessed by the multidisciplinary teams or indepen-
dently by two observers who knew them very well (physician and nurse)3. In case of 
disagreement, the case was discussed until consensus was reached. Subjects with PWS 
without weight gain or hyperphagia, defined as being in nutritional phase 1a or 1b, and 
subjects with weight gain and/or hyperphagia, defined as being in phases 2a, 2b and 3, 
were compared with age-matched controls.
collection of blood and plasma preparation
In children >2 years, blood samples were collected in the morning after a 12-h overnight 
fast. Infants <2 years were fasted for at least 5-h. To stabilize the plasma ghrelin levels, 
blood samples were collected in EDTA tubes and 4-(2-aminoethyl)benzenesulfonyl 
fluoride hydrochloride (AEBSF, Sigma-Aldrich Chemicals) was added to a concentration 
of 2 mg/ml at the time of collection. Blood was centrifuged at 4 ºC to prepare plasma, 
which was quickly frozen on dry ice. Samples were stored at -80 ºC and assayed within 3 
months following collection.
assays
Plasma AG and UAG levels were assessed in duplicate (10-50 µL per well) in one laboratory 
using two-step double antibody sandwich EIAs, obtained from SPIBio (Bertin Pharma, 
France; A05306 and A05319, resp.). Assays were performed according to manufacturer’s 
instructions. In summary, standards, quality controls and samples were incubated in the 
plate for 2 hours at room temperature without tracer. After a 3x wash, tracer antibody 
was added and incubated for 2 hours at room temperature. Following a 5x wash, Ell-
man’s reagent was added and incubated for approximately 45 minutes until satisfactory 
color development. Finally, the absorbance was measured at 405nm using a VictorX4 
plate reader (PerkinElmer, Groningen, Netherlands).
Data were analyzed using Graphpad Prism 5 (La Jolla, California). A sigmoidal third 
order (cubic) polynomial fitting was used to determine concentrations from the cali-
bration curves. This resulted in r2 values >0.99 in the majority of the assays. Intra-assay 
coefficient of variations (CVs) for AG and UAG were 8.2 and 11.4% and interassay CV for 
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AG and UAG were 3.9 and 11.0%. CVs were determined over 10 and 9 assays for AG and 
UAG, resp. Samples had inter-duplicate CV of <20% for both AG and UAG. The AG/UAG 
ratio was computed as AG divided by UAG.
In Rotterdam, insulin levels were assessed using the Immulite 2000 assay (Siemens 
Healthcare Diagnostics). Interassay CV was 4.4%. Serum glucose levels were determined 
using the Hitachi 917 (Hitachi Device Development Center), detecting glucose levels 
between 0 and 42 mmol/l. Serum IGF-I levels were assessed using the IDS-iSYS (Im-
munodiagnostic Systems). The intra-assay CV was <6.0% and the interassay CV was 
<2.1%. In France, insulin and glucose were enzymatically assessed on the Beckman AU 
2700 (Beckman Coulter Inc) and serum IGF-I levels were measured using IRMA assay 
from Immunotech. The intra-assay CV was <6.3% and the interassay CV was <8.8%. For 
Rotterdam and France, homeostasis model assessment of insulin resistance (HOMA-IR) 
was performed using the model HOMA-IR = (fasting insulin (mU/l) x fasting glucose 
(mmol/l))/22.528.
Statistics
Statistical analysis was performed by the Statistical Package for Social Sciences (version 
20.0; SPSS, Chicago, IL). Data are expressed as median [interquartile range (IQR)]. Differ-
ences between the groups were calculated using Kruskal Wallis tests when comparing 
three groups and Mann Whitney U tests when comparing two groups. Patients with PWS 
in each nutritional phase were compared with age-matched healthy controls. Obese 
PWS, defined as BMI>+2 SDS, were compared with obese controls. AG and UAG levels 
and AG/UAG ratios were log-transformed (natural logarithm), as they were not normally 
distributed. In PWS patients, we cross-sectionally assessed linear correlations between 
ghrelin levels and other parameters using Spearman’s rho correlation coefficient (ρ). As 
levels of AG and UAG decreased with age, linear regression analysis was used to com-
pare groups with adjustment for age. The AG/UAG ratio was not adjusted for age, as it 
remained stable across ages. Linear regression analysis was used to analyze correlations 
with adjustment for parameters such as age and gender. Regression coefficients are 
presented as percentages for better interpretation of the results. A positive value indi-
cates that the dependent variable is increased by that % for every unit increase of the 
independent variable. Differences were considered significant if the p-value was <0.05.
reSulTS
clinical characteristics
Median (interquartile range (IQR)) age of PWS was 9.9 (4.1-14.9) years (Table 1). There 
was no significant difference in age between the 138 PWS (61 boys), 39 controls (13 boys) 
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and 50 obese (16 boys). Height, weight and BMI were significantly different between the 
three groups and highest in obese (p<0.001). Fasting insulin and HOMA-IR were higher 
in obese (p<0.001 and p=0.001, resp.), while fasting glucose and IGF-I SDS were highest 
in PWS (p=0.043 and p<0.001, resp.).
PWS was genetically confirmed by an abnormal methylation test in all subjects with 
PWS. In 131 (94.9%) subjects, the genetic subtype was known; seventy (50.7%) had a 
deletion, 55 (39.9%) a uniparental maternal disomy (mUPD) and 6 (4.3%) an imprinting 
center mutation. One hundred and seven PWS used GH (77.5%) with a median dose of 
0.85 mg/m2/day (0.61-1.0) (≈0.028 mg/kg/day). Median age at start of GH treatment was 
1.9 (1.1-4.3) years and median duration of GH treatment was 7.0 (3.2-9.1) years.
Ghrelin levels in the three groups
Median (IQR) acylated ghrelin (AG) was significantly higher in the PWS group (129.1 
(67.1-227.9) pg/ml) than in controls (82.4 (56.3-130.4) pg/ml, p=0.016). Unacylated ghre-
lin (UAG) was similar in PWS and controls. As a result, the AG/UAG ratio was significantly 
higher in PWS than in controls (p=0.001)(Table 2 and Figure 1).
 In PWS, both AG and UAG levels were significantly higher than in obese (both p<0.001), 
as obese had the lowest AG and UAG levels of the three groups. Both PWS and obese 
had a significantly higher AG/UAG ratio than controls. The reason for the higher AG/UAG 
ratios in PWS and obese was, however, different. PWS had high AG levels, resulting in this 
higher AG/UAG ratio, while obese had low AG levels with even lower UAG levels.
In all three groups, both AG and UAG levels decreased with age, but the AG/UAG ratio 
remained stable.
Table 1. Baseline characteristics of 138 PWS, 39 controls and 50 obese subjects.
PWS n=138 Controls n=39 Obese n=50
p*median IQR median IQR median IQR
Age (yrs) 9.9 (4.1 to 14.9) 7.3 (3.6 to 13.6) 9.8 (7.9 to 13.0) 0.350
Weight for age (SDS) 0.8 (-0.6 to 2.4) -0.2 (-0.8 to 0.5) 5.9 (4.5 to 7.0) <0.001
Height for age (SDS) -0.3 (-1.3 to 0.6) -0.1 (-0.8 to 0.4) 1.3 (0.8 to 2.5) <0.001
BMI for age (SDS) 1.0 (-0.2 to 2.1) -0.2 (-0.8 to 0.8) 2.8 (2.6 to 3.1) <0.001
Fasting glycemia (mmol/l) 4.5 (4.0 to 5.0) 4.3 (3.9 to 4.7) 0.043
Fasting insulin (pmol/l) 62.5 (34.7 to 90.3) 100.7 (76.4 to 123.3) <0.001
HOMA-IR 1.8 (1.0 to 2.8) 2.6 (1.9 to 3.6) 0.001
IGF-I (SDS) 0.7 (0.7 to 1.7) -0.5 (-1.2 to 0.3) <0.001
*p-value between the three groups; 138 PWS, 39 healthy controls and 50 obese controls. Bold values are 
statistically significant (p<0.05).
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Table 2. Ghrelin levels of the three groups
Parameter
PWS
n=138
Controls
n=39
Obese
n=50
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median (IQR) median (IQR) median (IQR)
AG (pg/ml) 129.1 (67.1-227.9) 82.4 (56.3-130.4) 40.3 (26.4-82.5) <0.001 0.016 <0.001 0.001
UAG (pg/ml) 135.3 (66.0-284.2) 157.3 (79.3-261.0) 35.8 (26.0-64.4) <0.001 0.868 <0.001 <0.001
AG/UAG ratio 1.00 (0.57-1.49) 0.61 (0.37-0.81) 1.16 (0.92-1.43) <0.001 0.001 0.069 <0.001
*p-value between the groups, bold values are statistically signifi cant (p<0.05).
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figure 1. Ghrelin levels versus age for the three 
groups.
These fi gures show the AG and UAG levels and 
the AG/UAG ratio of children and young adults 
with PWS in black dots, of healthy controls in 
gray triangles and of obese controls in gray 
crosses.
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Ghrelin in nutritional phases in PWS
Of the 138 PWS who were classified according to the nutritional phases of Miller3, 13 
patients were in phase 1a, 37 in phase 1b, 12 in phase 2a, 44 in phase 2b, 31 in phase 3 
and 1 in phase 4 (Table 3). The median age of the children with PWS in nutritional phase 
1b was 8.9 years, while the median age of the children in nutritional phase 2a was 3.5 
years younger, namely 5.3 years. It shows that the rise of the nutritional phases was not 
in line with an older age. A considerable number of older subjects with PWS were still in 
nutritional phase 1b. Parallel with the rise of the nutritional phases, children with PWS 
in the higher nutritional phases had a higher BMI, ranging from -2.0 SDS in phase 1a to 
+3.2 SDS in phase 4.
Ghrelin levels and the switch in eating behaviour in PWS
Both AG and UAG levels of PWS patients decreased with the rise of the nutritional phases 
(Table 3, supplemental Figure). Between phase 1b and phase 2a, AG levels decreased 
from 161.0 to 117.2 pg/ml and UAG levels decreased from 252.0 to 125.5 pg/ml, but 
probably due to the low number in phase 2a this did not reach statistical significance. 
Subsequently, the AG and UAG levels of the patients in nutritional phase 2a, 2b and 3 
remained consistently low. The AG/UAG ratio showed a marked increase between phase 
1b and phase 2a and then remained consistently high in phases 2a, 2b and 3. This shows 
that the elevated AG/UAG ratio is already present in phase 2a, prior to phases 2b and 3 
in which the hyperphagia occurs.
Differences in ghrelin levels between nutritional phase 1b and 2a did not reach statis-
tical significance. As ghrelin levels were similar in phase 2a, 2b and 3, these nutritional 
phases were combined. Eighty-seven PWS had weight gain and/or hyperphagia (nutri-
tional phase 2a, 2b and 3). These 87 PWS had significantly higher AG/UAG ratios than 
the 50 PWS who did not have weight gain or hyperphagia (nutritional phases 1a and 
1b)(p=0.009)(Figure 2). This shows that the switch to weight gain and/or hyperphagia 
seems to occur simultaneously with the increase in the AG/UAG ratio.
Ghrelin levels in PWS and age-matched controls
While the AG/UAG ratio was similar in PWS in phase 1a and 1b as in age-matched con-
trols, the AG/UAG ratio was significantly higher in nutritional phase 2b and 3 than in 
age-matched controls. The AG/UAG ratio in PWS in phase 2a was similar as in phase 2b 
and 3, but was not significantly higher than age-matched controls, probably due to the 
low number in phase 2a (Table 3, Figure 2).
Non-obese PWS vs healthy controls and obese PWS vs obese controls
In an additional analysis, we compared 100 non-obese PWS with a median (IQR) BMI of 
+0.4 (-0.9-1.2) SDS with 39 healthy controls (BMI -0.2 SDS (-0.8-0.8)). The results were 
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comparable with the data of the total group (Table 4). The AG levels were signifi cantly 
higher in non-obese PWS than in healthy controls (median 140.1 vs 82.4 pg/ml, p=0.005), 
while the UAG levels were similar (median 150.7 vs 157.3 pg/ml, NS), resulting in a sig-
nifi cantly higher AG/UAG ratio in non-obese PWS (0.89 vs 0.61, p=0.003).
Obese 
controls
Healthy
controls
PWS
3
PWS
2b
PWS
2a
PWS
1b
PWS
1a
A
G
/U
A
G
 ra
tio
3.0
2.0
1.0
0.0
p=0.009*
N     13       37           12               44   31       39             50
 
Age (yrs)#    0.5       8.9           5.3              11.2          14.5       7.3           9.8
    (0.2-4.1)       (0.6-22.3)    (1.5-9.3)      (2.2-29.4)   (4.7-26.1)    (0.8-28.6)     (4.3-16.9)
BMI SDS
§
   -2.0       -0.6            0.9              1.6   2.7       -0.2            2.8
 
Deletion / mUPD^   7/6       14/18           4/6              27/14   17/11        _            _
 
P-value of   0.837       0.225           0.243          0.002   0.005         _            <0.001 
AG/UAG ratio
vs healthy controls◦         
 
Nutritional phase
               
figure 2. AG/UAG ratio of PWS per nutritional phase and of healthy and obese controls.
This boxplot shows the AG/UAG ratio of children and young adults with PWS in the 5 nutritional phases and 
of healthy controls and obese controls. The lower boundary is the 25th percentile and the upper boundary 
the 75th percentile. The line in the box represents the median. Lines are drawn from the smallest to the 
largest observed value that is not an outlier. #Median (range) age in years. §Median BMI SDS. ^Number of 
PWS patients with deletion and mUPD. ◦P-value of AG/UAG ratio of the subjects in each nutritional phase 
compared with age-matched healthy controls. *All subjects in phase 1a and 1b combined and compared 
with all subjects in phase 2a, 2b and 3 combined.
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We also compared the ghrelin levels of 38 obese PWS with a median (IQR) BMI of +2.7 
SDS (2.4-3.2) with 50 obese controls (BMI +2.8 SDS (2.6-3.1)). Both AG and UAG levels 
were significantly higher in obese PWS than in obese controls (median 100.1 and 94.9 
pg/ml vs 40.3 and 35.8 pg/ml resp., both p<0.001, even after adjustment for age), but 
the AG/UAG ratio was similar in both groups (1.08 vs 1.16, p=0.730).
associations between ghrelin levels and clinical characteristics and Homa-ir in 
PWS
There were no significant differences in AG and UAG levels and AG/UAG ratio between 
boys and girls, or between patients with a deletion and an mUPD. AG was inversely as-
sociated with age (p=0.012), weight SDS (p=0.004) and BMI SDS (p=0.001) and similar 
inverse associations were found between UAG and age, weight SDS and BMI SDS (all 
p<0.001). Since both AG and UAG decreased with age, the association analyses were 
adjusted for the variables age and gender. Higher BMI SDS was associated with lower 
AG and UAG levels, also after correction for age and gender (not shown). If the BMI SDS 
would increase with 1 SDS, the AG level would decrease by 22.8% and the UAG by 21.0%. 
The association between BMI SDS and AG/UAG ratio was not significant.
AG and UAG were both inversely associated with fasting insulin (p=0.023 and p<0.001, 
resp), and UAG with HOMA-IR (p=0.004). After adjustment for the variables age and gen-
der, these associations remained significant (p=0.048 and p=0.031 for insulin, p=0.050 
for HOMA-IR). The AG/UAG ratio was not associated with insulin or HOMA-IR.
associations between ghrelin and iGf-i levels in PWS
IGF-I levels were measured in 124 PWS of which 103 (83.1%) were treated with GH. IGF-I 
levels, adjusted for age and gender, were higher in the GH-treated versus untreated pa-
tients with PWS (p<0.001). The AG and UAG levels and AG/UAG ratio were not different 
between the GH-treated and untreated patients with PWS (p=0.423 for AG, p=0.374 for 
UAG and p=0.337 for AG/UAG ratio).
Table 4. Comparison between non-obese PWS and healthy controls, and obese PWS and obese controls
Gender Age (yrs)
BMI
(SDS)
AG
(pg/ml)
UAG
 (pg/ml)
AG/UAG
ratio
n m/f median median median median median
Non-obese PWS (BMI<2SDS) 100 43/57 8.9 0.4 140.1 150.7 0.89
Healthy controls 39 13/26 7.3 -0.2 82.4 157.3 0.61
Non-obese PWS vs healthy controls 139 NS NS NS 0.005 NS 0.003
Obese PWS (BMI>2SDS) 38 18/20 13.5 2.7 100.1 94.9 1.08
Obese controls 50 16/34 9.8 2.8 40.3 35.8 1.16
Obese PWS vs Obese controls 88 NS 0.013 NS <0.001 <0.001 NS
Bold values are statistically significant (p<0.05).
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After adjustment for age and gender, IGF-I was inversely associated with AG and UAG 
(p=0.011 and p=0.008), but there was no significant association between IGF-I and the 
AG/UAG ratio (p=0.993).
obese and controls
In healthy and obese controls, no significant differences in ghrelin levels between boys 
and girls were found. Younger age was associated with higher levels of AG and UAG 
(p<0.001 and p=0.001, resp), but the AG/UAG ratio remained stable across age. BMI SDS 
was inversely correlated with AG and UAG levels (both p<0.001), but positively with the 
AG/UAG ratio (p<0.001).
diScuSSioN
Our study shows that AG levels are significantly higher in PWS patients than in controls. 
In contrast to our expectations, UAG levels in PWS were similar to those in controls. This 
resulted in a significantly higher AG/UAG ratio in PWS than in controls. Remarkably, our 
study shows that PWS patients in nutritional phase 2a, 2b and 3, thus with weight gain 
and/or hyperphagia, had a higher AG/UAG ratio than those in nutritional phase 1a or 1b, 
without weight gain or hyperphagia, whose AG/UAG ratios were similar to age-matched 
controls.
In our large study group, we measured levels of acylated and unacylated ghrelin sepa-
rately using double-antibody sandwich ELISAs specific for each isoform. This approach 
prevents detection of inactive peptide fragments in the samples. We also inhibited the 
deacylation of AG to UAG by adding AEBSF to the blood samples18, 19. Many previous 
studies used radioimmunoassays for total ghrelin which detect both full-length, as well 
as inactive fragments, of both ghrelin isoforms4, 5, 20, 29-31, or samples were not stabilized 
with an esterase inhibitor to prevent deacylation of AG32, 33. As a result, our data cannot 
be compared with those in earlier studies.
Both PWS and obese had a significantly higher AG/UAG ratio than healthy controls. 
The reason for the higher AG/UAG ratio in both groups was, however, completely dif-
ferent. While PWS had higher AG levels with normal UAG levels, obese controls had low 
AG levels with even lower UAG levels. Based on the higher BMI in PWS patients, one 
would have expected lower AG and UAG levels like in obese subjects. This might indicate 
that the abnormalities of the ghrelin system are specific for PWS. Only two other studies 
reported AG or UAG levels in PWS and compared them with obese controls, but neither 
study added an inhibitor of AG degradation to the blood samples. Both demonstrated 
significantly higher AG levels in PWS than in obese controls32, 33. The ratio between AG 
and UAG was not presented. Paik et al. did not report a significant difference in UAG 
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levels between PWS and obese controls33. A possible explanation for these different 
observations might be the method that was used to collect the blood samples.
In contrast to our expectation, the median age of patients with PWS in nutritional 
phase 1b was 3.5 years higher than in phase 2a. Although hyperphagia is a constitu-
tive marker of PWS, we found in our large group that several older patients were still in 
nutritional phase 1b, thus without weight gain or hyperphagia. An explanation might 
be that the patients in our group had an earlier diagnosis with earlier attention for diet, 
physical exercise and growth hormone treatment starting at a young age34, although 
it is not proven that this approach can prevent hyperphagia. Parallel to the rise of the 
nutritional phases, we found an increasing BMI, supporting that the nutritional phases 
were correctly attributed.
Our results confirm our hypothesis that patients with PWS without hyperphagia have a 
similar AG/UAG ratio as age-matched controls, while patients with PWS with weight gain 
and/or hyperphagia have an AG/UAG ratio higher than that of age-matched controls. 
In nutritional phase 2a, children with PWS gain weight without a change in appetite or 
caloric intake. Phase 2b is associated with weight gain and an increased interest in food, 
and phase 3 is characterized by hyperphagia, typically accompanied by food-seeking 
and lack of satiety3. So, in nutritional phases 2a, 2b and 3 the switch to the typical weight 
and eating problems of PWS has already occurred. We found that the AG/UAG ratio of 
children with PWS is already increased in nutritional phase 2a, when there is only weight 
gain but no hyperphagia. There is a considerable change in the AG/UAG ratio between 
phase 1b and phase 2a and the AG/UAG ratio remained at a similar high level in phases 
2b and 3. Compared to age-matched controls, the AG/UAG ratio in phase 2a, 2b and 3 
was higher, although not significantly in phase 2a, probably due to the low number of 
patients in phase 2a. This considerable change in AG/UAG ratio between phase 1b and 
higher nutritional phases is in line with the switch to weight gain followed by hyper-
phagia, which happens in the same period and supports the hypothesis that ghrelin 
might be involved in this. Whether this modification is the cause or the consequence 
of the switch in the nutritional phases cannot be unraveled by our study. Delhanty et 
al. suggested that UAG is a functional inhibitor of AG which might suppress AG levels 
in humans16, 17. Elaborating on this idea, the ratio between AG and UAG levels (AG/UAG 
ratio) might be a more important parameter than individual AG and UAG levels. If this 
hypothesis is correct, it could be that in patients with PWS without weight gain and/or 
hyperphagia, in which the AG/UAG ratio is normal, UAG levels are sufficiently high to 
compensate for the elevated AG levels. However, the UAG levels in patients with PWS 
from phase 2a onwards are likely to be too low to modulate the effects of elevated AG 
levels. The resulting higher AG/UAG ratio might induce or contribute to the weight gain 
and hyperphagia. It is unknown which factors determine UAG levels in healthy subjects 
and PWS patients. Previous studies showed that somatostatin (agonist) administration 
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did not result in reduction of weight, food intake or appetite35-37, but it might be that 
AG and UAG levels are equally affected by this treatment and that the AG/UAG ratio 
is not influenced. UAG might be secreted via different mechanisms than AG and rates 
of acylation and/or deacylation of AG might be differently modulated. Also differences 
in clearance of UAG relative to AG might play a role, but no reports are available. Our 
findings provide a rationale for a role of relatively decreased UAG levels in the abnormal 
eating behaviour in PWS. It would be interesting to investigate whether a more physi-
ological AG/UAG ratio could be achieved by increasing the plasma UAG or decreasing 
the plasma AG levels and/or bioactivity, and whether this normalization of the AG/UAG 
ratio results in a reduction of the hyperphagia.
AG and UAG levels and the AG/UAG ratio at various ages in PWS show a wide varia-
tion. In the total group there was a distinct pattern with higher AG/UAG ratios in the 
higher nutritional phases than in age-matched controls. For individuals, this implies that 
a patient with PWS with a higher AG/UAG ratio has a higher chance to be in a higher 
nutritional phase.
As expected, PWS patients had a more favourable metabolic profile with lower insulin 
levels and a lower HOMA-IR than obese controls7, while the IGF-I levels were higher in 
the PWS than in the obese group. In PWS, we found an inverse correlation between 
AG and UAG levels and BMI and in addition also an inverse association between UAG 
levels and HOMA-IR. This suggests that low UAG levels in PWS are associated with less 
favourable health aspects, such as a higher BMI and insulin resistance. Previous studies 
have reported similar results in non-PWS subjects, but no inhibitor was added to their 
blood samples38-40.
Our study showed no difference in AG/UAG ratios between GH-treated patients and 
untreated patients with PWS and there was also no significant association between IGF-I 
levels and AG/UAG ratio. Thus, in our study GH treatment seems to have no effect on the 
AG/UAG ratio, despite earlier notes of Hauffa and Petersenn in which GH treatment was 
assigned as confounding factor in the natural course of ghrelin concentrations41. We 
assume that this study was not designed to investigate the effects of GH treatment on 
ghrelin levels.
As blood sampling in children and young adults with PWS is difficult and quite in-
vasive, we collected only one fasting sample. In our opinion, fasting samples are most 
appropriate and we present the AG and UAG levels of a large group of patients. It would 
be informative, however, to conduct a longitudinal study in children with PWS, to inves-
tigate whether the switch in eating behaviour is closely correlated with an increase in 
the AG/UAG ratio. In addition, it would be of interest to determine whether PWS patients 
show a postprandial decline in AG and UAG levels.
In conclusion, we report that PWS patients have higher AG levels but similar UAG 
levels compared to healthy controls, resulting in a significantly higher AG/UAG ratio in 
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PWS patients than in controls. Obese controls have significantly lower AG and UAG levels 
than PWS patients and healthy controls, but also a high AG/UAG ratio. The reason for the 
higher AG/UAG ratio in PWS and obese was, however, completely different, as PWS had 
a high AG and obese a very low UAG.
PWS patients without weight gain or hyperphagia had a similar AG/UAG ratio as age-
matched controls, in contrast to those with weight gain and/or hyperphagia who had 
an elevated AG/UAG ratio. The switch to excessive weight gain in PWS seems to coincide 
with an increase in the AG/UAG ratio, even prior to the start of hyperphagia.
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Supplemental figure 2. AG and UAG levels of PWS per nutritional phase and of healthy and obese con-
trols. This boxplot shows the AG (in white) and UAG (in gray) levels of children and young adults with PWS in 
the 5 nutritional phases and of healthy controls and obese controls. The lower boundary is the 25th percen-
tile and the upper boundary the 75th percentile. The line in the box represents the median. Lines are drawn 
from the smallest to the largest observed value that is not an outlier.
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abSTracT
background Prader-Willi syndrome (PWS) is characterized by hyperphagia with im-
paired satiety. PWS patients have very high acylated ghrelin (AG) with normal unacyl-
ated ghrelin (UAG) levels, resulting in an elevated AG/UAG ratio, suggesting an intrinsic 
defect in the ghrelin regulation. Normally, food intake induces satiety and a drop in AG 
and UAG levels, but it is unknown if these levels also decline in PWS.
objective To evaluate whether the high AG levels in PWS decline in response to glucose 
intake during an oral glucose tolerance test (OGTT), and to investigate the effects of 
growth hormone (GH) treatment on this response.
method Serum levels of AG, UAG and AG/UAG ratio during an OGTT were determined 
in 24 GH-treated patients with PWS (median age 19.0, range 14.2-25.9 years) and in 10 
GH-stop patients (of whom 5 were in GH-treated group; 18.5, 14.5-20.3 years).
results In GH-treated and GH-stop young adults with PWS, there was a sharp decline 
of AG levels and a decrease of UAG levels in the first 30 minutes after the glucose load, 
which resulted in a lower AG/UAG ratio. GH-treated patients had significantly lower AG 
levels than GH-stop patients at baseline and during the OGTT. All UAG levels and AG/
UAG ratios were lower in the GH-treated patients, although not significantly.
conclusions In young adults with PWS, an oral glucose load significantly reduces AG 
and UAG levels, suggesting normal regulation of the ghrelin axis by food intake. GH 
treatment results in lower AG levels at baseline and during OGTT, suggesting a more 
favourable metabolic profile. Our findings might suggest that the impaired satiety is not 
the result of an abnormal response of the orexigenic ghrelin to food intake.
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iNTroducTioN
Prader-Willi syndrome (PWS) is a neurogenetic disorder caused by lack of expression of 
the paternally derived genes on chromosome 15 at locus q11-q131. PWS is characterized 
by a number of signs and symptoms, including an abnormal body composition with a 
high body fat percentage and a low lean body mass (LBM), and hyperphagia resulting in 
morbid obesity when uncontrolled2-4. Nevertheless, euglycemic children and adults with 
PWS have lower fasting insulin and higher insulin sensitivity than weight-comparable 
subjects5 and PWS children have higher adiponectin levels than healthy peers6. The 
mechanism behind the hyperphagia with impaired satiety is not yet known, but the 
appetite-stimulating hormone ghrelin seems to be involved7-9.
To date, most studies measured total ghrelin levels, but did not differentiate between 
the two forms, acylated and unacylated ghrelin, in circulation10-12. Acylated ghrelin (AG) 
is known to be diabetogenic and has many actions such as stimulating appetite and 
inducing a positive energy balance, which can lead to weight gain13-16. The enzyme 
ghrelin O-acyl transferase (GOAT) mediates the acylation of the ghrelin peptide and the 
presence of the acyl group of AG is necessary for the binding to the growth hormone 
secretagogue receptor (GHSR-1a)12. For that reason, unacylated ghrelin (UAG) was 
considered to be inactive11, 17, but nowadays there is increasing evidence that UAG has 
also several actions. UAG has protective effects on beta cells, endothelial progenitor 
cells and muscle cells, and it improves glycemic control16, 17. In addition, UAG acts as 
a functional inhibitor of AG and may suppress AG levels in humans17, 18. Thus, the ratio 
between AG and UAG levels (AG/UAG ratio) might be crucial in glucose homeostasis and 
maintenance of weight balance.
The fasting AG/UAG ratio is elevated in children and young adults with PWS, mainly 
due to very high levels of AG7. The effect of food intake on the AG/UAG ratio in PWS is 
unknown. During food intake, children with PWS continue to eat for a longer time than 
obese and normal weight controls19. This non-decelerating eating curve in PWS suggests 
impaired satiation rather than increased hunger. In healthy people, AG and UAG levels 
increase during the night, while feeding induces a strong decline of these levels20. After 
a standardized meal with 50% carbohydrates, AG declined by approximately 65% and 
UAG by 40%20. An OGTT proved to be as effective as a standardized meal in inhibiting 
ghrelin secretion21.
It might be that the impaired satiation in PWS is related to a lack of decline of AG levels 
and particularly the AG/UAG ratio during food intake. Only one study has investigated 
both AG and UAG levels, but not the AG/UAG ratio, in PWS during an OGTT22. The inhibi-
tor AEBSF was not added to the samples to prevent deacylation of AG to UAG23, therefore 
these data must be interpreted with caution. Similar UAG levels, but higher AG levels 
with a larger AG decline after a glucose load were found in the 11 prepubertal obese 
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children with PWS who were not treated with GH, compared with 10 obese controls. But 
the change in AG/UAG ratio during an OGTT is unknown.
Considering the elevated AG/UAG ratio in fasting PWS patients and their impaired 
satiety during food intake, we hypothesized that ghrelin regulation is disturbed. We 
expected that glucose intake during an OGTT would neither influence the AG and UAG 
levels nor the AG/UAG ratio in PWS and that these levels would remain high, as high AG 
levels are a hallmark of patients with PWS. Given the fact that AG is diabetogenic and 
UAG improves glycemic control, we expected to find a positive correlation between the 
AG/UAG ratio and the insulin/glucose ratio. In addition, as GH treatment seems to have 
favourable influences on the natural course of PWS, we expected to find lower AG/UAG 
ratios in GH-treated than in GH-stop young adults. To further clarify the role of food in-
take and GH treatment in the regulation of AG and UAG levels and the AG/UAG ratio, we 
investigated the response of these levels to a standard oral glucose load in GH-treated 
compared to GH-stop young adults with PWS. AEBSF, an inhibitor of deacylation of AG, 
was immediately added to the blood samples to prevent deacylation of AG to UAG.
meTHodS
Subjects
The study group consisted of 29 young adults with PWS, participating in the Dutch 
PWS studies coordinated by the Dutch Growth Research Foundation. PWS was ge-
netically confirmed in all patients. Fourteen (48.3%) young adults received sex steroid 
replacement therapy. During childhood, all patients were treated with GH without oral 
glucose tolerance tests (OGTT) being performed. GH treatment was stopped due to 
attainment of adult height, as there is no registration of this treatment for adults with 
PWS. After stop an OGTT was performed (GH-stop group). A Young Adult study protocol 
was started in which patients were allowed to restart GH treatment. During the Young 
Adult study, patients had an OGTT (GH-treated group). After fasting blood collection, a 
standard OGTT according to the World Health Organization was performed with 75-g 
oral glucose. Blood samples for glucose and insulin determination were obtained after 
30, 60, 90 and 120 minutes and for AG and UAG levels after 30 and 120 minutes after the 
oral glucose load.
Standing height was measured with a calibrated Harpenden stadiometer. Weight was 
determined on a calibrated scale (Servo Balance KA-20-150S; Servo Berkel Prior) and BMI 
was calculated. Final height and BMI were expressed as SDS, adjusted for age and sex24, 25, 
and calculated with Growthanalyser (version 4.0; www.growthanalyser.org). The Medi-
cal Ethics Committee of Erasmus University Medical Center approved the study. Written 
informed consent was obtained from the young adults with PWS and their parents.
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eating behaviour
The nutritional phases according to Miller were used to score the eating behaviour of 
the subjects with PWS26: 1a Hypotonia with difficulty feeding, 1b No difficulty feeding 
and growing appropriately on growth curve, 2a Weight increasing without an increase 
in appetite or excessive calories, 2b Weight increasing with an increase in appetite, 
3 Hyperphagia, rarely feels full, 4 Appetite no longer insatiable. For each subject with 
PWS, the nutritional phase was assessed by the multidisciplinary teams or indepen-
dently by two observers who knew them very well (physician and nurse)26. In the event 
of disagreement, the case was discussed until consensus was reached.
collection of blood and plasma preparation
Baseline blood samples were collected in the morning after an overnight fast for as-
sessment of glucose, insulin, IGF-I, AG, UAG and AG/UAG ratio. Subsequently, a standard 
75-g oral glucose tolerance test (OGTT) according to the World Health Organization was 
performed. Blood samples for glucose and insulin determination were obtained after 30, 
60, 90 and 120 minutes after ingestion and immediately assayed as described elsewhere7. 
AG and UAG levels were determined after 30 and 120 minutes after oral glucose load. To 
prevent deacylation of AG to UAG, thus to stabilize the plasma AG and UAG levels, blood 
samples were collected in EDTA tubes and 4-(2-aminoethyl)benzenesulfonyl fluoride 
hydrochloride (AEBSF, Sigma-Aldrich Chemicals) was added to a concentration of 2 mg/
ml at the time of collection. Blood was centrifuged at 4 ºC to prepare plasma, which was 
quickly frozen on dry ice. Samples were stored at -80 ºC and assayed within 6 months 
following collection. The assay and its intra- and interassay coefficient of variation (CV) 
used in this study has been described7.
To evaluate the overall responses to the oral glucose load, apart from the plasma levels 
at various time points, the insulin/glucose ratio at 0, 30 and 120 minutes was calculated 
as an index of relative insulin resistance.
Statistics
Statistical analysis was performed by the Statistical Package for Social Sciences (version 
20.0; SPSS, Chicago, IL). Data are expressed as median (interquartile range (IQR)) as 
they were not normally distributed. Differences between two groups were calculated 
using Mann Whitney U tests. As data were not normally distributed, Friedman’s ANOVA 
was used for testing the ghrelin levels of the three different time points, and Wilcoxon 
Ranks tests were used to follow up this. Within the different groups, we cross-sectionally 
assessed linear correlations between ghrelin levels and other parameters using Spear-
man’s rho correlation coefficient. Differences were considered significant if the p-value 
was <0.05.
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reSulTS
clinical characteristics
The 29 young adults underwent a total of 34 oral glucose tolerance tests (OGTT). Twenty-
four tests were performed during GH treatment (GH-treated) and 10 tests after stop of 
GH treatment (GH-stop). Of the 29 young adults, five patients had two tests, one in the 
period after stop of GH treatment and one after restart of GH treatment.
The 24 young adults with PWS (6 male, 18 female) who underwent an OGTT during GH 
treatment, had a median (IQR) age of 19.0 (17.2-22.2) years and a BMI of 24.9 (22.2-29.1) 
kg/m2, being +1.0 (0.5 to 2.0) SDS. Eleven (45.8%) had a paternal deletion, 9 (37.5%) a 
uniparental disomy (mUPD), 3 (12.5%) an imprinting center mutation and one (4.2%) a 
translocation (Table 1). Median (IQR) dose of GH was 0.45 (0.35-0.67) mg/m2/day ≈ 0.015 
(0.012-0.022) mg/kg/day.
Ten young adults with PWS (2 male, 8 female) underwent an OGTT in the period after 
stop of GH treatment (GH-stop group). Median (IQR) duration between the discontinu-
ation of GH and the OGTT was 9 (6-12) months. Their age and BMI were similar to the 
GH-treated patients (Table 1).
Ghrelin during oGTT in GH-treated young adults
Figure 1 shows the median fasting AG and UAG levels and AG/UAG ratio at baseline, and 
then 30 and 120 minutes after an oral glucose load in 24 GH-treated young adults. Levels 
of AG and UAG changed significantly during the OGTT (AG p<0.001 and UAG p=0.001, 
resp.). Median (IQR) baseline AG levels were 88.4 (37.0-143.1) pg/ml, but declined sharply 
after the glucose load to a nadir of 10.8 (2.0-60.2) pg/ml after 30 minutes (p=0.001)
(Table 2). Median (IQR) decrease of AG was 90.8% (52.5-95.0%). In the second part of the 
OGTT, AG levels increased to 40.5 (2.0-83.7) pg/ml at 120 minutes (p=0.020). UAG levels 
showed a similar pattern with a significant decline (p=0.001) from 94.6 (67.4-295.2) pg/
ml at baseline to 52.4 (36.2-151.0) pg/ml at 30 minutes after glucose load (median (IQR) 
decrease 48.9% (24.5-63.8%)), but it was followed by a more moderate increase to 84.9 
(35.6-180.0) pg/ml after 120 minutes (p=0.058). As a result, the AG/UAG ratio declined 
significantly from 0.68 (0.48-1.81) to 0.29 (0.02-1.08) in the first 30 minutes (p=0.045) 
followed by a stable ratio of 0.44 (0.02-1.65) in the second part (p=0.178).
associations with aG and uaG levels and their ratio in GH-treated young adults
At baseline, there were no differences in fasting AG and UAG levels and AG/UAG ratio 
between boys and girls (p-values above 0.698), or between young adults with a dele-
tion and an mUPD (p-values above 0.798). There were no associations with age, BMI, fat 
percentage, nutritional phase, sex steroid replacement therapy or IGF-I SDS.
Ghrelin levels during OGTT in young adults with PWS 67
3
In the 24 GH-treated young adults, a lower UAG at 30 and 120 minutes after glucose 
load was associated with a higher insulin/glucose ratio at 120 minutes (p=0.017 and 
p=0.006), while a lower baseline UAG tended to be associated with a higher insulin/
glucose ratio at 120 minutes (p=0.082). Since there was no association between AG 
levels and the insulin/glucose ratio at the different time points, this resulted in a positive 
association with the AG/UAG ratio. A higher AG/UAG ratio at 0 and 120 minutes was as-
sociated with a higher insulin/glucose ratio at 120 minutes (both p=0.010), and a higher 
Table 1. Baseline characteristics of 24 GH-treated and 10 GH-stop young adults with PWS.
GH-treated GH-stop p-value
N 24 10
Age (yrs) 19.0 (17.2 to 22.2) 18.5 (16.6 to 20.0) 0.406
Age range 14.2 to 25.9 14.5 to 20.3
Gender
- Male 6 (25.0%) 2 (20.0%) 0.758
- Female 18 (75.0%) 8 (80.0%)
Genetic subtype
- Deletion 11 (45.8%) 4 (40.0%) 0.967
- mUPD 9 (37.5%) 5 (50.0%)
- ICD 3 (12.5%) 1 (10.0%)
- Translocation 1 (4.2%) -
Adult height SDS -1.7 (-2.1 to -1.1) -1.9 (-3.1 to -0.4) 0.664
BMI (kg/m2) 24.9 (22.2 to 29.1) 27.1 (23.6 to 34.0) 0.257
BMI SDS 1.0 (0.5 to 2.0) 1.9 (0.7 to 2.7) 0.162
Fat percentage 43.8 (37.4 to 48.0) 46.6 (39.7 to 55.5) 0.174
Waist (cm) 77.3 (71.9 to 88.5) 82.5 (73.7 to 91.9) 0.347
Waist-to-hip ratio 0.76 (0.72 to 0.79) 0.77 (0.72 to 0.81) 0.611
Duration of GH (years) 10.7 (9.7 to 11.6) 9.9 (8.4 to 11.5) 0.210
Pubertal stage Tanner
- M or G 2 / 3 / 4 / 5 1 / 5 / 12 / 6 0 / 4 / 4 / 2 0.564
- P 4 / 5 1 / 23 0 / 10 0.287
Sex steroid therapy 12 (50%) 5 (50%) 1.000
Nutritional phasea 0.275
- Phase 1b 10 (41.7%) 2 (20.0%)
- Phase 2b 9 (37.5%) 5 (50.0%)
- Phase 3 5 (20.8%) 3 (30.0%)
Characteristics at time of OGTT. Age, Adult height SDS, BMI, fat percentage, waist circumference, waist-to-
hip ratio and duration of GH are expressed in median (IQR); gender, genetic subtype, sex steroid therapy 
and nutritional phase are expressed in n(%). Pubertal stage according to Tanner is expressed in n. P-value 
between GH-treated and GH-stop patients.
aNutritional phase according to Miller et al.
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AG/UAG ratio at 30 minutes tended to be associated with a higher insulin/glucose ratio 
at 120 minutes (p=0.071). Remarkably, AG and UAG levels and AG/UAG ratio at the diff er-
ent time points were not associated with the insulin/glucose ratio at 0 and 30 minutes.
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figure 1. AG and UAG levels and AG/UAG ratio of 24 GH-treated and 10 GH-stop young adults with PWS.
AG and UAG levels and AG/UAG ratio before and at 30 and 120 minutes after the glucose load of 24 GH-
treated (solid line) and 10 GH-stop (dotted line) young adults with PWS. Lines are drawn from the 25th to 
the 75th percentile. P-value is given in case of a signifi cant diff erence between GH-treated and GH-stop.
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As these associations might be due to GH treatment, we also investigated the associa-
tions in the 10 GH-stop patients and found similar results; a higher AG/UAG ratio at 0, 30 
and 120 minutes after glucose load was associated with a higher insulin/glucose ratio at 
120 minutes (p=0.016, p=0.014 and p=0.004, resp.).
effects of GH treatment on ghrelin
To evaluate the effects of GH treatment, the AG and UAG levels of the 24 GH-treated 
young adults were compared with those of 10 GH-stop patients (Figure 1). At baseline, 
AG levels of the GH-treated young adults were significantly lower than those of the 
GH-stop patients (p=0.006), while baseline UAG levels were not significantly different. 
GH-treated and GH-stop young adults had a similar significant decline of AG and UAG 
levels after the oral glucose load to a nadir after 30 minutes (both p=0.001 in GH-group, 
both p=0.012 in GH-stop group, resp., relative to baseline). In the second part of the 
OGTT, from 30 to 120 minutes after the glucose load, AG and UAG increased in both the 
GH-treated and GH-stop young adults, although this increase was only significant for 
AG in the GH-treated group (p=0.020). As a result, the AG/UAG ratio declined in the first 
30 minutes and did not change significantly in the second part (p=0.045 and p=0.178, 
resp.). At every time point of the OGTT, the AG/UAG ratio was lower in the GH-treated 
group, but not significantly.
Table 2. Biochemical characteristics during OGTT of GH-treated and GH-stop adolescents with PWS.
Parameter GH-treated
n=24
GH-stop
n=10
p-value°
Fasting glucose (mmol/l) 4.7 (4.4 to 5.0) 4.3 (4.0 to 4.6) 0.034
Fasting insulin (mU/l) 69.5 (36.8 to 162.0) 46.5 (25.3 to 74.5) 0.145
Fasting AG (pg/ml) 88.4 (37.0 to 143.1) 157.1 (141.7 to 251.5) 0.006
30 min AG (pg/ml) 10.8 (2.0 to 60.2) 59.1 (40.5 to 96.1) 0.044
120 min AG (pg/ml) 40.5 (2.0 to 83.7) 89.2 (66.0 to 103.6) 0.028
Fasting UAG (pg/ml) 94.6 (67.4 to 295.2) 142.4 (131.8 to 193.7) 0.290
30 min UAG (pg/ml) 52.4 (36.2 to 151.0) 98.3 (68.1 to 138.3) 0.498
120 min UAG (pg/ml) 84.9 (35.6 to 180.0) 128.4 (56.1 to 198.5) 0.225
Fasting AG/UAG ratio 0.68 (0.48 to 1.81) 1.11 (0.67 to 1.83) 0.345
30 min AG/UAG ratio 0.29 (0.02 to 1.08) 0.76 (0.26 to 0.91) 0.223
120 min AG/UAG ratio 0.44 (0.02 to 1.65) 0.64 (0.33 to 1.70) 0.433
Insulin/glucose ratio t=0* 14.0 (7.1 to 33.6) 13.3 (6.5 to 16.9) 0.292
Insulin/glucose ratio t=30* 47.8 (30.8 to 88.6) 41.4 (36.5 to 46.9) 0.396
Insulin/glucose ratio t=120* 56.0 (30.0 to 83.0) 35.2 (30.2 to 43.3) 0.048
°P-value between GH-treated and GH-stop patients, bolded p-values are p-values below 0.05. *Insulin/glu-
cose ratio in mU/mmol.
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To further elucidate the effect of GH, we compared the ghrelin levels of 5 individuals 
who underwent two OGTTs: one in the period with and one without GH treatment. The 
median time difference between the two OGTTs was 1.0 year. The pattern of the AG lev-
els and the AG/UAG ratio showed similar dynamics during OGTT in the period with and 
without GH treatment, with a sharp decline during the first 30 minutes after the glucose 
load in both periods. During GH treatment, AG levels declined from 99.0 to 60.2 pg/ml 
and the AG/UAG ratio from 0.80 to 0.40, while after stop of GH the AG levels declined 
from 150.2 to 95.0 pg/ml and the AG/UAG ratio from 1.18 to 0.89. The decline in the first 
30 minutes was followed by an increase towards baseline levels in the second part. At 
every time point (0, 30 and 120 minutes) the AG levels and AG/UAG ratios were lower 
in the GH-treated than in the GH-stop period, although not significantly. In contrast, 
the baseline UAG levels were similar in both periods. In the GH-treated period, UAG 
decreased sharply in the first 30 minutes after the glucose load from 127.7 to 52.4 pg/
ml, while it only slightly decreased in the GH-stop period from 133.5 to 115.0 pg/ml. This 
difference tended to be significant (p=0.068).
diScuSSioN
As high AG levels are a hallmark of patients with PWS, we expected that glucose intake 
would neither influence the AG and UAG levels nor the AG/UAG ratio in PWS and that 
these levels would remain high. In contrast to our expectation, our study shows that glu-
cose intake reduces AG and UAG levels in young adults with PWS. In the first 30 minutes 
after the glucose load, there was a sharp decline of AG levels and to a lesser extend of 
UAG levels, which resulted in a lower AG/UAG ratio. This demonstrates that even in the 
presence of very high fasting AG/UAG ratios7, the ghrelin system of young adults with 
PWS shows a physiological response with a strong decline of AG and UAG levels after 
glucose intake.
Patients with PWS have hyperphagia and a non-decelerating eating curve, suggesting 
impaired satiety19. The exact mechanism of impaired satiety is not yet elucidated, but in 
the fasting state, the appetite-stimulating hormone AG is significantly elevated in PWS 
compared to healthy controls. AG’s functional inhibitor UAG is similar in subjects with 
PWS and healthy controls, but in the presence of the high AG level in PWS, there is a state 
of relative UAG deficiency7. We expected that glucose intake would neither influence the 
AG and UAG levels nor the AG/UAG ratio in PWS and that these levels would remain high, 
as high AG levels are a hallmark of patients with PWS. In contrast to our expectation, we 
found that both AG and UAG levels strongly declined and that they reached a nadir at 
30 minutes after an oral glucose load. The AG levels decreased markedly more than the 
UAG levels, which resulted in lower AG/UAG ratios at 30 minutes. The decline was similar 
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to the strong decline in AG of 65% and UAG of 40% after a standard meal in healthy 
controls20, indicating that patients with PWS show a physiological response to the intake 
of glucose, in spite of the fact that they continue to eat. This suggests that there might 
be another explanation for the presence of impaired satiety in PWS. The hypothalamus 
is involved in many functions in the body such as regulating hormones, temperature 
control, circadian rhythm and respiratory control. In PWS, disturbances in these func-
tions are common and it is most likely that also the hyperphagia and impaired satiety are 
related with a hypothalamic dysregulation. Our findings do suggest, however, that the 
impaired satiety is not the result of an abnormal response of the orexigenic ghrelin to 
food intake. The impaired satiety could e.g. be due to an insufficient response of anorexi-
genic hormones like GLP-1 after food intake. Oxytocin could also be involved, as recent 
studies demonstrated that this hormone controls food intake and weight balance, while 
dysfunction of oxytocin results in obesity27.
Lower levels of UAG and AG/UAG ratio at 120 minutes, but also the UAG and the AG/
UAG ratios at earlier time points, were associated with a higher insulin/glucose ratio at 
120 minutes. This might suggest that a lower fasting UAG and higher fasting AG/UAG 
ratio are predictors for late insulin resistance. It would be interesting to further unravel 
this findings and investigate whether an elevated AG/UAG ratio can be used as a screen-
ing tool for insulin resistance. One may speculate that this association was induced by 
GH treatment, as GH increases insulin levels. For this reason, we also investigated the as-
sociation between ghrelin levels and insulin/glucose ratio at 120 minutes in the GH-stop 
group, but found similar results. Our findings are in line with St-Pierre et al. who dem-
onstrated that the AG/UAG ratio was higher in insulin-resistant than in insulin-sensitive 
non-diabetic obese individuals28. Our data support that AG is diabetogenic and UAG has 
protective effects on beta cells and improves glycemic control16, 17. Thus, it appears that 
the association between ghrelin and relative insulin resistance is not different for PWS.
At baseline, fasting AG levels were significantly lower in GH-treated patients than in 
GH-stop patients. During the OGTT, AG and UAG levels and the AG/UAG ratio followed 
the same pattern in the GH-treated and GH-stop patients, but during the entire test, 
the AG levels of the GH-treated patients remained lower. GH-treated patients had also 
lower fasting UAG levels and AG/UAG ratios although this did not reach significance. This 
lack of significance could be explained by the lower number of patients in the GH-stop 
group and the observed large variation in ghrelin levels. Similar results were found in 
the 5 patients in whom we performed an OGTT during both the GH-stop and GH-treated 
period. Apparently, GH treatment reduces AG levels, and to a lesser extent UAG levels, 
which results in a lower AG/UAG ratio. The acylated form of ghrelin stimulates appetite 
and induces a positive energy balance13-16, while UAG seems to oppose these effects, 
acting as a functional inhibitor of AG17, 18. The lower AG/UAG ratio during GH treatment 
may, therefore, contribute to GH’s more favourable metabolic effects. It is conceivable 
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that this contributes to the lower percentage of hyperphagia in our older GH-treated 
patients7. Ten out of 24 GH-treated young adults were still in nutritional phase 1b while 
their ages were between 14.2 and 23.1 years. This is in contrast to Miller et al. who re-
ported a young median (IQR) age at onset of nutritional phase 2b of 4.5 (3.0-5.3) years 
and of phase 3 of 8.0 (5.0-13.0) years and showed that nearly all children and young 
adults with PWS progressed to the high nutritional phases26. It might be that GH reduces 
the severity of the hyperphagia. The 24 GH-treated young adults started GH treatment 
in infancy or childhood and used it for a median (IQR) duration of 10.7 (9.7-11.6) years. 
After attainment of adult height, young adults had to stop GH treatment for at least 6 
weeks in order to perform a GH stimulation test. About half of the parents reported an 
aggravation of the hyperphagia with more food seeking behaviour (data not shown). 
Ghrelin is able to bind the GHSR, which stimulates GH release11, but it has not been 
elucidated whether a reverse system exists in which GH influences ghrelin production or 
release. In our study it appears that GH affects especially AG and therefore the AG/UAG 
ratio. Hauffa et al. demonstrated that GH treatment was able to decrease both elevated 
basal and postcarbohydrate total ghrelin levels in PWS children and young adults, but 
AG levels were not changed by GH29, 30. However, they did not add an inhibitor to prevent 
deacylation of AG to UAG and they used other assays, which could explain the differ-
ence. Furthermore, UAG levels were not measured.
In our study, in contrast to our expectations, the ghrelin system in PWS works appro-
priately after an oral glucose load with a physiological decline of AG and UAG levels. In 
healthy controls, similar magnitudes of decline of AG (between 42% and 71%) and UAG 
(between 30% and 58%) after a glucose load31, 32 and standardized breakfast meal20 have 
been reported. The choice of a control population is difficult since obese patients have 
reduced levels of AG and UAG compared to healthy controls7, whereas PWS patients 
have elevated AG levels, so that the comparison with obese patients would not be ap-
propriate. Since the effect of a glucose load on AG and UAG levels is clearly defined in 
literature, the testing of new healthy controls was considered unethical, since it would 
add no new information, while causing unnecessary burden on the subjects involved. 
Our results show the decline of AG and UAG levels after an oral glucose load. An OGTT 
proved to be as effective as a standardized light breakfast in inhibiting ghrelin secre-
tion21. Since the nadir of these levels was lowest after the ingestion of carbohydrates, 
compared to lipids and proteins32, 33, our results might also be applicable for meals.
In conclusion, we found a sharp decline of AG levels and a decrease of UAG levels in 
the first 30 minutes after the glucose load in GH-treated and GH-stop young adults with 
PWS. This resulted in a lower AG/UAG ratio after glucose intake. Our observation that 
the ghrelin system in PWS responds similarly as in healthy controls suggests a normal 
regulation of the ghrelin axis by food intake. GH treatment results in lower AG levels at 
baseline and during OGTT, suggesting a more favourable metabolic profile. Our findings 
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might suggest that the impaired satiety is not the result of an abnormal response of the 
orexigenic ghrelin to food intake.
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abSTracT
background Prader-Willi syndrome (PWS) is known for hyperphagia with impaired 
satiety and a specific behavioural phenotype with stubbornness, temper tantrums, 
manipulative and controlling behaviour and obsessive-compulsive features. PWS is 
associated with hypothalamic and oxytocinergic dysfunction. In humans without PWS, 
intranasal oxytocin administration had positive effects on social and eating behaviour, 
and weight balance.
objective To evaluate the effects of intranasal oxytocin compared to placebo adminis-
tration on social behaviour and hyperphagia in children with PWS.
design Randomized, double-blind, placebo-controlled, cross-over study in a PWS Refer-
ence Center in the Netherlands.
method Cross-over intervention with twice daily intranasal oxytocin (dose range 24-48 
IU/day) and placebo administration, both during 4 weeks, in 25 children with PWS (aged 
6 to 14 years).
results In the total group, no significant effects of oxytocin on social behaviour or 
hyperphagia were found, but in the 17 children younger than 11 years, parents reported 
significantly less anger (p=0.001), sadness (p=0.005), conflicts (p=0.010) and food-related 
behaviour (p=0.011), and improvement of social behaviour (p=0.018) during oxytocin 
treatment compared with placebo. In the 8 children older than 11 years, the items hap-
piness (p=0.039), anger (p=0.042) and sadness (p=0.042) were negatively influenced by 
oxytocin treatment compared to placebo. There were no side effects or adverse events.
conclusion This randomized, double-blind, placebo-controlled study suggests that 
intranasal oxytocin administration has beneficial effects on social behaviour and food-
related behaviour in children with PWS younger than 11 years of age, but not in those 
older than 11 years of age.
Oxytocin versus placebo in children with PWS: Effects on social behaviour and hyperphagia 79
4
iNTroducTioN
Prader-Willi syndrome (PWS) is characterized by neonatal hypotonia with suckling 
problems, early onset of hyperphagia with impaired satiety, endocrine disturbances and 
a specific behavioural phenotype with stubbornness, temper tantrums, manipulative 
and controlling behaviour, obsessive-compulsive features and difficulties in changing 
routines1-3. This results from the absence of expression of the paternally derived genes 
located on chromosome 15 at the locus q11.2-13, caused by a paternal deletion, mater-
nal uniparental disomy, imprinting center disorder or paternal chromosomal transloca-
tion1. One of the non-expressed genes in this region is MAGEL2.
MAGEL2-deficient mice have a major reduction of oxytocin in the hypothalamus and 
an altered onset of suckling activity resulting in impaired feeding and 50% mortality4. 
Injection of a specific oxytocin receptor antagonist in wild-type mouse pups resulted in 
a similar feeding deficiency as seen in MAGEL2 mutants4. Administration of oxytocin to 
MAGEL2-deficient mouse pups 3-5 hours after birth normalized suckling and feeding 
behaviour and rescued all of them4. Human newborns with PWS show similar suckling 
problems as found in the MAGEL2-deficient mice, which suggests that the lack of MA-
GEL2 gene might play a role in the suckling deficit seen in PWS newborns.
In adult patients with PWS, the number of oxytocin-expressing neurons in the hy-
pothalamus was significantly decreased by 42% and plasma levels of oxytocin were 
relatively low in relation to their obesity5, 6. However in 23 children with PWS between 
5 and 11 years of age, high plasma levels of oxytocin were reported7. Altogether, the 
oxytocin system in patients with PWS appears to be dysfunctional.
Oxytocin is known to be involved in food intake8, 9, body weight10, 11 and social skills12, 
all of which are seriously affected in patients with PWS. The majority of patients with 
PWS have hyperphagia with impaired satiety and they are severely at risk to become 
obese. They show symptoms of autistic spectrum disorder (ASD) and 36% of them 
fulfill the criteria of ASD13. Social cognitive functioning is markedly reduced, which has 
major consequences for the family and surrounding and for the approach of patients 
with PWS14, 15. Currently, there are no treatment options for the hyperphagia and social 
behavioural problems of patients with PWS, but the oxytocin system is a promising 
target. Studies on intranasal oxytocin administration showed that oxytocin reduced 
body weight of obese non-PWS patients10. Also, a single oxytocin gift improved emotion 
recognition in healthy and autistic adults16, 17 and reduced repetitive behaviours in those 
with ASD18.
Only two studies have investigated the effects of oxytocin treatment in PWS. Tauber 
et al. administered a single gift of 24IU intranasal oxytocin to 24 adults with PWS. After 
two days, they showed increased trust in others and decreased sadness tendencies with 
less disruptive behaviour19. In the placebo-controlled cross-over study by Einfeld et al., 
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22 individuals with PWS aged 12-30 years received 18-40IU intranasal oxytocin twice 
daily during 8 weeks, but they showed no benefit in the target behaviours or weight20.
Given the possible dysfunction of the oxytocin system in PWS and the involvement of 
oxytocin in socials skills, food intake and body weight, we hypothesized that oxytocin 
supplementation in children with PWS would improve social behaviour and hyperpha-
gia. We, therefore, investigated the effects of intranasal oxytocin administration on social 
behaviour, food intake and satiety in children with PWS in a randomized, double-blind, 
placebo-controlled, cross-over study.
meTHodS
Subjects
In order to be eligible to participate in this study, subjects (1) had a genetically confirmed 
diagnosis of PWS; (2) were aged 6 to 14 years; (3) had social behavioural problems and/
or a preoccupation with food; (4) were naïve for oxytocin treatment at time of enroll-
ment; and (5) used growth hormone therapy for at least 1 year and were still receiving 
it. Exclusion criteria were (1) severe psychiatric problems such as psychosis, serious 
illness or cardiac abnormalities; (2) allergic reactions or hypersensitivity to oxytocin; (3) 
medication to reduce weight (fat) other than GH; and (4) non-cooperative behaviour 
resulting in inability to comply with intranasal administration and/or hospital visits.
Forty-two children with PWS were eligible. Parents of 17 children refused to partici-
pate; 10 due to too large burden, 5 due to practical issues and 2 because the children 
themselves did not want to participate. The study group consisted of 25 children (14 
boys, 11 girls) with PWS, aged 6-14 years. GH therapy was prescribed at an initial dose of 
1 mg/m2/day and dose was lowered in case of high IGF-I levels. One child used levothy-
roxine and another used citalopram and aripiprazole.
design
A randomized, double-blind, placebo-controlled, cross-over study was conducted to 
investigate the effects of intranasal oxytocin administration on social behaviour, food 
intake and satiety. Children received either oxytocin or placebo for 4 weeks, after which 
they crossed-over to the alternative treatment for a further 4 weeks. No wash-out period 
was implemented, as the half life time of oxytocin is only 3-20 minutes. An independent 
statistician generated the random allocation sequence and only he and the independent 
pharmacist were unblinded. The children were stratified according to gender and age 
(6-10.99 or 11-14.99 years) and then randomly and blindly assigned to receive intranasal 
administration twice daily, before breakfast and dinner, of either oxytocin (Syntocinon®, 
4IU/puff, Sigma Tau) or identical appearing placebo (placebo, 0IU/puff, Sigma Tau). The 
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dose was based on doses used in other trials12, 20 and calculated according to body sur-
face: a child of 0.8-1.15m2 received 2dd3 puffs (12IU twice daily); 1.15-1.45m2 had 2dd4 
puffs (16IU twice daily); 1.45-1.75m2 had 2dd5 puffs (20IU twice daily); and of >1.75m2 
had 2dd6 puffs (24IU twice daily).
measurements
Children were examined at the outpatient clinic, at baseline, after 4 weeks and after 8 
weeks. Standing height was measured with a calibrated Harpenden stadiometer and 
weight was determined on a calibrated scale (Servo Balance). Height, weight and BMI 
were expressed as SDS according to Dutch reference data, adjusted for age and sex21, 22. 
Percentage fat was measured by DXA (Lunar Prodigy; GE Healthcare). All scans were 
made on the same machine and daily quality assurance was performed.
Blood samples were collected in the morning after 12-h overnight fast. Samples were 
quickly frozen on dry ice and stored at -80ºC until assayed. A breakfast meal consisting of 
270 grams (560 kcal) industrially produced multigrain pancakes cut into pieces was used 
to examine the food intake and satiety. This amount was determined in collaboration 
with a dietitian; weight was 150%, and calorie-intake 185% of a normal healthy breakfast 
for a child with PWS. After blood collection, the fasted children were instructed to eat as 
much as they wished of the meal. The weight of the plate with pancakes was measured 
at baseline and after the child finished eating. Besides, the duration of eating was deter-
mined. The child stayed in the room together with the investigator, while their parents 
waited elsewhere.
Social and eating behaviour were carefully monitored by the parents at home and in-
vestigated by two parent questionnaires. Dykens Hyperphagia Questionnaire was used 
to determine (changes in) eating behaviour and hyperphagia23. Although the Dykens 
Hyperphagia Questionnaire is validated, we have experienced that not all items of this 
questionnaire are applicable nowadays. The new generation of children with PWS had 
an early diagnosis and received intensive support from (para)medics, and started with 
GH treatment at a young age, which has markedly changed the phenotype, but they are 
still preoccupied with food. Therefore, the Oxytocin Study Questionnaire was developed 
by three physicians and a psychologist, all very experienced in PWS. The questionnaire 
unravels (changes in) emotions, social and eating behaviour and possible side effects. 
Parents were asked to fill in the applicable change from -3 (much less frequently) to +3 
(much more frequently), in which 0 was ‘no difference’. An example of a question is ‘In 
the last 4 weeks, my child was…sad’. Comparable questions were asked regarding being 
angry, being happy, showing food-seeking behaviour, having conflicts with others, etc.
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assays
All blood samples were determined in the same laboratory according to a standardized 
procedure. Levels of serum creatinine, hepatic enzymes and glucose were measured 
with COBAS 8000 systems of Roche and thyroid function was measured with Vitros ECIQ 
immunoanalyzer system of Ortho Clinical Diagnostics. Oxytocin levels in blood samples 
were measured in duplo with an oxytocin ELISA kit (Enzo Life Sciences). To assure the 
content of the vials, one puff per child per phase was measured by the same oxytocin 
ELISA kit. In summary, all children had one vial with and one vial without oxytocin, which 
confirmed perfect execution of the randomization.
Statistics
Statistical analysis was performed by SPSS version 23.0. Calculation of the sample 
size was based on the Oxytocin Study Questionnaire. Parents answer questions about 
changes in eating behaviour and social behaviour, from -3 (much less frequently) to 
+3 (much more frequently), in which 0 was ‘no difference’. A decrease of 4 points was 
considered clinically relevant. Based on an SD of 4, a power of 0.9 and significance 
level of 0.05, a total of 24 patients had to enter the two-treatment cross-over study. 
Data was not normally distributed, therefore non-parametric tests were used and data 
is expressed as median (interquartile range (IQR)) unless otherwise stated. Statistical 
analysis appropriate for cross-over trials were used, taking into account any carry-over 
or treatment-period effect, calculated by Wilcoxon Signed Rank test and Mann Whitney 
U tests, but these were not found. Depending on the data, results of the visit (ie ques-
tions about changes) or differences (∆) between visit 1 and 2, and between visit 2 and 
3 (ie ∆weight) were used. The effect of oxytocin versus placebo was tested by Wilcoxon 
tests in case of continuous data and McNemar tests in case of binary data. Correlations 
between effect of oxytocin or oxytocin levels and other parameters were assessed using 
Spearman’s rho. Differences were considered significant if p-value was <0.05.
Study approval
Written informed consent was obtained from parents and from children older than 12 
years; assent was obtained in children younger than 12 years. The study protocol was 
approved by the Medical Ethics Committee of Erasmus University Medical Center, The 
Netherlands, and registered at Nederlands Trial Register NTR4950 (www.trialregister.nl).
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reSulTS
baseline characteristics
Table 1 shows the baseline characteristics of the 25 children with PWS who were included 
between January and September 2015. Median age was 9.3 (range 6.0-13.7) years and 
BMI was 2.4 (0.7-4.3) SDS. Thirteen (52%) patients had a deletion and 12 (48%) an mUPD. 
All received GH treatment with a median dose of 0.8 (0.6-1.0) mg/m2/day (≈0.024 mg/
kg/day), started at a median age of 1.3 (1.0-2.2) years, with a median duration of GH 
treatment of 8.0 (5.7-9.2) years. The median dose of oxytocin was 16IU (range 12-24) 
twice daily. All 25 children completed the study.
effects on social behaviour, food intake and satiety
In the total group of 25 children with PWS between 6 and 14 years of age, no effects 
of oxytocin versus placebo treatment were found on social behaviour, food intake and 
satiety. In contrast to these nonsignificant effects of oxytocin in the total group, correla-
tion analyses showed that a younger age was strongly associated with beneficial effects 
of oxytocin treatment on social and eating behaviour (ρ=-0.553, p=0.004 and ρ=-0.485, 
p=0.014, resp.) and therefore subanalyses were performed. In line with the stratification, 
we divided the total group in 17 patients younger than 11 years and 8 patients older 
than 11 years.
Subanalysis in the younger children
Effects on social behaviour
Parents filled out questionnaires about their child. The items anger, sadness and con-
flicts improved significantly during oxytocin treatment compared to placebo (p=0.001, 
p=0.005 and p=0.010, resp.)(Table 2, Figure 1). The total Oxytocin Study Questionnaire 
score showed a significant improvement of -4 (-7.5 to -1) points during oxytocin treat-
ment compared to placebo (p=0.001). Ten of 17 (58.8%) parents reported an improve-
ment in social behaviour during oxytocin treatment, while 4 (23.5%) parents reported 
improvement during placebo (p=0.059).
Effects on eating behaviour
The 17 younger children showed a significant improvement in food-related behaviour 
during oxytocin treatment (p=0.011). During 4 weeks of oxytocin treatment, food-
seeking behaviour and satiety remained similar (p=0.429 and p=0.713, resp.), however, 
at baseline, food-seeking behaviour was only reported by six (35.3%) of the 17 parents, 
and in three of them, food-seeking behaviour was seen a few times per year. In both 
phases, almost all children finished their standardized breakfast meal. Only three chil-
dren left pancakes (median 95, range 70-140 gram) during oxytocin treatment and one 
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Table 1. Baseline characteristics of total group and per treatment schedule
ToTal GrouP of PaTieNTS of 6 To 14 yearS
PWS
(n=25)
Oxytocin / Placebo
(n=11)
Placebo / Oxytocin
(n=14) p*
Gender 14 boys, 11 girls 6 boys, 5 girls 8 boys, 6 girls
Genetic subtype (DEL/mUPD) 13 / 12 6 / 5 7 / 7
Age (yrs) 9.3 (6.9 to 11.9) 9.0 (6.4 to 11.2) 10.3 (7.0 to 12.5) 0.403
Height for age (SDS) 0.8 (0.2 to 1.6) 1.2 (0.4 to 1.7) 0.5 (0.0 to 1.1) 0.222
Weight for height (SDS) 2.0 (0.6 to 4.1) 2.3 (0.3 to 6.1) 1.9 (1.0 to 4.1) 0.809
BMI for age (SDS) 2.4 (0.7 to 4.3) 2.4 (-0.1 to 6.3) 2.2 (1.2 to 3.9) 1.000
Age at start GH treatment (yrs) 1.3 (1.0 to 2.2) 1.3 (0.9 to 2.2) 1.5 (1.0 to 2.6) 0.609
Duration of GH treatment (yrs) 8.0 (5.7 to 9.2) 7.3 (5.3 to 9.0) 8.2 (5.9 to 9.3) 0.687
GH dosage (mg/m2/day) 0.8 (0.6 to 1.0) 0.8 (0.5 to 1.0) 0.8 (0.6 to 1.0) 0.851
Prepubertal/pubertal 16 / 9 7 / 4 9 / 5
PaTieNTS of 6 To 11 yearS
PWS
(n=17)
Oxytocin / Placebo
(n=8)
Placebo / Oxytocin
(n=9) p*
Gender 9 boys, 8 girls 4 boys, 4 girls 5 boys, 4 girls
Genetic subtype (DEL/mUPD) 9 / 8 4 / 4 5 / 4
Age (yrs) 7.3 (6.4 to 9.7) 7.8 (6.1 to 9.3) 7.3 (6.7 to 10.3) 0.606
Height for age (SDS) 0.5 (0.0 to 1.3) 1.2 (0.0 to 1.6) 0.3 (-0.2 to 0.8) 0.277
Weight for height (SDS) 1.7 (0.6 to 3.9) 1.7 (0.4 to 5.3) 1.7 (0.9 to 3.9) 0.743
BMI for age (SDS) 1.9 (0.6 to 3.9) 2.1 (0.0 to 5.7) 1.8 (1.0 to 3.6) 0.963
Age at start GH treatment (yrs) 1.3 (0.9 to 1.7) 1.3 (0.8 to 2.0) 1.2 (0.9 to 1.5) 0.743
Duration of GH treatment (yrs) 6.3 (5.3 to 8.4) 6.3 (5.2 to 8.2) 6.3 (5.5 to 8.8) 0.541
GH dosage (mg/m2/day) 0.7 (0.5 to 1.0) 0.7 (0.5 to 1.0) 0.7 (0.5 to 1.0) 0.963
Prepubertal/pubertal 14 / 3 6 / 2 8 / 1
PaTieNTS of 11 To 14 yearS
PWS
(n=8)
Oxytocin / Placebo
(n=3)
Placebo / Oxytocin
(n=5) p*
Gender 5 boys, 3 girls 2 boys, 1 girl 3 boys, 2 girls
Genetic subtype (DEL/mUPD) 4 / 4 2 / 1 2 / 3
Age (yrs) 12.5 (11.6 to 13.7) 12.3 (11.8 to 13.0) 12.6 (11.9 to 13.7) 0.393
Height for age (SDS) 1.2 (0.6 to 1.6) 1.6 (1.1 to 1.8) 1.0 (0.2 to 1.6) 0.571
Weight for height (SDS) 2.2 (0.6 to 4.3) 2.3 (0.4 to 4.6) 2.0 (0.8 to 4.3) 1.000
BMI for age (SDS) 2.8 (0.9 to 5.6) 3.2 (1.3 to 5.5) 2.5 (1.2 to 5.4) 1.000
Age at start GH treatment (yrs) 2.7 (1.8 to 4.3) 2.2 (1.6 to 2.9) 2.9 (2.1 to 4.9) 0.393
Duration of GH treatment (yrs) 9.5 (8.5 to 11.1) 9.9 (9.5 to 10.6) 8.5 (8.2 to 11.0) 0.393
GH dosage (mg/m2/day) 1.0 (0.7 to 1.0) 0.9 (0.8 to 1.0) 1.0 (0.7 to 1.0) 0.786
Prepubertal/pubertal 2 / 6 1 / 2 1 / 4
*p-value at baseline between the two treatment schedules. Data expressed as median with interquartile range.
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of them also left 88 grams during placebo. During the standardized breakfast meal, the 
rate and duration of eating was similar during oxytocin and placebo treatment (23.8 vs 
22.9 gram/minute, p=0.887 and 10.5 vs 11.6 minutes, p=0.102)(Table 2).
The difference in weight, BMI and fat percentage between start and end (∆) of the 
4 weeks of oxytocin treatment were similar as during placebo (p=0.055, p=0.149 and 
p=0.136, resp.).
Subanalyses in the older children
Effects on social behaviour
We did not find beneficial effects of oxytocin in the 8 children older than 11 years (Table 
2). The items happiness, anger and sadness were negatively influenced by oxytocin 
treatment compared to placebo (p=0.039, p=0.042 and p=0.042, resp.). The Oxytocin 
Study Questionnaire showed an unfavourable score of +1.5 (0.3-5) points during 
oxytocin treatment compared to placebo (p=0.027). Three (37.5%) parents reported a 
deterioration of social behaviour during oxytocin treatment, while four (50%) parents 
reported an improvement during placebo treatment (p=0.038).
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figure 1. Effect of 4 weeks oxytocin versus placebo treatment on 6 items of social behaviour in children 
with PWS younger than 11 years of age. Individual differences between oxytocin and placebo treatment 
are presented as a black dot and the black horizontal lines display the median difference. In case of a sig-
nificant difference between the oxytocin and placebo phase, p-values are given.
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Effects on eating behaviour
During oxytocin treatment, food-related behaviour, food-seeking behaviour and satiety 
remained similar (p=0.066, p=0.102 and p=0.317, resp.) in the children older than 11 
years. In both treatment phases, all children finished their standardized breakfast meal, 
while the rate and duration of eating was similar during oxytocin and placebo treat-
ment (23.8 vs 24.5 gram/minute, p=0.779 and 12.0 vs 11.6 minutes, p=0.889)(Table 2). 
∆weight, ∆BMI and ∆fat percentage were similar in the two phases (all p>0.092).
associations
There were no significant differences in oxytocin versus placebo effects between boys 
and girls, between children with a deletion or mUPD, or between children with or with-
out serious behavioural problems. The effects of oxytocin treatment were not associated 
with baseline BMI or BMI SDS. In the total group, the association between age and social 
and eating behaviour during oxytocin treatment was stronger than the association 
between pubertal stage and these outcomes (ρ=-0.553, p=0.004 and ρ=-0.485, p=0.014 
versus ρ=-0.452, p=0.023 and ρ=-0.396, p=0.050, resp.).
oxytocin levels in blood
Serum oxytocin levels before and during study were determined to further unravel the 
different effects in younger and older children (Figure 2). At baseline, children younger 
than 11 years had a median fasting oxytocin level of 3156 (1864-5325) pg/ml, and 12-14 
hours after the last oxytocin dose after 4 weeks of treatment it was 4685 (2809-9490) pg/
ml (p=0.134). Children older than 11 years had a baseline fasting oxytocin level of 2692 
(1737-3754) pg/ml, and 4750 (1976-7831) pg/ml after oxytocin treatment (p=0.327).
In the younger children, lower oxytocin levels after 4 weeks of oxytocin treatment 
were associated with positive effects on social behaviour (ρ=-0.540, p=0.027). This as-
sociation was not found in older children. Baseline oxytocin levels or change in oxytocin 
levels during treatment were not associated with positive effects.
Only one patient older than 11 years had benefit from oxytocin treatment. Remark-
ably, this patient had the highest baseline oxytocin level of patients older than 11 years, 
which decreased considerably to the lowest level of 1126 pg/ml during oxytocin treat-
ment (Figure 2). The other older patients without benefit had lower baseline oxytocin 
levels (Figure 2), which increased or only slightly decreased during oxytocin treatment.
dosing
The oxytocin/placebo dose was based on body surface (see Methods). In the total group, 
median dose was 16IU (12-20) twice daily, which was 12.3 (12.0-13.3) IU/m2 and 0.39 
(0.34-0.44) per kilogram body weight (IU/kg). Given the different effects of oxytocin in 
the younger and older group of patients, the correlation between dosage and age was 
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investigated. The dose in IU/m2 did not correlate with age, but the given dose recal-
culated as IU/kg correlated inversely with age (ρ=-0.663, p<0.001), meaning that older 
patients received a lower dose when recalculated in IU/kg (Figure 3). The median dose 
was 0.42 (0.37-0.45) IU/kg in the children younger than 11 years and 0.34 (0.30-0.37) IU/
kg in the older children (p=0.002). Remarkably, the only patient older than 11 years who 
had benefi t from oxytocin treatment, had one of the lowest recalculated doses in IU/kg 
of the older patients and the lowest dose in IU/kg of all patients with benefi cial eff ects 
of oxytocin.
Safety parameters
The intranasal administration of oxytocin was very well tolerated and there were no side 
eff ects. Renal function, hepatic enzymes, thyroid function and glucose remained stable 
and normal for all patients, as did the systolic blood pressure. Diastolic blood pressure 
was lower during oxytocin treatment (median 64 vs 73 mmHg, p=0.008), but within 
normal limits. Similar results were found in patients younger and older than 11 years.
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figure 2. Fasting serum oxytocin levels at baseline in pg/ml per age. ● represents a patient with positive 
eff ect of oxytocin treatment. ○ represents a patient without eff ect of oxytocin treatment. x represents a 
patient with negative eff ect of oxytocin treatment. The grey line indicates the age of 11 years.
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diScuSSioN
Our randomized, double-blind, placebo-controlled, cross-over study is the first oxytocin 
study in children with PWS aged between 6 and 14 years. Although there were no effects 
in the group as a whole, subanalyses demonstrated that children with PWS between 
6 and 11 years had beneficial effects of intranasal oxytocin administration on social 
behaviour and hyperphagia. Their parents reported significantly less anger, sadness, 
conflicts and food-related behaviour, and improvement of social behaviour during 
oxytocin treatment compared with placebo. In children with PWS older than 11 years 
the beneficial effects of oxytocin on social behaviour and hyperphagia were not found. 
We did not find side effects or adverse events.
Until now, there have been no effective treatment options for behaviour and food-
related problems in PWS. Our study suggests that intranasal oxytocin administration is 
a novel and promising treatment for young children with PWS. Children with PWS have 
a specific behavioural phenotype with stubbornness, temper tantrums, manipulative 
and controlling behaviour, obsessive-compulsive features and difficulties in changing 
routines1-3. The social behavioural problems and hyperphagia seriously affect the quality 
of life of the children and their parents and care-takers.
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figure 3. Dose of oxytocin recalculated as IU/kg versus effect of oxytocin on social and/or eating behaviour. 
∆ represents a patient younger than 11 years. ▲ represents a patient older than 11 years.
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Nowadays, most parents of children with PWS have made all kind of adjustments in 
everyday life to limit access to food, such as locks on the fridge24. This explains why, prior 
to the study, children had a low prevalence of food-seeking behaviour. It is, therefore, not 
surprising that we found no effects of oxytocin on food-seeking behaviour. However, the 
baseline food-related behaviour scores show that these children are still preoccupied 
with food, characterized by talking about food, asking for food, playing that they are 
cooking, etc., despite all the adjustments to control hyperphagia. Oxytocin treatment 
decreased this food-related behaviour, which argues that oxytocin has an inhibiting 
effect on the hyperphagia, despite the lack of effects on food-seeking behaviour and sa-
tiety. Studies on the long-term effects of 4 weeks treatment and also long-term oxytocin 
treatment trials are warranted to confirm our findings on efficacy and safety.
 In contrast to the beneficial effects of oxytocin in the younger children, no positive 
effects were found in children with PWS older than 11 years. Some parents of the older 
subgroup even reported negative effects of oxytocin on social behaviour, especially 
regarding happiness, anger and sadness, in contrast to none of the parents of younger 
children. These findings are in line with the results of an 8-week oxytocin trial in 22 indi-
viduals with PWS between 12 and 29 years20, in which no benefits in target behaviours or 
weight were found. The only significant difference found in that study was an increase in 
temper outbursts when the oxytocin dose was increased. Tauber et al. reported positive 
effects of oxytocin on social behaviour in adults with PWS, but comparison is difficult 
because they investigated a single dose of intranasal administration19.
We measured plasma oxytocin levels prior and during the oxytocin trial. At baseline, 
oxytocin levels in children with PWS younger than 11 years showed high inter-individual 
variability, in line with findings in children with PWS of similar age by Johnson et al.7, and 
there was no relation between baseline oxytocin levels and positive effects during treat-
ment. In contrast, a lower oxytocin level after 4 weeks of oxytocin treatment was associ-
ated with stronger positive effects on social behaviour, suggesting that it is beneficial for 
young children to have a lower plasma oxytocin level during oxytocin treatment. Those 
older than 11 years had, however, lower and less widespread baseline oxytocin levels 
and their levels increased during oxytocin treatment. The only older boy with beneficial 
effects of oxytocin treatment, had a declining oxytocin level during treatment, like most 
of the younger children.
Why did the oxytocin treatment work in the younger, but not in the older children? 
One explanation could be that mistakes had been made in the preparation or delivery 
of the intranasal sprays in the older children. For that reason, an independent laboratory 
measured the content of the vials and was able to reject that explanation. Second, it 
could be that the sample size of the older subgroup was too small to show significant 
changes, but that argument is unlikely as several significant negative effects of oxytocin 
administration were found in the older subgroup. Third, there could have been a dosing 
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issue. We calculated the oxytocin doses according to body surface, a common way of 
hormone dosing in children, which resulted in a relatively lower dose in IU/kg in children 
older than 11 years. However, an inappropriately low dose is also an unlikely explanation, 
as the only older boy with positive effects of oxytocin had the second lowest dose of all 
children in IU/kg. Besides, Einfeld et al. reported adverse effects of higher oxytocin doses 
in older patients20. A fourth explanation could be that the behaviour and coping style of 
older patients with PWS are more embedded in their personality and are therefore not 
easy to change. A treatment period of 4 weeks is not short, but it could be that a longer 
period than 4 or 8 weeks of oxytocin treatment might be needed to induce beneficial 
effects in older children.
Another, more pathophysiological explanation might be that older children with PWS 
have developed an unresponsive oxytocin system over the years, with a lower number 
of oxytocin receptors and neurons in the hypothalamus. Adults with PWS have a 42% 
decrease in oxytocin neurons in the hypothalamus and relatively low plasma levels 
of oxytocin in relation to their obesity5, 6. One of the non-expressed genes in the PWS 
region on chromosome 15 is MAGEL2. This gene is known to be expressed in mouse 
hypothalamus during development and their knock-out alters the number and/or 
function of oxytocin neurons25. MAGEL2-knockout pups were not hypotonic, but had an 
altered onset of suckling activity resulting in impaired feeding and 50% mortality4, while 
the survivors had deficits in social recognition and social interaction on the long-term26. 
These suckling problems in infancy and social problems later on are similar to children 
with PWS, suggesting that this gene might play a role in the suckling and behavioural 
problems in PWS. Adult MAGEL2-knockout mice expressed a significantly reduced num-
ber of oxytocin receptors in several regions of the brain26. Children with PWS, who are 
MAGEL2 deficient, could therefore be less or nonresponsive to oxytocin treatment when 
they become older, because their oxytocin system deteriorated over time. In contrast, 
it was shown that daily administration of oxytocin in the first postnatal week prevents 
the deficits in social behaviour in the adult mutant mice and partly restores a normal 
oxytocin system in the brain. This suggests that the postnatal period is a critical period 
for the oxytocin system in which social behaviour is programmed. Nevertheless, our 
study shows that oxytocin treatment has beneficial effects in children with PWS until 
the age of approximately 11 years, thus also beyond the postnatal period.
It is remarkable that the changeover in oxytocin effects occurred around the age of 
11 years, the time of puberty onset. We previously demonstrated that GH-treated chil-
dren with PWS have a normal age at onset of puberty, but that the majority shows a 
deterioration in pubertal development after Tanner stage 2-3 with a decline in gonadal 
function in boys27-29. It might be that the reactivation of the GnRH-axis just before the 
onset of puberty together with the lack of expression of MAGEL2 and other yet unknown 
genes, not only result in a rapid gonadal failure after the onset of puberty but also in an 
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enhanced deterioration of the oxytocin system in patients with PWS. We acknowledge 
that our supposition is very hypothetical, but we consider it noteworthy to mention that 
these processes seem to occur in the same timeframes. Studies are warranted to further 
unravel the pathophysiology and to determine whether others also find the 11-year cut-
off for benefit of oxytocin treatment.
Present study was a placebo-controlled study in which we calculated the dose ac-
cording to body surface, based on doses used in other trials12, 20. We did not perform a 
dose-finding study and no wash-out period was included to limit the number of hospital 
visits. We found no differences in food intake during the breakfast meal test between 
the oxytocin and placebo phase. This might be due to the lack of a satiety level in PWS 
or that their satiety level was much higher than the maximum amount of food that we 
offered30, but we considered it unethical to present an unlimited amount of food as 
patients with PWS feel never satiated and have an increased risk of gastric rupture.
In conclusion, administration of intranasal oxytocin appears to have beneficial effects 
on social behaviour and food-related behaviour in children with PWS younger than 11 
years of age without side effects or adverse events. Parents reported significantly less an-
ger, sadness, conflicts and food-related behaviour, and improvement of social behaviour 
during oxytocin treatment compared with placebo. In contrast to the younger children 
with PWS, those older than 11 years of age did not benefit from oxytocin treatment.
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abSTracT
context Patients with Prader-Willi syndrome (PWS) are severely at risk to develop 
morbid obesity, diabetes mellitus type 2 and cardiovascular disease, leading to high 
mortality. They have an increased fat mass (FM) and decreased lean body mass (LBM). 
During childhood, growth hormone (GH) treatment counteracts the natural course of 
increasing obesity. Discontinuation of GH treatment at attainment of adult height (AH) 
might deteriorate their improved clinical condition, whereas continuation might benefit 
them.
objective To investigate the effects of GH versus placebo on body composition in 
young adults with PWS who were GH-treated for many years during childhood and had 
attained AH.
design 2-year, randomized, double-blind, placebo-controlled cross-over study with 
stratification for gender and BMI in 27 young adults with PWS.
Setting PWS Reference Center in the Netherlands.
intervention Cross-over intervention with GH (0.67 mg/m2/day) and placebo, both dur-
ing 1 year.
main outcome measures Body composition, measured by DXA.
results During placebo, FM increased (relative change +21.5%, p<0.001). Compared to 
placebo, GH treatment resulted in lower FM (-2.9 kg, p=0.004) and higher LBM (+1.5 
kg, p=0.005), representing relative changes of -17.3% FM and +3.5% LBM. Both FM%limb 
and FM%trunk were lower during GH versus placebo (relative change +17.3% and +15.6%, 
p<0.001 and p=0.007, respectively). No GH-related adverse events occurred.
conclusion GH-treated young adults with PWS who have attained AH benefit from 
continuation of GH treatment. FM increases during placebo, whereas GH versus placebo 
results in lower FM and higher LBM. Thus, GH treatment maintains the improved body 
composition without safety concerns.
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iNTroducTioN
Prader-Willi syndrome (PWS) is the most common genetic cause of life-threatening 
childhood obesity1. Hypothalamic dysfunction appears to be responsible for symptoms 
like severe hyperphagia, endocrine disorders, hypotonia, short stature, hypogonadism 
and an abnormal body composition2. Patients have a high body fat mass percentage 
(FM%) and a low lean body mass (LBM), even in the presence of a normal BMI3-6.
The benefits of recombinant human growth hormone (GH) treatment in children with 
PWS are well established and GH treatment is approved by EMA and FDA. In children 
with PWS, BMI, FM% and LBM improve significantly during the first year of GH treatment 
and persist on the long-term5, 7. In addition, it is reported that GH has positive effects 
on BMD, psychomotor development, cognition, adaptive functioning, linear growth and 
adult height (AH)5, 7-11, indicating that GH treatment is able to counteract the clinical 
course of PWS and has substantially changed the phenotype of children with PWS5, 7.
When young adults with PWS without GH deficiency have attained AH, they have to 
cease GH treatment. We experienced that their body composition deteriorated after dis-
continuation of GH with an increase of FM% and a decrease in LBM. There are, however, 
no studies in PWS about the consequences of discontinuing GH treatment at AH. In ad-
dition, the effects of GH versus placebo on body composition in this new generation of 
PWS patients are also unknown. Studies in older PWS patients who were GH-untreated 
at inclusion, demonstrated that GH treatment decreased FM% and increased LBM12, 13.
Given the well-established beneficial effects of GH on body composition during child-
hood, we hypothesized that placebo would deteriorate the body composition of young 
adults with PWS after attaining AH. Furthermore, we expected that GH versus placebo 
would maintain the improved body composition. We, therefore, investigated the effects 
of GH versus placebo on body composition, measured by DXA, in young adults with 
PWS who had attained AH, in a 2-year, randomized, double-blind, placebo-controlled 
cross-over study.
meTHodS
Subjects
Inclusion criteria were (1) genetically confirmed diagnosis of PWS by a positive methyla-
tion test; (2) GH treatment during childhood for at least 2 years and being on GH at time 
of inclusion; and (3) AH attainment, defined as a height velocity less than 0.5 cm per 
6 months and a complete epiphyseal fusion. Exclusion criteria were (1) medication to 
reduce weight (fat) or (2) non-cooperative behaviour.
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From June 2008 to January 2014, 33 young adults with PWS fulfilled the inclusion 
criteria, but 2 did not want to continue daily injections and 3 refused due to too large 
burden of hospital visits. As low GH doses were not effective in improving body com-
position in children with PWS14, patients were treated with the standard GH dose of 
1.0 mg/m2/day during childhood. GH dose was lowered in eight children, due to high 
serum IGF-I levels. In the present study, adolescent patients were in the transition phase 
and therefore GH dose was considerably lowered to 0.67 mg/m2/day (≈0.023 mg/kg/
day). Other medications were sex steroid replacement therapy in 12 (42.9%) young 
adults, thyroid hormone supplementation in eight (28.6%), modafinil in two (7.1%), and 
risperidone and citalopram in one (3.6%), and doses were not changed during the study. 
All patients were on a strict diet and exercise programs.
design
Two-year, randomized, double-blind, placebo-controlled, cross-over study investigating 
the effects of 1 year placebo versus 1 year GH on body composition. Young adults were 
stratified according to gender and BMI (below/above 25 kg/m2) and then randomly and 
blindly assigned to receive 1 year of subcutaneous injections once daily at bedtime of 
either 0.67 mg/m2/day GH (Genotropin®, 5 mg/ml, Pfizer) or 1 year of identical appearing 
placebo (Pfizer), after which they crossed-over to the alternative treatment for another 
year. An independent statistician generated the random allocation sequence. Investiga-
tors were blinded for the allocation. An independent physician monitored the safety 
during the study. During the entire study period, unblinding was not necessary.
measurements
Patients were assessed every 3 months by the PWS-team of the Dutch Growth Research 
Foundation in collaboration with pediatric endocrinologists and pediatricians. At each 
visit, the injection dose was adjusted to the calculated body surface area. In addition, 
patients visited the Sophia’s Children Hospital at baseline, 6, 12, 18 and 24 months, to 
obtain: fat mass, FM%, LBM, height, weight, blood pressure, fasting blood levels of IGF-I, 
IGFBP-3, glucose and insulin, and (severe) adverse events ((S)AE).
FM and LBM were measured by DXA (Lunar Prodigy; GE Healthcare). All scans were 
made on same machine, with daily quality assurance. The intra-assay coefficients of 
variation were 0.41-0.88% for fat tissue and 1.57-4.49% for LBM15. LBM was calculated 
as fat-free mass minus bone mineral content. FM was also expressed as percentage of 
total body weight (FM%). FM% SDS and LBM SDS were calculated according to age- and 
sex-matched Dutch reference values16.
Standing height was measured with a calibrated Harpenden stadiometer, weight was 
determined on a calibrated scale (ServoBalance KA-20-150S) and BMI was calculated. 
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Height, weight and BMI were expressed as SDS, adjusted for age and sex17, 18. SDS values 
were calculated with GrowthAnalyser 4.0.
After this 2-year study, GH treatment was discontinued for at least 6 weeks and fasting 
GH-stimulation test with bolus infusion of GHRH (1 µg/kg) and infusion of arginine (0.5 
mg/kg) during 30 minutes was performed. The cut-off for GH deficiency19 was 11.5 µg/l 
for BMI <25 kg/m2, 8.0 µg/l for BMI 25-30 kg/m2, and 4.2 µg/l for BMI >30 kg/m2.
assays
Blood samples were collected after an overnight fast and measured in one laboratory. 
Glucose and insulin were immediately assayed20. IGF-I was measured using an immu-
nometric technique on Immulite 1000 (LKGF1, Siemens Medical Solutions Diagnostics) 
with an interassay variation <7.3%, and IGFBP-3 by a specific RIA with an interassay 
variation <7.5%21. Levels of IGF-I and IGFBP-3 were expressed as SDS, adjusting for age 
and gender21.
Statistics
Statistical analysis was performed with SPSS 23.0. Calculation of sample size indicated 
that 20 subjects were required for a power of >90% with a significance level of 0.05. To 
account for attrition, 8 more patients were added. As data were normally distributed, 
parametric tests were used and data expressed as mean (standard deviation (SD)). 
Paired sample t-tests were used for differences over time during placebo. Effects of GH 
versus placebo were calculated using linear mixed model analysis with the outcomes 
measured at the end of the two treatment periods as dependent variable and with an 
unstructured covariance matrix. LBM was not adjusted for body size, as all had attained 
AH. Possible carry-over effects were analyzed by adding the interaction between period 
and treatment, but not found. Relative change during placebo was calculated as (delta 
during placebo)/(value at start of placebo). Relative change of GH versus placebo was 
calculated by (value after GH minus value after placebo)/(value after GH).
In addition to the 2-year cross-over data analysis, FM% SDS16, LBM SDS16, trunk and 
limb FM%, and GH dose during 4 years prior to attainment of AH were analyzed using 
mixed model analysis.
Study approval
Written informed consent was obtained from patients and parents. The study protocol 
was approved by the Medical Ethics Committee of Erasmus University Medical Center, 
Rotterdam, and registered at Dutch Trial Register (www.trialregister.nl NTR1038).
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baseline characteristics
Twenty-eight subjects were included, but one 16.7-year old participant (BMI 25.0 kg/m2) 
died due to gastric rupture 3 months after start while receiving placebo. Her data were 
not significantly different from the other patients and were excluded from analysis.
Mean age of the 27 young adults with PWS (8 boys, 19 girls) who completed all visits 
was 17.2 (1.8) years and BMI +0.9 (1.3) SDS (Table 1). At baseline (AH), FM% was sig-
nificantly higher (1.9 SDS, p<0.001) and LBM significantly lower (-2.1 SDS, p<0.001) than 
average for age- and sexmatched controls, but similar in both treatment regimens (all 
p>0.487). During childhood, GH treatment was started at a mean age of 8.5 (3.5) years 
and continued for 8.7 (3.2) years until AH.
efficacy
Placebo
Figure 1 shows body composition during the 2-year cross-over study. During placebo, 
mean FM increased significantly (+4.1 kg, p<0.001), while LBM tended to decrease (-0.9 kg, 
p=0.069)(Table 2). This represents a relative change in FM of +21.5% and in LBM of -2.0%.
Table 1. Baseline characteristics of total group and per treatment schedule
PWS
(n=27)
Placebo / GH
(n=14)*
GH / Placebo
(n=13)*
Boys / girls (n) 8/19 4/10 4/9
Genetic subtype
Deletion 9 2 7
mUPD 15 10 5
ICD / translocation 3 2 1
Age (yrs) 17.2 (1.8) 17.2 (2.2) 17.3 (1.2)
Height for age (SDS) -1.3 (0.9) -1.3 (0.9) -1.2 (0.9)
Adult height (SDS) -1.6 (1.0) -1.7 (1.1) -1.5 (0.9)
BMI for age (SDS) 0.9 (1.3) 1.0 (1.2) 0.7 (1.3)
BMI for age PWS (SDS) -1.4 (1.2) -1.2 (1.2) -1.5 (1.2)
Age at start GH treatment (yrs) 8.5 (3.5) 8.2 (3.8) 8.9 (3.2)
Duration of GH treatment (yrs) 8.7 (3.2) 8.9 (3.8) 8.4 (2.5)
IGF-I (SDS) 2.2 (1.0) 1.8 (1.2) 2.5 (0.8)
FM% 38.0 (10.9) 39.4 (10.9) 36.4 (11.0)
FM (kg) 25.2 (10.0) 26.3 (10.3) 24.0 (9.9)
Lean (kg) 37.5 (7.8) 37.1 (8.3) 37.9 (7.6)
Data expressed as mean with (SD). *no significant differences between the two treatment schedules, all p-values 
above 0.128. GH: growth hormone, FM%: fat mass percentage, FM: fat mass.
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figure 1a-f. Changes in body composition, GH dose and IGF-I SDS over time, presented as Means with 
95%CI of 27 adolescents with PWS during the 2 years of this cross-over study (in dark and light grey). Lon-
gitudinal changes in Estimated Marginal Means with 95%CI in body composition and GH dose during the 
4 years prior to attainment of AH (in white). FM% SDS, LBM SDS and IGF-I SDS were calculated according to 
age- and sex-matched Dutch references16, 21. Dotted lines to the white symbols represent the course during 
placebo.
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GH versus placebo
Table 2 shows the effects of GH versus placebo on body composition. Compared with 
placebo, GH treatment resulted in a lower mean FM (-2.9 kg, p=0.004) and higher LBM 
(+1.5 kg, p=0.005), representing a relative change of -17.3% FM and +3.5% LBM.
Effects GH versus placebo on limb and trunk FM%
During placebo, limb and trunk FM% increased (relative change +17.3% and +15.6%, 
both p<0.001), while limb LBM decreased (-3.0%, p=0.004). Compared to placebo, GH 
treatment decreased FM% of limbs and trunk with respectively -4.7% and -3.3% (p<0.001 
and p=0.007, relative change -17.1% and -13.1%), and increased LBM of limbs with +0.8 
kg (p<0.001, relative change +4.7%)(Table 2).
GH-dose effect
As GH effects might be dose-dependent14, we investigated GH dose and serum IGF-I 
levels. The mean administered GH dose prior to present study was 0.88 (0.25) mg/m2/
day. In the 2-year cross-over study, GH dose was lower with 0.67 mg/m2/day (p<0.001). 
Concurrent with the GH-dose reduction, IGF-I SDS decreased from 2.2 (1.0) SDS at base-
line (AH) to 1.7 (1.2) during the GH year, although this was not significant (p=0.124). FM% 
increased in the group where the GH dose was lowered from 0.88 at baseline to 0.67 mg/
m2/day in the first year, while LBM remained stable (p=0.018 and p=0.122, resp.).
GH deficiency
After the 2-year study, twenty-four (88.9%) young adults underwent an arginine-GHRH 
test. Only 3 (12.5%) had a GH peak below the BMI-dependent cut-off19. There was no 
significant influence of the GH peak on the effects of GH versus placebo treatment on 
FM%, FM or LBM (p=0.649, p=0.170 and p=0.093).
Other
There was no difference in effect of GH versus placebo on FM, LBM or BMI between boys 
and girls, or between those whether or not receiving sex steroid replacement therapy.
Safety
Safety parameters
GH treatment was very well tolerated. Compared to placebo, GH treatment resulted in a 
higher mean fasting glucose and insulin (+0.2 mmol/l, p=0.012, +18.4 pmol/l, p=0.037, 
resp.)(Table 3), but both remained below the upper limit in both phases. None of the 
patients developed T2DM. IGF-I and IGFBP-3 SDS were significantly lower during pla-
cebo than during GH (both p<0.001). Systolic and diastolic blood pressure were similar 
in both treatment phases.
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Adverse events
No (S)AEs considered to be GH-related were observed. During GH, no SAEs and 7 AEs 
occurred, all viral respiratory tract infections. During placebo, there were 2 SAEs and 
12 AEs. First, a 16-year old female died 3 months after start of placebo due to gastric 
rupture with hemodynamic failure. Second, a 19-year old male with mUPD had a recur-
rence of psychosis after 6 months of placebo. He was treated with valproic acid in a 
psychiatric institution, whereupon he recovered. In both cases, unblinding was consid-
ered unnecessary, and after the study it appeared that both received placebo during the 
event. The 12 AEs during placebo were 1 patellar luxation, 1 knee rotation and 10 viral 
respiratory tract infections. In both phases, there were no cases of edema, arthralgia or 
carpal tunnel syndrome.
diScuSSioN
This is the first randomized, double-blind, placebo-controlled cross-over GH study in 
young adults with PWS who were treated with GH during childhood and had attained 
AH. We demonstrate that the improved body composition which was attained during 
childhood deteriorates during placebo, with an increase in FM and BMI. Compared to 
placebo, GH treatment resulted in a lower FM and BMI, and higher LBM. We did not find 
GH-related adverse events. Thus, discontinuation of GH deteriorates body composition, 
while GH maintains the improved FM and LBM without adverse events.
Long-term GH treatment during childhood counteracts the clinical course of increas-
ing obesity in PWS, with FM in the upper normal range and LBM in the lower normal 
range5, 7. Our study is the first placebo-controlled GH trial in young adults with PWS 
who had to cease GH because of attaining AH. In line with our expectations, we found 
a deterioration of FM during placebo. A study in 11 older GH-naïve adults with PWS 
showed that the improved body composition during 1-year GH treatment declined to 
pre-treatment levels after GH-withdrawal in the second year22. Another study in 14 ado-
lescents with PWS who were GH-treated for 4 years demonstrated a significant increase 
of BMI SDS in the 2 years after cessation of GH23. These results concur with our findings 
that continuation of GH after attainment of AH benefits young adults with PWS, even in 
those without GH deficiency.
During placebo, mean FM rose impressively with a relative increase of 21.5% in 1 year. 
As FM references for the natural course of untreated PWS patients do not exist, BMI was 
used to compare. BMI of adolescent girls and boys with PWS aged 15-20 years increases 
with respectively +0.8 and +1.2 kg/m2 per year24. Thus, the mean BMI-rise of +1.4 kg/
m2 during 1 year placebo aligns this natural development of increasing obesity in PWS.
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Our trial shows that GH versus placebo results in a lower FM and BMI, and higher LBM. 
In the general population, less FM and lower BMI decrease the high risk of metabolic 
syndrome, T2DM and cardiovascular diseases25, 26. Not only total FM, but also the location 
of fat accumulation is important as more abdominal adipose tissue is associated with an 
unfavourable metabolic profile27. GH versus placebo reduced not only limb FM%, but 
also trunk FM%, emphasizing the importance of GH treatment for adults with PWS, as its 
continuation during adulthood might reduce the risk of future comorbidity.
It was demonstrated that children with PWS require high-normal to high serum IGF-I 
levels to maintain an improved body composition5, 14. However, we considered the ap-
proved GH dose for children with PWS of 1.0 mg/m2/day too high for young adults dur-
ing the transition phase and we therefore treated all patients with 0.67 mg/m2/day. This 
GH-dose seems correct for the young adults during transition phase, as the majority had 
high-normal IGF-I levels without side effects. In the present study, we did neither titrate 
the GH dose on serum IGF-I levels nor on body composition. Further research is required 
to find the optimal GH dosing for young adults with PWS. Serum IGF-I levels seem inap-
propriate for titrating the GH dose in PWS, as they have a disrupted correlation between 
serum IGF-I levels and IGF-bioactivity, although this disruption is more pronounced in 
younger children than in the older ones28.
Our other safety findings demonstrate that GH treatment induced only slightly higher 
fasting glucose and insulin levels compared to placebo, but both levels remained within 
normal ranges and no patients developed T2DM, in contrast to the high prevalence 
described29. GH versus placebo had no adverse effects on blood pressure. The two SAEs 
occurred during placebo, while none were reported during GH treatment. These findings 
indicate that GH during 1 year is not only an effective, but also a safe and well-tolerated 
treatment, although more research regarding the long-term effects, optimal dosing and 
clinical significance is required.
Our inclusion time was quite long, but PWS is a rare disorder and patients had to be 
GH-treated for at least 2 years. More female than male patients were included, probably 
due to the fact that the girls attained AH at a younger age. The ethical dilemma of 1 year 
placebo injections in mentally disabled young adults was extensively discussed with 
patients’ caregivers. The high clinical relevance ensured them to vote for the strongest 
design, being a 2-year cross-over study allowing a smaller sample size.
Should GH treatment be continued when a young adult with PWS has attained adult 
height? The findings of our study suggest that the answer to the question is YES. The 
deterioration of body composition during placebo can be prevented by GH treatment.
In conclusion, this cross-over trial in young adults with PWS who were treated with 
GH during childhood shows that placebo treatment after AH deteriorates the improved 
body composition with an increase of FM. Compared to placebo, GH treatment results 
in a lower FM and higher LBM. This indicates that discontinuing GH treatment at AH 
GH versus placebo in young adults with PWS: Effects on body composition 109
5
leads to deteriorated body composition, while GH maintains the improved FM and LBM 
without safety concerns.
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abSTracT
context Patients with Prader-Willi syndrome (PWS) have an increased fat mass and 
decreased lean body mass. GH-treated young adults with PWS who have attained adult 
height benefit from continuation of growth hormone (GH) treatment, as GH maintained 
their improved body composition, whereas fat mass increased during the placebo 
period. Adults with PWS are predisposed to develop diabetes mellitus type 2 and car-
diovascular disease. Whether GH affects metabolic health profile of this patient group 
is unknown.
objective To investigate the effects of GH versus placebo on metabolic health, in young 
adults with PWS who were GH-treated for many years during childhood and had at-
tained adult height (AH).
method 2-year, randomized, double-blind, placebo-controlled cross-over study with 
stratification for gender and BMI in 27 young adults with PWS. Intervention with GH 
(0.67 mg/m2/day) and placebo, both during 1 year.
results Compared to placebo, GH treatment resulted in similar glucose and insulin levels 
during oral glucose tolerance test. Only fasting glucose and insulin were slightly higher 
during GH versus placebo (+0.2 mmol/l and +18.4 pmol/l), although both remained 
within normal ranges in both phases. Blood pressure and lipid profile were similar 
after GH versus placebo. At baseline (AH) and during GH, no patients had metabolic 
syndrome, while 1 developed it during placebo.
conclusion GH treatment has no adverse effects on metabolic health profile. Thus, GH-
treated young adults with PWS who have attained AH benefit from continuation of GH 
treatment without safety concerns regarding metabolic health.
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iNTroducTioN
Prader-Willi syndrome (PWS) is a neurogenetic disorder caused by the lack of expression 
of paternally expressed genes located on the PWS region of chromosome 151, 2, with 
clinical findings that change over age. Infancy is characterized by muscular hypotonia 
and failure to thrive, while obesity, hyperphagia, psychomotor delay and behavioural 
problems are prominent during childhood and adulthood3, 4. The body composition of 
patients with PWS is abnormal with increased fat mass (FM) and decreased lean body 
mass (LBM), even if there is no obesity2, 4-8.
In children with PWS, the benefits of growth hormone (GH) treatment are well estab-
lished without adverse effects on glucose parameters, lipid profile and blood pressure5. 
GH improves body composition, bone mineral density, psychomotor development, 
cognition, adaptive functioning, linear growth and adult height (AH)5, 9-12 and has sub-
stantially changed the phenotype of children with PWS. Currently, when young adults 
with PWS without GH deficiency have attained AH, they have to cease GH treatment. 
We recently demonstrated an impressive increase in FM during the placebo period in 
GH-treated young adults with PWS who have attained AH, while continuation of GH 
maintains the improved body composition, indicating that they benefit from continua-
tion of GH treatment13.
Adults with PWS are predisposed to develop diabetes mellitus type 2 (T2DM) due 
to their abnormal body composition14, and cardiovascular disease (CVD) as risk factors 
for CVD such as hypertension and hyperlipidemia occur more often in PWS15. GH has 
diabetogenic effects, but there are no studies about the metabolic effects of GH versus 
placebo in young adults with PWS who were treated with GH during childhood and had 
attained AH. Studies in older PWS-patients who were GH-untreated at inclusion, found 
no major side-effects of GH on metabolic health profile16, 17.
As there were no negative effects of GH on the metabolic health profile in GH-treated 
children and GH-untreated adults with PWS, we hypothesized that GH versus placebo 
would result in a similar or even more favourable metabolic profile after attainment 
of AH. We, therefore, investigated the effects of GH versus placebo on the metabolic 
health profile in young adults with PWS after attainment of AH, in a 2-year, randomized, 
double-blind cross-over study.
SubjecTS aNd meTHodS
Subjects
Inclusion criteria were (1) genetically confirmed diagnosis of PWS by a positive methyla-
tion test; (2) GH treatment during childhood for at least 2 years and being on GH at time 
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of inclusion; and (3) AH attainment, defined as a height velocity less than 0.5 cm per 
6 months and a complete epiphyseal fusion. Exclusion criteria were (1) medication to 
reduce weight (fat) or (2) non-cooperative behaviour.
From June 2008 to January 2014, 33 young adults with PWS aged 14.1-20.2 years 
fulfilled the inclusion criteria, but 2 did not want to continue daily injections and 3 
refused to participate due to too large burden of hospital visits. Twenty-eight subjects 
were included, but one 16.7-year old participant (BMI 25.0 kg/m2) died due to gastric 
rupture 3 months after start while receiving placebo. Her baseline characteristics were 
not significantly different from the other patients and were excluded from analysis.
GH treatment was prescribed during childhood at an initial dose of 1 mg/m2/day and 
dose was lowered in 8 children due to high serum IGF-I levels. In the present study, 
GH dose was 0.67 mg/m2/day (≈0.023 mg/kg/day), which was considerably lower than 
during childhood. The most important other medications were sex steroid replacement 
therapy in 12 (44.4%) young adults, thyroid hormone supplementation in 8 (29.6%), 
modafinil in 2 (7.4%) and risperidone and citalopram in 1 (3.7%) adolescent, and doses 
were not changed during the study. All patients were on a strict diet and exercise pro-
grams.
design
Two-year, randomized, double-blind, placebo-controlled, cross-over study investigating 
the effects of 1 year placebo versus 1 year GH on metabolic health profile. Young adults 
were stratified according to gender and BMI (below/above 25 kg/m2) and then randomly 
and blindly assigned to receive 1 year of subcutaneous injections once daily at bedtime 
of either 0.67 mg/m2/day GH (Genotropin®, 5 mg/ml, Pfizer) or 1 year of identical appear-
ing placebo (placebo, Pfizer), after which they crossed-over to the alternative treatment 
for another year. According to the FDA, a wash-out period should be at least 3 times 
the half life time of a drug. As the half life time of GH is only 2-3 hours and the study 
duration per phase was 1 year, no wash-out period was implemented. An independent 
statistician generated the random allocation sequence. Investigators were blinded for 
the allocation. An independent physician monitored the safety during the study. During 
the entire study period, unblinding was not necessary.
measurements
Patients were assessed every 3 months by the PWS team of the Dutch Growth Research 
Foundation in collaboration with pediatric endocrinologists and pediatricians. At each 
visit, the injection dose was adjusted to the calculated body surface area. In addition, 
patients visited the Sophia’s Children Hospital at baseline, 6, 12, 18 and 24 months, to 
obtain: height, weight, waist circumference (WC), blood pressure, fasting blood levels 
of glucose and insulin, total cholesterol (TC), low-density lipoprotein cholesterol (LDLc) 
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and high-density lipoprotein cholesterol (HDLc), triglyceride (TG), IGF-I and IGFBP-3. 
In addition, a standard 75-g oral glucose tolerance test (OGTT) according to the World 
Health Organization was performed. To evaluate the overall responses to the oral glu-
cose load, apart from the plasma levels at various time points, the 120-min area under 
the curve (AUC) for time-concentration for glucose and insulin was calculated using the 
trapezoidal rule. The insulin/glucose ratio at 0, 30 and 120 minutes was calculated as an 
index of relative insulin resistance. Impaired glucose tolerance (IGT) was defined as a 
fasting glucose level <6.1 mmol/l, and glucose between 7.8 and 11.1 mmol/l (140-200 
mg/dl) 120 minutes after glucose load 18.
Standing height was measured with a calibrated Harpenden stadiometer, weight was 
determined on a calibrated scale (ServoBalance KA-20-150S) and BMI was calculated. 
Height, weight and BMI were expressed as SDS, adjusted for age and sex19, 20. SDS val-
ues were calculated with GrowthAnalyser 4.0 (www.growthanalyser.org). Systolic and 
diastolic blood pressure (BP) were measured using an appropriately sized cuff while 
patients were in sitting position. As height is an important determinant of BP, BP was 
expressed as SDS, adjusted for height and sex21. Fat mass percentage (FM) was measured 
by DXA13.
assays
Blood samples were collected after an overnight fast and measured in one laboratory: 
glucose, insulin, IGF-I, IGFBP-3, TC, HDLc and TG. LDLc was calculated using the Friede-
wald formula: LDLc (mmol/l) = TC–HDLc–0.45*TG22. Blood samples during the OGTT for 
glucose and insulin determination were obtained after 30, 60, 90 and 120 minutes after 
ingestion and immediately assayed23. Levels of IGF-I and IGFBP-3 were measured and ex-
pressed as SDS, adjusting for age and gender13, 24. Lipids were determined as described25.
metabolic syndrome
Revised criteria of the National Cholesterol Education Program (NCEP; Adult Treatment 
Panel III) were used to determine components of metabolic syndrome26. Metabolic 
syndrome was defined as having 3 or more of the following risk factors: 1) Abdominal 
obesity: waist circumference in men greater than 102 cm, and in women greater than 88 
cm; 2) TG above 1.7 mmol/l; 3) HDLc in men below 1.03, in women below 1.3 mmol/l; 4) 
BP ≥130/≥85 mm Hg; 5) Fasting glucose above 5.6 mmol/l.
Statistics
Statistical analysis was performed with SPSS version 23.0. Calculation of sample size 
indicated that 20 subjects would be sufficient for detection at a power of >90% with a 
significance level of 0.05. To account for attrition, 8 more patients were added. As data 
were normally distributed, parametric tests were used and data expressed as mean 
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(standard deviation (SD)). Effects of GH versus placebo were calculated using linear 
mixed model analysis with the outcomes measured at the end of the two treatment 
periods as dependent variable and with an unstructured covariance matrix. Possible 
carry-over effects were analyzed by adding the interaction between period and treat-
ment, but not found. In addition to the 2-year results, we also presented systolic and 
diastolic BP SDS and lipid levels during the 4 years prior to attainment of adult height, 
as significant changes in the years prior to the study might influence the interpretation. 
Linear mixed model analysis was used.
Study approval
Written informed consent was obtained from the patients and their caregivers. The 
study protocol was approved by the Medical Ethics Committee of the Erasmus Univer-
sity Medical Center, Rotterdam, and registered at Dutch Trial Register (www.trialregister.
nl NTR1038).
reSulTS
baseline characteristics
Table 1 shows the clinical characteristics of 27 young adults (8 boys, 19 girls) with PWS 
at adult height (AH). Their mean age was 17.2 (1.8) years and BMI +0.9 (1.3) SDS. Nine 
Table 1. Baseline characteristics of total group and per treatment schedule
PWS
(n=27)
GH / Placebo
(n=13)
Placebo / GH
(n=14) p*
Boys / girls (n) 8/19 4/9 4/10
Genetic subtype
Deletion 9 7 2
mUPD 15 5 10
ICD / translocation 3 1 2
Age (yrs) 17.2 (1.8) 17.3 (1.2) 17.2 (2.2) 0.877
Height for age (SDS) -1.3 (0.9) -1.2 (0.9) -1.3 (0.9) 0.695
Adult height (SDS) -1.6 (1.0) -1.5 (0.9) -1.7 (1.1) 0.660
Weight for height (SDS) 0.6 (1.3) 0.5 (1.4) 0.8 (1.2) 0.563
BMI for age (SDS) 0.9 (1.3) 0.7 (1.3) 1.0 (1.2) 0.527
BMI for age PWS (SDS) -1.4 (1.2) -1.5 (1.2) -1.2 (1.2) 0.506
Fat mass percentage (%) 38.0 (10.9) 36.4 (11.0) 39.4 (10.9) 0.487
Age at start GH treatment (yrs) 8.5 (3.5) 8.9 (3.2) 8.2 (3.8) 0.646
Duration of GH treatment (yrs) 8.7 (3.2) 8.4 (2.5) 8.9 (3.8) 0.679
Data expressed as mean with (SD). *p-value at baseline between the two treatment schedules.
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(33.3%) patients had a deletion, 15 (55.6%) an mUPD, 2 (7.4%) an ICD and 1 (3.7%) a 
translocation. During childhood, GH treatment was started at a mean age of 8.5 (3.5) 
years and continued for 8.7 (3.2) years until AH. Boys had a mean AH of 174.1 (3.0) cm, 
being -1.4 (0.4) SDS and girls reached 159.9 (7.3) cm, being -1.7 (1.1) SDS. Both treatment 
regimens had similar baseline characteristics.
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figure 1. Mean glucose and insulin levels during OGTT after long-term GH treatment during childhood at 
baseline (AH) (black circles), after 1 year of GH treatment (grey circles), and after 1 year of placebo (white 
triangles) of 27 young adults with PWS. #GH vs placebo p-value <0.05, ¤Baseline vs placebo p-value <0.05, 
other not significantly different.
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metabolic Health Profile
Carbohydrate metabolism
Figure 1 and Table 2 show glucose and insulin levels during OGTT after long-term GH 
treatment during childhood, at baseline of the present study at adult height (AH), after 
1 year of GH and after 1 year of placebo. At baseline, fasting glucose was in none of the 
patients above 5.6 mmol/l, while IGT, defined as a glucose between 7.8 and 11.1 mmol/l 
at 120 minutes after glucose load, was present in 4 patients and none had T2DM.
Compared to placebo, GH treatment resulted in similar glucose and insulin levels at 
30, 60, 90 and 120 minutes after glucose load (Figure 1). Only fasting glucose and insulin 
levels were higher after GH treatment versus placebo, although both remained within 
the normal ranges in both phases (glucose 4.7 versus 4.5 mmol/l, p=0.012, and insulin 
65.8 versus 47.4 pmol/l, p=0.037, resp.)(Table 2). All other carbohydrate parameters 
were similar after GH versus placebo. Mean glucose at 120 minutes after glucose intake 
was similar (GH vs placebo 6.0 versus 6.1 mmol/l, p=0.998). The 120-min area under the 
curves (AUC) for glucose and insulin during OGTT were not significantly different after 
both treatment phases (p=0.343 and p=0.457, resp.), and the insulin/glucose ratios at 
30 and 120 minutes were similar after GH and placebo. IGT was present in 2 patients 
after 1 year of GH and in 2 other patients after 1 year of placebo. None of the patients 
developed T2DM.
Blood pressure
Figure 2 shows systolic and diastolic BP during the 2-year cross-over study. At baseline, 
mean systolic and diastolic BP were significantly higher than height- and sexmatched 
controls (0.5 and 0.7 SDS, p=0.016 and p<0.001, resp.)(Table 2), but there were only 2 
patients with a systolic BP above +2 SDS (both +2.2 SDS).
Compared to placebo, GH treatment resulted in a similar systolic and diastolic BP 
(p=0.547 and p=0.779). Four young adults had a systolic BP above +2 SDS after 1 year of 
GH, while 2 of them and 1 other had an elevated systolic BP after 1 year of placebo. Two 
young adults had a diastolic BP above +2 SDS after both GH and placebo, and 1 only 
after 1 year of placebo.
Serum lipid levels
Figure 3 shows fasting serum lipid levels during the 2-year cross-over study. At baseline, 
all mean lipid levels were within the normal range (Table 2). Levels above the normal 
range of TC and LDLc were found in respectively 2 and 1 patients, while 1 patient had a 
HDLc below the normal range.
Compared to placebo, GH treatment resulted in similar levels of TC, LDLc, HDLc and 
TG (p>0.415). One young adult had a TC above the upper limit of 5.5 mmol/l after 1 year 
of GH, while another had an elevated TC after 1 year of placebo. LDLc and TG were not 
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elevated after 1 year of GH treatment, while after 1 year of placebo, 1 patient had an 
LDLc higher than the upper limit of 3.8 mmol/l, and this and another patient had TG level 
higher than 1.6 mmol/l. HDLc was in none below the lower limit of 0.9 mmol/l.
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figure 2a-c. Changes in systolic (fig 2a) and diastolic blood pressure (fig 2b), and total cholesterol, LDLc 
and HDLc (fig 2c) presented as Means with 95%CI of 27 adolescents with PWS during the 2 years of this 
cross-over study (in dark and light grey). Longitudinal changes in Estimated Marginal Means with 95%CI 
during the 4 years prior to attainment of AH (in white). BP SDS was calculated according to height- and 
sex-matched references 21. Normal ranges for lipids are shown on the right side of figure 2c. Black lines with 
black symbols represent the course during GH treatment and dotted lines with white symbols represent 
the course during placebo.
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Metabolic syndrome
Table 3 shows the different components of the metabolic syndrome (MS). At baseline 
(AH), none of the patients had MS according to the revised NCEP criteria26.
After 1 year of GH treatment, 12 components of MS were present; 4 patients had 
central obesity, 3 low HDLc levels and 5 a high BP, while none had high TG levels or high 
fasting glucose. After 1 year of placebo, there were 17 components of MS; 5 had central 
obesity, 1 high TG levels, 6 low HDLc levels, 4 high BP and 1 a high fasting glucose.
Compared to placebo, GH treatment did not result in MS. During the two years of 
study, one girl (3.7%) developed MS. She had no MS-symptoms after 1 year of GH, but 
after the subsequent year with placebo 3 symptoms were present.
diScuSSioN
To our knowledge, this is the first two-year, randomized, double-blind, placebo-
controlled study in young adults with PWS who were treated with GH during childhood 
until AH, which investigates the effects of GH versus placebo on metabolic health. Our 
findings demonstrate that the glucose-stimulated glucose and insulin levels during 
OGTT were similar during GH treatment versus placebo. Compared to placebo, GH 
treatment did not affect other carbohydrate parameters as AUC of glucose and insulin, 
and insulin/glucose ratios. Fasting glucose and insulin levels were slightly higher during 
GH versus placebo, but remained within the normal ranges during both phases and 
none developed T2DM. The prevalence of IGT and MS were similar after GH treatment 
and placebo, and BP and lipid profiles were not significantly different after GH versus 
placebo. This indicates that GH versus placebo does not affect carbohydrate parameters 
excepted a slightly higher fasting glucose and insulin, and that GH versus placebo does 
not disturb components of metabolic health profile.
Table 3. Metabolic syndrome components during the study according to ATP III criteria26
Symptoms
Stage of the study
Baseline During 1 year GH During 1 year placebo
Central Obesity 2/27 (7.4%) 4/27 (14.8%) 5/27 (18.5%)
High TG levels None None 1/27 (3.7%)
Low HDLc levels 6/27 (22.2%) 3/27 (11.1%) 6/27 (22.2%)
High BP 3/27 (11.1%) 5/27 (18.5%) 4/27 (14.8%)
High fasting glucose None None 1/27 (3.7%)
More than 3 symptoms None None 1/27 (3.7%)
Number of patients (%) with MS-symptoms. No significant difference between GH and placebo year.
GH: growth hormone, TG: triglyceride, BP: blood pressure.
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Compared to placebo, GH treatment did not affect glucose-stimulated glucose and 
insulin levels, AUC for glucose and insulin and insulin/glucose ratios. These results of 
the OGTT are reassuring and demonstrate that glucose and insulin homeostasis reacts 
properly without developing glucose intolerance during GH versus placebo. The minor 
increase in fasting insulin with minimal influences on glucose metabolism is a well-
known and physiological phenomenon during GH treatment5, 27. Our finding that GH 
treatment has only minimal effects without being pathologic concur with the conclusion 
of Höybye et al. that GH treatment did not elicit pronounced adverse effect on glucose 
and insulin homeostasis in older previously GH-untreated adults with PWS16.
Lipid levels remained similar during GH versus placebo, while studies in other patient 
groups such as GHD or obesity found beneficial effects of GH treatment on lipid pro-
files28, 29. Our findings might be the result of the already quite favourable lipid profile of 
patients with PWS and the fact that hypercholesterolemia does not seem to be frequent, 
probably due to the smaller amount of visceral fat30. Findings in older adults with PWS 
who were GH-untreated at inclusion were in line with our results27, although Sode-
Carlsen et al. reported a small reduction in only LDLc during GH compared to placebo17. 
Their patients were, however, GH-untreated and heavier at baseline, while our patients 
received already 8 years of GH treatment before they participated in the present study, 
and this might have influenced the findings.
In our cohort with patients who were GH-treated during childhood for many years, 
none had MS at attainment of AH and none developed MS during GH after AH, while 
one developed MS during placebo. In obese adults with PWS a presence of MS of 41.4% 
was found, while it was with 4.7% much lower in the non-obese PWS subjects31. The 
authors concluded that obesity status plays a main role in metabolic health. Elaborating 
on this, it might be that the role of body composition, and subsequently GH treatment, 
is even larger. Continuation of GH prevents deterioration of body composition13, and 
thus favorably affects metabolic health.
Patients with PWS have a relatively high insulin sensitivity with high adiponectin 
levels, which are thought to be protective with regard to T2DM and CVD30, 32-34. Besides 
the favourable effects of GH on adiponectin33, it is even more important that continu-
ation of GH treatment at AH prevents the deterioration of body composition in young 
adults with PWS. During placebo, FM rose dramatically with a relative increase of 21.5% 
in only 1 year, while GH treatment maintained the improved body composition with less 
FM and more LBM13. Thus, when GH treatment stops, the natural course of increasing 
obesity in PWS is not counteracted anymore. As LBM is the primary tissue of insulin-
stimulated glucose uptake, disposal and storage35, and obesity and FM are associated 
with MS, T2DM and CVD36, it is likely that the deterioration of the body composition due 
to discontinuation of GH will impair the glucose and insulin homeostasis over time. This 
argues that discontinuation of GH at AH might result in a worse metabolic health profile 
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on the long-term in young adults with PWS, and that the benefits of GH far outweigh the 
minimal effects on glucose and insulin homeostasis.
The percentage of patients with an mUPD was higher than previously described37, 
but nowadays an mUPD is more often found, probably related to the increasing mater-
nal age at conception in Western countries. Not only being diagnosed with PWS, but 
also other aspects such as obesity, advanced age, positive family history and low LBM 
are risk factors for metabolic health. By choosing a cross-over design, inter-individual 
risk factors were eliminated and this strong design allowed a smaller sample size as PWS 
is a rare disorder. Ongoing monitoring of young adults with PWS receiving GH treatment 
is highly recommended as they are at risk to develop T2DM and CVD, although our study 
demonstrates reassuring findings. Additional studies are needed to confirm this on the 
longer term, as patients are still young and received only 1 year of GH treatment.
In conclusion, this cross-over study demonstrates that 1 year of GH treatment has 
no adverse effects on glucose homeostasis, with similar glucose-stimulated glucose 
and insulin levels during OGTT, AUC of glucose and insulin, and insulin/glucose ratios 
during GH treatment and placebo. Fasting glucose and insulin levels remained within 
the normal ranges and were only slightly higher during GH treatment versus placebo. 
Blood pressure and lipid profile remained similar in both phases. None of the patients 
developed MS during GH treatment, while 1 developed MS during placebo. Thus, GH-
treated young adults with PWS who have attained AH benefit from continuation of GH 
treatment without safety concerns regarding their metabolic health profile.
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abSTracT
background Patients with Prader-Willi syndrome (PWS) have a cognitive impairment. 
Growth hormone (GH) treatment during childhood improves cognitive functioning, 
while cognition deteriorates in GH-untreated children with PWS. Cessation of GH treat-
ment at attainment of adult height (AH) might deteriorate their GH-induced improved 
cognition, while continuation might benefit them. We, therefore, investigated the ef-
fects of placebo versus GH administration on cognition in young adults with PWS who 
were GH-treated for many years during childhood and had attained AH.
method Two-year, randomized, double-blind, placebo-controlled cross-over study in 25 
young adults with PWS. Cross-over intervention with placebo and GH (0.67 mg/m2/day), 
both during 1 year.
results Total (TIQ), verbal (VIQ) and performance IQ (PIQ) did not deteriorate during 1 
year of placebo, compared to GH treatment (p>0.322). Young adults with a lower TIQ 
had significantly more loss of TIQ points during placebo versus GH, in particular VIQ 
decreased more in those with a lower VIQ. The effect of placebo versus GH on TIQ, VIQ 
and PIQ was not different for gender or genotype.
conclusions Compared to GH treatment, 1 year of placebo did not deteriorate cogni-
tive functioning of GH-treated young adults with PWS who have attained AH. However, 
patients with a lower cognitive functioning had more loss in IQ points during placebo 
versus GH treatment. Our findings are reassuring, but do, however, not exclude that 
cessation of GH treatment for many years could result in a gradual deterioration of 
cognitive functioning on the long term.
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iNTroducTioN
Prader-Willi syndrome (PWS) is a neurogenetic disorder resulting from the lack of expres-
sion of the PWS region on the paternally derived chromosome 15, caused by paternal 
deletion, maternal uniparental disomy (mUPD), imprinting center defect (ICD) or bal-
anced translocation1. PWS is characterized by a number of symptoms, such as muscular 
hypotonia, short stature, abnormal body composition with high fat mass and low lean 
body mass, severe hyperphagia, behavioural problems and cognitive impairment1-4.
MRI studies in PWS suggested that lower cortical complexity partially underlies cogni-
tive impairment and developmental delay5, with structural brain abnormalities and dif-
ferent neurodevelopmental patterns between children with a deletion and an mUPD6. 
Certain cognitive skills improved significantly during GH treatment, while GH-untreated 
children with PWS showed a deterioration of cognitive functioning7, 8. Children with an 
mUPD started off with lower visuospatial skills, but showed a significant improvement 
during 4 years of growth hormone (GH), resulting into a similar cognitive functioning in 
all genotypes7.
GH treatment has also positive effects on body composition, BMD, psychomotor 
development, adaptive functioning, linear growth and adult height (AH)4, 7-11. As a result, 
GH treatment has substantially changed the phenotype of children with PWS4, 11, but 
when they attain AH, they have to stop GH treatment because most do not fulfill the 
criteria of adult GH deficiency. There are no studies about cognition after stop of GH 
treatment in this new generation of PWS patients. In untreated adults with PWS, lower 
IGF-I levels were correlated with poorer intellectual skills12, which might suggest that 
discontinuation of GH treatment, which decreases IGF-I, could be disadvantageous.
Given the positive effects of GH and IGF-I levels on cognition in children with PWS, we 
hypothesized that the cognition in young adults with PWS would deteriorate after ces-
sation of GH treatment compared to the continuation of GH administration. We, there-
fore, investigated the effects of placebo versus GH on cognition in young adults with 
PWS who had attained AH, in a 2-year, randomized, double-blind, placebo-controlled 
cross-over study.
meTHodS
Subjects
Inclusion criteria of the present study were (1) genetically confirmed diagnosis of PWS; 
(2) GH treatment during childhood for at least 2 years and being on GH at time of inclu-
sion; and (3) AH attainment, defined as a height velocity less than 0.5 cm per 6 months 
and complete epiphyseal fusion. Exclusion criteria were (1) use of medication to reduce 
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weight; (2) non-cooperative behaviour; or (3) inability to perform cognitive tests. Due 
to the last exclusion criterion, 2 patients could not participate; 1 due to poor cognitive 
skills and a severe hearing impairment, and with an IQ of 58 who refused to speak in the 
hospital. From June 2008 to January 2014, 33 young adults fulfilled the inclusion criteria. 
Two did not want to continue GH-injections and 3 parents refused participation due to 
too large burden of hospital visits. Twenty-eight young adults (8 boys, 20 girls) with PWS 
aged 14.1-20.2 years were included in the GH/placebo study. One participant died due 
to gastric rupture 3 months after start while receiving placebo. Twenty-five young adults 
completed the present study.
During childhood, the standard GH dose was 1 mg/m2/day. In the present study dur-
ing transition from childhood into adulthood, GH dose was set lower at 0.67 mg/m2/day 
(≈0.023 mg/kg/day). Twelve (48%) young adults used sex steroid replacement therapy, 
7 (28%) thyroid hormone supplementation, 2 (8%) modafinil and 1 (4%) risperidone and 
citalopram. All patients were on a strict diet and an exercise program.
design
Two-year, randomized, double-blind, placebo-controlled, cross-over study investigating 
the effects of 1 year placebo versus 1 year GH on cognitive functioning. The duration 
per phase was 1 year in order to prevent retesting phenomenon. A clinically relevant 
deterioration of cognitive functioning was defined as a decrease of 5 IQ points, taking 
into account the significant improvement of IQ during 4 years GH treatment in children 
with PWS7. Young adults were stratified according to gender and BMI (below/above 25 
kg/m2) and then randomly and blindly assigned to receive 1 year of subcutaneous injec-
tions once daily at bedtime of either 0.67 mg/m2/day GH (Genotropin®, 5 mg/ml, Pfizer) 
or 1 year of identical appearing placebo (placebo, Pfizer), after which they crossed-over 
to the alternative treatment for another year. An independent statistician generated the 
random allocation sequence. Investigators were blinded for the allocation. An indepen-
dent physician monitored the safety during the study. During the entire study period, 
unblinding was not necessary.
measurements
Patients were three-monthly seen by the PWS-team of the Dutch Growth Research 
Foundation in collaboration with pediatric endocrinologists and pediatricians. At each 
visit, the injection dose was adjusted to the calculated body surface area. In addition, 
patients visited the Sophia’s Children Hospital every 6 months and at baseline, 12 and 
24 months the following data were obtained: cognitive functioning, anthropometric 
measurements, fasting blood levels of IGF-I, and (S)AE.
All cognitive measurements were performed by a psychologist experienced in testing 
young adults with PWS. The 11 recommended subscales of Wechsler Adult Intelligence 
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Scale 3rd Edition (WAIS-III) were used to assess total IQ (TIQ) in patients over 16 years of 
age13. Verbal IQ (VIQ) subtests were Vocabulary, Similarities, Arithmetic, Digit Span, In-
formation and Comprehension. Performance IQ (PIQ) subtests were Picture Completion, 
Coding, Block design, Matrix Reasoning and Picture Arrangement. The 10 recommended 
subscales of Wechsler Intelligence Scale for Children 3rd Edition (WISC-III) were used to 
assess TIQ in 4 patients younger than 16 years14. VIQ subtests were Information, Similari-
ties, Arithmetic, Vocabulary and Comprehension. PIQ subtests were Picture Completion, 
Coding, Picture Arrangement, Block Design and Visual Puzzles. It was reported that WISC 
IQ and WAIS IQ are comparable in 16 year old young adults15. In both tests, scores on all 
subtests were expressed as standard deviation scores, based on Dutch population data 
for the same age13, 14. Standard subtest scores ranged from 1 (-3 SDS) to 19 (+3 SDS), with 
a mean of 10 (0 SDS).
Standing height was measured with a calibrated Harpenden stadiometer, weight was 
determined on a calibrated scale (ServoBalance KA-20-150S) and BMI was calculated. 
Height, weight and BMI were expressed as SDS, adjusted for age and sex16, 17. SDS values 
were calculated with GrowthAnalyser 4.0.
assays
Blood samples were collected after an overnight fast and measured in one laboratory. 
Serum levels of IGF-I were measured and expressed as SDS, adjusting for age and gen-
der18, 19.
Statistics
Statistical analysis was performed with SPSS version 23.0. Calculation of sample size 
indicated that 22 subjects were required for a power of >80% with a significance level 
of 0.05. As data were not normally distributed, nonparametric tests were used and data 
expressed as median (interquartile range (IQR)), unless otherwise described. Statistical 
analysis appropriate for cross-over trials were used, taking into account any carry-over 
or treatment-period effect, calculated by Wilcoxon Signed Rank test and Mann Whitney 
U tests, but these were not found. Correlations between effect of GH treatment and 
other parameters were assessed using Spearman’s rho. Differences were considered 
significant if p-value was <0.05.
Study approval
Written informed consent was obtained from patients and parents. The study protocol 
was approved by the Medical Ethics Committee of Erasmus University Medical Center, 
Rotterdam, and registered at Dutch Trial Register (www.trialregister.nl NTR1038).
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reSulTS
baseline characteristics
Median age of the 25 young adults with PWS (7 boys, 18 girls) with cognitive functioning 
tests was 17.8 (15.7 to 18.5) years and BMI was +1.1 (-0.8 to +1.7) SDS (Table 1). Nine 
(36%) patients had a deletion, 13 (52%) an mUPD, 2 (8%) an ICD and 1 (4%) a transloca-
tion. At baseline (AH), both treatment arms had similar characteristics.
cognitive functioning at aH
During childhood, GH treatment was started at a median (IQR) age of 8.8 (6.3 to 10.1) 
years and patients were treated for 8.6 (7.0 to 10.5) years until AH. Median total IQ (TIQ) 
at AH was 62 (56 to 73) points, with a non-significantly higher verbal IQ (VIQ) of 65 (57 to 
72) points than performance IQ (PIQ) of 60 (54 to 72) points (p=0.157)(Table 1).
Placebo
TIQ, VIQ and PIQ had not changed after 1 year of placebo (p=0.422, p=0.220 and p=0.488)
(Figure 1). The young adults had similar scores on the 11 subtests before and after 1 year 
of placebo (Table 2).
Table 1. Baseline characteristics of total group and per treatment schedule
PWS (n=25) Placebo / GH (n=12) GH / Placebo (n=13) p*
Boys / girls (n) 7/18 3/9 4/9
Genetic subtype
Deletion 9 2 7
mUPD 13 8 5
ICD / translocation 3 2 1
Age (yrs) 17.8 (15.7 to 18.5) 17.2 (14.9 to 19.4) 17.8 (16.9 to 18.0) 0.852
Adult height (SDS) -1.7 (-2.2 to -1.0) -1.7 (-2.4 to -1.1) -1.8 (-2.0 to -0.9) 0.852
BMI for age (SDS) 1.1 (-0.8 to 1.7) 1.3 (-0.4 to 1.7) 1.1 (-0.8 to 2.0) 0.936
BMI for age PWS (SDS) -1.1 (-2.2 to -0.6) -1.2 (-2.2 to -0.6) -1.1 (-2.3 to -0.5) 0.689
Age at start GH treatment (yrs) 8.8 (6.3 to 10.1) 8.1 (5.8 to 9.8) 8.8 (6.9 to 11.2) 0.376
Duration of GH treatment (yrs) 8.6 (7.0 to 10.5) 8.7 (7.2 to 11.4) 8.3 (6.5 to 10.5) 0.650
IGF-I (SDS) 2.1 (1.7 to 3.0) 1.7 (1.1 to 3.0) 2.2 (2.0 to 3.0) 0.051
FM% 38.6 (32.3 to 44.9) 39.0 (32.4 to 45.6) 37.3 (30.5 to 44.9) 0.810
Lean body mass (kg) 36.5 (30.6 to 41.5) 35.0 (29.6 to 43.9) 37.0 (33.2 to 40.2) 0.611
Total IQ 62 (56 to 73) 60 (54 to 63) 67 (57 to 78) 0.095
Verbal IQ 65 (57 to 72) 66 (60 to 72) 65 (55 to 74) 0.713
Performance IQ 60 (54 to 72) 59 (54 to 67) 66 (52 to 74) 0.635
Data expressed as median with (IQR). *p-value at baseline between the two treatment schedules.
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associations during placebo
After 1 year of placebo, young adults scored lowest on subtest Coding (-2.7 SDS) and 
highest on the subtests Similarities, Information and Picture Arrangement (median score 
-1.7 SDS). After 1 year of placebo, there was no difference in TIQ, VIQ or PIQ between 
boys and girls (p>0.166) or between patients with a deletion and mUPD+ICD (p>0.138). 
The IGF-I SDS during placebo was not associated with TIQ, VIQ or PIQ (p>0.602).
Placebo versus GH administration
Table 2 and Figure 1 show the effects of 1 year of placebo versus 1 year of GH administra-
tion on cognition. Compared with GH treatment, placebo did not deteriorate TIQ, VIQ 
or PIQ (p>0.322). The difference between placebo and GH administration was strongest 
in the subtest Block Design, as patients scored 0.3 SDS worse during placebo (median 
score placebo -2.0 SDS, GH administration -1.66 SDS, p=0.075), but the difference did 
not reach significance. The young adults had similar scores on the other 10 different 
subtests during placebo and GH administration (all p>0.123).
The effect of placebo versus GH administration on TIQ, VIQ or PIQ was neither differ-
ent between boys and girls (p>0.418), nor between young adults with a deletion versus 
mUPD+ICD (p>0.138). Young adults with a lower TIQ had more loss in TIQ points during 
placebo versus GH (ρ=-0.407, p=0.043), in particular those with a lower VIQ had more 
decrease in VIQ points during placebo (ρ=-0.467, p=0.021).
Limited cognitive functioning is commonly defined as an IQ score below 70 points20. 
Seven (28%) young adults had a VIQ and 9 (36%) a PIQ higher than 70 points, during 
both placebo and GH treatment.
associations with GH peak during stimulation test
After the 2-year study, twenty-three young adults underwent an arginine-GHRH test. 
Only 3 (13%) had a GH peak below the BMI-dependent cut-off21. There was no significant 
influence of the GH peak on the effects of placebo versus GH administration on TIQ, VIQ 
or PIQ (p>0.604).
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figure 1. Cognitive functioning at baseline, after 1 
year of GH treatment and after 1 year of placebo.
Total, performance and verbal IQ at baseline (in 
light grey), after 1 year of placebo (in white) and 
after 1 year of GH treatment (in dark grey). Boxes 
represent 1st and 3rd quartile, with median in the 
middle. Whiskers indicate range. There are no sig-
nificant differences.
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diScuSSioN
This is the first two-year, randomized, double-blind, placebo-controlled GH study in 
young adults with PWS who were treated with GH during childhood until AH, investi-
gating the effects of cessation of GH (placebo) versus GH administration on cognitive 
functioning. Our data show that, compared to GH administration, one year of placebo 
did not deteriorate TIQ, VIQ or PIQ in the total group of young adults with PWS. However, 
patients with a lower cognitive functioning had more loss in IQ points during placebo 
versus GH treatment.
In this study, we investigated whether the GH-induced improvement in cognitive 
functioning during childhood would be lost during one year of placebo. Our results are 
reassuring, as there was no significant deterioration in TIQ, VIQ or PIQ after 1 year of pla-
cebo in young adults with PWS. If IQ had deteriorated after cessation of GH treatment, 
this would have suggested that sustained activation with GH was required to retain the 
improved cognitive functioning achieved during childhood. We found, however, that IQ 
remained similar after 1 year of placebo, which might indicate that GH treatment during 
childhood has long-lasting effects. To our knowledge, there are no studies investigating 
the effects of cessation of GH treatment on cognition after AH attainment.
The scores of the subtest Block Design, however, tended to deteriorate after 1 year 
of placebo compared to GH treatment, but the decrease of 0.3 SDS was not significant. 
An RCT in children with PWS showed that 2 years of GH treatment did not significantly 
improve Block Design scores compared to baseline. Only after 4 years of GH treatment, 
Block Design scores had increased approximately 0.3 SDS, which was significantly 
higher than at baseline7. Thus, our finding that TIQ did not change during 1 year of pla-
cebo compared to GH treatment, while Block Design scores tended to deteriorate, does 
not exclude that stop of GH treatment for many years could result in a deterioration of 
cognitive functioning on the long term. It might be that 1 year of placebo is too short to 
show a significant decrease in cognitive functioning.
There are no other studies on cognitive functioning in young adults with PWS who 
received long-term GH during childhood. Only one study investigated the effects of GH 
treatment versus placebo on cognitive functioning in adults with PWS, but these PWS 
adults were older and GH-untreated at inclusion. They demonstrated that the subtest 
Block Design and Coding improved during GH treatment and benefits were more pro-
nounced in patients who were GH-treated for the longest time22. In untreated adults 
with PWS, lower IGF-I levels were correlated with poorer intellectual skills12, which is in 
line with the beneficial effects of GH treatment, which increases IGF-I.
In contrast to our current findings of unaltered cognitive functioning after 1 year of 
placebo versus GH administration, we found an impressive deterioration of the body 
composition within this period19. This might suggest that the beneficial effects on cogni-
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tion of GH treatment during childhood last into adulthood. The exact mechanism how 
GH exerts its beneficial effects on cognitive functioning is unknown. It has been sug-
gested that GH may directly affect its GH receptors which are widespread throughout 
the brain, or through release of IGF-I. The neurotrophic effects of GH continue during 
adulthood, and it has been proposed that the age-related decline in GH secretion is 
involved in the decreased neurogenesis in healthy elderly23. Amongst them, those 
with higher IGF-I levels have better cognitive functioning and lower rates of cognitive 
decline24, 25. Besides, an RCT showed that GHRH administration in healthy elderly and in 
adults with a mild cognitive impairment had favourable effects on cognition26. Like in 
other syndromes, ageing in PWS might occur prematurely, and lower GH levels might be 
involved in this, but data are very limited27, 28. In other syndromes, like Down syndrome, 
age-related diseases as dementia with loss of function in multiple cognitive domains 
are more prevalent and occur earlier29. A deterioration in cognitive functioning over 
time is also seen in patients with Alzheimer’s disease, and GH administration reduced 
learning and memory deficits in animals with this disease23. In adults with GH deficiency, 
GH administration improved long-term and working memory functions30, 31. Altogether, 
these results support the hypothesis that the GH-IGF-I axis is involved in cognitive func-
tioning32. How GH treatment achieves its beneficial effects needs to be elucidated, but 
it suggests that GH might have neuroprotective effects. Thus, continuation of GH treat-
ment might also benefit adults with PWS, while it cannot be excluded that cessation of 
GH impairs cognitive functioning on the long term.
Although there was no deterioration in TIQ, VIQ or PIQ during 1 year of placebo, we 
found that young adults with a lower cognitive functioning lost more IQ points during 
placebo versus GH treatment, indicating more benefit from GH treatment. This is in line 
with our previous finding that GH treatment was more beneficial for children with PWS 
with lower cognitive functioning7. In elderly and in patients with GH deficiency or Al-
zheimer, there was a positive correlation between IGF-I levels and cognitive functioning, 
while this was not found in a healthy adult group. The authors postulate that IGF-I levels 
are not involved in cognition in case of relatively good cognitive performance33. This is 
in line with our findings and suggests that patients with poor cognitive skills are more 
vulnerable for loss of function. The mechanism is, however, not clear.
Young adults with PWS in our study showed a moderate cognitive impairment, with 
median IQ scores being about 5 to 10 points higher than documented by other stud-
ies, who reported IQ scores between 50-60 or around 52 points in adults with PWS22, 34. 
These patients had not received GH treatment during childhood34. An explanation for 
the higher IQ scores in our groups might be that all our participants were treated with 
GH treatment for many years during their childhood, which is a crucial period for matu-
ration of the brain. GH treatment during childhood prevents deterioration of cognitive 
skills and improves cognition on the longer term7.
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Besides the higher IQ scores than reported in the literature, we also found a very wide 
variation in IQ scores. One patient had a PIQ of 100 during GH and subsequently 92 
during placebo, which is exceptionally high for an individual with PWS. Furthermore, 
the 3rd quartile of TIQ, PIQ and VIQ was higher than the cut-off for intellectual disabil-
ity20, meaning that more than 25% of the young adults had an IQ above 70 points. On 
the other hand, there was a patient who was not able to participate in this part of the 
study, as she had poor cognitive skills in addition to her hearing impairment. Previously 
reported percentages of poor cognitive skills in individuals with PWS were around 14%, 
while this was present in only 1 of 27 patients in our group34, 35.
Cognition after stop of GH treatment and the effects of placebo versus GH administra-
tion on cognition were not different between patients with a deletion and those with an 
mUPD or ICD. It has been described that patients with an mUPD have better verbal skills 
than those with a deletion7, 35. These patients were, however, not treated with GH. During 
4 years of GH treatment, children with an mUPD showed a larger improvement than 
children with a deletion, resulting in a similar Block Design score as those with a deletion 
after 4 years of GH treatment7. We now found no difference in cognition between those 
with a deletion versus mUPD+ICD, which suggests that long-term GH treatment during 
childhood improved cognitive functioning, particularly of those with mUPD+ICD.
The ethical dilemma of 1 year placebo injections in mentally disabled young adults 
was extensively discussed with patients’ caregivers. The high clinical relevance ensured 
them to vote for the strongest design, being a 2-year cross-over study. It might be that 
1 year placebo was too short to demonstrate alteration in cognitive functioning and 
that no GH treatment will lead to a deterioration on the longer term. It was, however, 
considered unethical to extend the placebo period beyond 1 year given the convincing 
positive effects of GH on body composition. It might be that the effect of GH versus 
placebo on cognitive skills would have reached significance if we could have studied a 
larger group. This was, however, not feasible as PWS is a rare disorder.
In conclusion, this cross-over trial in young adults with PWS who were treated for 
many years with GH during childhood shows that compared to GH treatment, 1 year 
of placebo did not deteriorate cognitive functioning. However, patients with a lower 
cognitive functioning had more loss in IQ points during placebo versus GH treatment. 
Our findings are reassuring, but do, however, not exclude that cessation of GH treatment 
for many years could result in a gradual deterioration of cognitive functioning on the 
long term.
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GeNeral diScuSSioN
Almost fifteen years ago, in April 2002, the Dutch GH RCT was initiated by the Dutch 
Growth Research Foundation to investigate the effects of GH treatment in children with 
PWS. Over time, it grew into the Dutch PWS Reference Center providing high-quality 
care, performing scientific research and sharing knowledge. Nowadays almost all Dutch 
infants with PWS are included in the PWS Cohort, receiving care by the PWS-team in 
close collaboration with pediatric-endocrinologists in The Netherlands.
GH treatment proved to have many beneficial effects in children with PWS and 
considerably changed their phenotype. The extreme classic hyperphagia appears to 
be less pronounced in this new generation of patients, but the persisting hyperphagia 
and clear preoccupation with food remains a large burden for these families. As the 
appetite-regulating hormone ghrelin might be involved, we investigated ghrelin in fast-
ing state and after glucose intake. We also investigated the effects of oxytocin treatment 
on hyperphagia and social behaviour in children with PWS. In young adults with PWS 
who were GH-treated during childhood and had attained adult height, we studied the 
effects of (placebo) versus GH treatment on body composition, metabolic health profile 
and cognition. In this chapter, our results are discussed, also in view of literature data. 
Subsequently, clinical implications of our results are presented and recommendations 
for future research are provided.
8.1 GHreliN
In PWS, clinical features change during the different life stages and one of the most 
striking symptoms is the abnormal eating behaviour. The first period after birth is char-
acterized by feeding problems and failure to thrive, while excessive weight gain and 
hyperphagia with impaired satiety are prominent during childhood and adulthood1. 
Studies reported high serum levels of the appetite-regulating hormone ghrelin, but in-
vestigators did not distinguish between acylated (AG) and unacylated ghrelin (UAG), did 
not describe AG/UAG ratios and did not use an inhibitor to prevent deacylation of AG 
into UAG2-7. In the study described in Chapter 2, we evaluated the fasting AG and UAG 
levels, and AG/UAG ratios in patients with PWS in comparison with obese and healthy 
controls and investigated their associations with eating behaviour.
We showed that AG levels were significantly higher in PWS patients than in healthy 
controls. In contrast to our expectations, however, UAG levels in PWS were similar to 
those in healthy controls. This resulted in a significantly higher AG/UAG ratio in PWS 
than in healthy controls. Obese controls had significantly lower AG and UAG levels than 
PWS patients, but also a high AG/UAG ratio.Based on the higher BMI in PWS patients 
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than in healthy controls, one could expect similar levels in PWS as in obese subjects, but 
our data indicate that the abnormalities of the ghrelin system are specific for PWS.
Hypothalamic dysfunction is assumed to be the underlying cause of various signs and 
symptoms of PWS, such as abnormal temperature control, excessive daytime sleepiness, 
hypogonadotropic hypogonadism and hormonal insufficiencies8-11. The physiological 
regulation of some of these hormones is well-known8-11. Regarding appetite regulation, 
the mechanisms are not yet clear and there are still a lot of uncertainties. It seems obvi-
ous that the hypothalamic dysfunction in PWS is responsible for the disturbances in 
the appetite-regulating hormone ghrelin as well as the other hormonal insufficiencies 
in PWS, but as far as we know, this is not yet ascertained. On the other hand, some 
studies demonstrated that ghrelin might influence the hypothalamus12, 13. Intravenous 
administration of ghrelin in healthy males strongly stimulated GH secretion, but also 
ACTH, cortisol and prolactin were mildly elevated12. Combined administration of ghrelin 
and GHRH synergistically increased GH levels13. Besides, ghrelin is mainly produced in 
the stomach and this organ works differently in PWS who are known for their delayed 
gastric emptying, decreased ability to vomit and lack of satiety after a meal14-16. It might 
be that the production of ghrelin in PWS is different, resulting in elevated AG levels 
and AG/UAG ratios. It is unknown whether these high levels could induce desensitiza-
tion resulting in a functional GH deficiency and other hormonal insufficiencies. More 
research on whether hypothalamic dysfunction is either the cause or consequence of 
abnormalities in the appetite regulating hormones can help to contrive a solution. An 
effective treatment would relief parents from the ongoing responsibility to retain food 
from their children, and would reduce the risk for obesity and comorbidities.
We have the clinical impression that GH treatment has an inhibiting effect on food 
intake. About half of young adults showed increasing hyperphagia after stop of GH 
treatment after attainment of adult height. We found, however, no difference in AG/UAG 
ratios between GH-treated patients and untreated patients with PWS and there was no 
significant association between IGF-I levels and AG/UAG ratio. The untreated patients 
were, however, very young (before start of GH) or older (after attainment of adult height) 
and this might have influenced these results.
We also subdivided the patients according to the nutritional phases and found that 
PWS patients in nutritional phase 2a, 2b and 3, thus with weight gain and/or hyper-
phagia, had a higher AG/UAG ratio than those in nutritional phase 1a or 1b, without 
weight gain or hyperphagia. The AG/UAG ratios of the latter were similar to age-matched 
controls1. Furthermore, the AG/UAG ratio changed considerably between phase 1b and 
higher nutritional phases, indicating that the switch in eating behaviour coincides with a 
change in the AG/UAG ratio, supporting the hypothesis that ghrelin might be involved in 
this. It would be valuable to determine longitudinally when the AG/UAG ratio is chang-
ing in parallel with the eating behaviour and which factors are involved. As there are 
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no other scoring systems for the switch in eating behaviour than the nutritional phases 
according to Miller et al.1 we used this one. However, in practice the clinical presentation 
of children with PWS has significantly changed in today’s population. We found a higher 
median age in patients with PWS in nutritional phase 1b than in those in phase 2a. 
Several older patients were still in nutritional phase 1b and have controlled hyperphagia 
without increased weight or food-seeking behaviour, which makes it difficult to catego-
rize these children according to the nutritional phases. The phenotype has changed in 
the last decade, probably due to early diagnosis, improved health care, GH treatment, 
physiotherapy, diet regimen and the awareness of parents to limit the food intake.
In conclusion, our study demonstrates that children and young adults with PWS have higher 
AG levels but similar UAG levels compared to healthy controls, resulting in a significantly 
higher AG/UAG ratio in PWS patients than in healthy controls. Obese controls have signifi-
cantly lower AG and UAG levels than PWS patients, but also a high AG/UAG ratio.
PWS patients without weight gain or hyperphagia had a similar AG/UAG ratio as age-
matched healthy controls, in contrast to those with weight gain and/or hyperphagia who 
had an elevated AG/UAG ratio. The switch to excessive weight gain in PWS seems to coincide 
with an increase in the AG/UAG ratio, even prior to the start of hyperphagia.
8.2 GHreliN afTer GlucoSe iNTake
For a long time it was thought that patients with PWS are continuously hungry due 
to the higher ghrelin levels, but studies demonstrated a non-decelerating eating curve 
with impaired satiety in patients with PWS compared to obese and healthy controls16. In 
healthy individuals, AG and UAG levels are high in fasting state and food intake induces 
a strong decline of these levels17. Intravenous AG administration in healthy subjects 
increased food intake and appetite18. We demonstrated higher fasting AG and AG/UAG 
ratios in patients with PWS than in healthy controls19, which might be involved in their 
hyperphagia. It was unknown why patients with PWS do not feel satiated after a meal, 
but findings suggested that the ghrelin system in PWS was not able to react physiologi-
cally with a decline of ghrelin levels after food intake. In the study described in Chapter 
3, we investigated the response of AG and UAG levels and the AG/UAG ratio to a standard 
oral glucose load in young adults with PWS.
We showed that the ghrelin system in young adults with PWS responded physi-
ologically after glucose intake, even in the presence of high fasting AG/UAG ratios. In 
the first 30 minutes after the glucose load, there was a sharp decline of AG levels and 
to a lesser extent of UAG levels, which resulted in a lower AG/UAG ratio. The magnitude 
of decline of these levels in PWS was similar as described in healthy controls17, 20, 21. Our 
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findings suggest that the impaired satiety is not the result of an abnormal response of 
ghrelin to food intake and that there must be other reasons. Hypothalamic dysfunction 
might play a role, but it could also be that abnormalities in other appetite-regulating 
hormones cause the impaired satiety in patients with PWS. Ghrelin is the only known 
appetite-regulating hormone which is high in the fasting state and decreases after food 
intake, while all other known appetite-regulating hormones are low when an individual 
is hungry and increase after food intake22. If patients with PWS have a lack of increase 
of anorexigenic hormones after food intake, this might result in a decreased satiation as 
well. Oxytocin is one of these hormones and studies demonstrated that it is involved in 
food intake, weight balance and obesity23.
Our findings suggest that GH treatment reduces AG levels, and to a lesser extent UAG 
levels, leading to a lower AG/UAG ratio during GH treatment. One other study demon-
strated that GH treatment in children with PWS seems to decrease high fasting total 
ghrelin levels, whereas they found no effects on AG levels24. These data of AG must be 
interpreted with caution, as no inhibitor was used to prevent the deacylation of AG into 
UAG. No other studies investigated the effects of GH treatment on UAG levels, and AG/
UAG ratio in PWS.
AG has diabetogenic effects, stimulates appetite and induces a positive energy 
balance which might result in weight gain25-28. UAG on the other hand has protective 
effects, seems to improve glycemic control and acts as a functional inhibitor of AG28-30. 
Therefore, the ratio between AG and UAG is crucial and a lower AG/UAG ratio seems to 
be more favourable. We found that GH treatment had a decreasing effect on the AG/UAG 
ratio, which is in line with our impression that GH treatment influences eating behaviour 
in a positive manner (reduction of hyperphagia) and that young adults with PWS benefit 
from continuation of GH treatment after attainment of adult height.
In conclusion, our study demonstrates that the ghrelin system of young adults with PWS 
shows a physiological response with a strong decline of AG and UAG levels after glucose 
intake, even in the presence of very high fasting AG/UAG ratios. This resulted in a lower AG/
UAG ratio after glucose intake. Our findings suggest that the impaired satiety is not the result 
of an abnormal response of the orexigenic ghrelin to food intake.
Continuation of GH treatment after attainment of adult height results in lower AG levels 
during OGTT, suggesting a more favourable metabolic profile.
8.3 oxyTociN TreaTmeNT iN cHildreN WiTH PWS
The quality of life of patients with PWS is hampered by temper tantrums and the preoc-
cupation with food, which makes every day a challenge for patients and their caregivers. 
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Worldwide, there is ongoing research to find a solution for this major problem. There 
is increasing interest in the hormone oxytocin, as it is known to be involved in food 
intake, body weight and social skills23, 31, 32. In patients with PWS, the number of oxytocin-
expressing neurons in the hypothalamus is significantly decreased by 42% and plasma 
levels of oxytocin are lower than in healthy controls8, 33. Thus, it seems that patients with 
PWS have a disturbance in the oxytocin system with an oxytocin deficiency.
Genetic information supports this hypothesis, as mice with a deficiency of one of the 
genes on the PWS region on chromosome 15 have a major reduction of oxytocin secretion 
in the hypothalamus32. These Magel2-deficient mice show an altered onset of suckling 
activity resulting in impaired feeding and 50% mortality after birth32. Human neonates 
with PWS show similar suckling problems. Oxytocin administration to Magel2-deficient 
mouse pups normalized suckling and feeding behaviour and rescued all of them32.
Chapter 4 describes the results or our PWS Oxytocin Study. We conducted a random-
ized, double-blind, placebo-controlled, cross-over study to investigate the effects of 
4 weeks of intranasal oxytocin versus 4 weeks of placebo administration in children 
with PWS aged between 6 and 14 years. Although there were no effects in the group 
as a whole, subanalyses demonstrated that children with PWS between 6 and 11 years 
had beneficial effects of intranasal oxytocin administration on social behaviour and 
hyperphagia. Significantly less anger, sadness, conflicts and food-related behaviour, and 
improvement of social behaviour were reported by the parents during oxytocin treat-
ment compared with placebo.
In children with PWS older than 11 years, no beneficial effects of oxytocin on social 
behaviour and hyperphagia were found. Comparable results were reported by an Aus-
tralian study in individuals with PWS between 12 and 29 years. For that reason, they 
doubled the oxytocin dose, but subsequently temper outbursts increased instead of the 
desired decrease34. It might be that a higher oxytocin dose not only simulates oxytocin 
receptors, but also the receptors of oxytocin’s sister hormone arginine vasopressin (AVP), 
which is associated with stress-adaptation, anxiety and aggression34. If this hypothesis 
is true, a lower oxytocin dose might be better for older children. Other explanations like 
development of an unresponsive oxytocin system over the years with a lower number 
of oxytocin receptors and neurons in the hypothalamus, or an enhanced deterioration 
of the oxytocin system in patients with PWS around onset of puberty are also possible.
In conclusion, administration of intranasal oxytocin appears to have beneficial effects on 
social behaviour and food-related behaviour in children with PWS younger than 11 years of 
age without side effects or adverse events. Parents reported significantly less anger, sadness, 
conflicts and food-related behaviour, and improvement of social behaviour during oxytocin 
treatment compared with placebo. In contrast to the younger children with PWS, those older 
than 11 years of age did not benefit from oxytocin treatment with the given dose.
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8.4 body comPoSiTioN iN youNG adulTHood
After several years of participation in the Dutch GH RCT, the oldest children attained 
adult height. Their phenotype had changed during GH treatment with a normalization 
of height, improvement of body composition, and a better psychomotor development. 
It was, however, disconcerting for parents to discontinue GH treatment when children 
had attained adult height. They had experienced the benefits for their child, but there 
was no information about the effects of GH in this new generation of young adults with 
PWS after adult height attainment. A few patients ceased GH treatment and parents 
and investigators saw a deterioration of the condition and behaviour of these young 
adults within 3 months after GH stop. We, therefore, started a new randomized, placebo-
controlled GH trial investigating the effects of 1 year of continuation of GH treatment 
versus 1 year of placebo injections on body composition of young adults with PWS 
who were GH-treated during childhood and had attained adult height. The results are 
described in Chapter 5.
In children with PWS, the most important reason for treating them with GH is to 
optimize the body composition35. Without GH treatment, BMI and body composition 
deteriorate with age36. Our present results demonstrate that GH treatment remains 
required to maintain the body composition after attainment of AH. During 1 year of 
placebo, fat mass (FM) raised dramatically with a relative increase of 21.5%. The BMI 
increased by +1.4 kg/m2, but it is debatable whether the change in BMI is representa-
tive in patients with PWS as BMI underestimates true body composition. Compared to 
placebo, GH treatment resulted in a lower FM and higher lean body mass (LBM). Thus, 
our data show that GH-treated young adults with PWS who have attained AH benefit 
from continuation of GH treatment.
The benefits of an improved body composition are clear. Less obesity and FM result in 
a more favourable metabolic profile and decrease the risk of cardiovascular diseases and 
T2DM37. Although BMI is not very representative in patients with PWS, it is known that 
a higher BMI is associated with higher mortality and morbidity, such as cardiovascular 
diseases, T2DM, kidney diseases, osteoarthritis and psychosocial problems38-43. Increase 
of LBM affects the metabolic profile positively, as LBM is the primary tissue for insulin-
stimulated glucose uptake, disposal and storage44. In addition, a higherLBM has positive 
effects on energy expenditure, BMD and psychomotor development45-51. Thus, as we 
proved that discontinuation of GH treatment after AH attainment deteriorates body 
composition, cessation of GH treatment might result in more morbidity and mortality.
The majority of the parents reported a clear difference between the year with and the 
year without GH administration. Most important reported changes during the placebo 
period were more problem behaviour, worsening of weight and body composition, more 
preoccupation with food, less endurance and lower energy level. This clinical picture 
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during the placebo period resembles that of young adults with untreated GHD during 
the transition period, who also show altered body composition, low BMD, unfavourable 
lipid profile and decreased energy and quality of life52, 53. Although only 12.5% of the 
young adults with PWS had a GH peak below the BMI-dependent cut-off in a arginine-
GHRH test54, it seems that children and adults with PWS have a functional GHD11. This 
would explain why patients with PWS do not only benefit from GH treatment during 
childhood, but also in adulthood.
In conclusion, this randomized cross-over trial in young adults with PWS who were treated 
with GH during childhood shows that placebo treatment after AH deteriorates the improved 
body composition with an increase of FM. Compared to placebo, GH treatment results in a 
lower FM and higher LBM. This indicates that discontinuing GH treatment at AH leads to 
deteriorated body composition, while GH maintains the improved FM and LBM. This is very 
important, because development towards morbid obesity is a major threat to these patients. 
Thus, it is likely that continued GH administration contributes to a better future health for 
these young adults.
8.5 meTabolic HealTH Profile iN youNG adulTHood
Adults with PWS are predisposed to develop T2DM due to their abnormal body com-
position55, and risk factors for CVD such as hypertension and hyperlipidemia are more 
often present in PWS56. GH treatment is known for its diabetogenic effects, but there 
were no studies about the metabolic effects of GH versus placebo in young adults with 
PWS who were treated with GH during childhood and had attained AH. Studies in older 
PWS-patients who were GH-untreated at inclusion, found no major side-effects of GH on 
metabolic health profile57, 58.
In Chapter 6, we report the results of the metabolic health profile of young adults 
with PWS during GH treatment versus placebo. Our study showed that the glucose-
stimulated glucose and insulin levels during OGTT were similar during 1 year of GH 
treatment versus 1 year of placebo. Compared to placebo, GH treatment did not affect 
other carbohydrate parameters as AUC of glucose and insulin, and insulin/glucose ratios 
after glucose load. Fasting glucose and insulin levels were slightly higher during GH 
versus placebo, but remained within the normal ranges during both phases and none 
of the patients developed T2DM. The prevalence of IGT and MS were similar during GH 
treatment and placebo, and BP and lipid profiles were not significantly different during 
GH versus placebo. This indicates that GH versus placebo does not affect carbohydrate 
parameters except for a slightly higher fasting glucose and insulin, and that GH versus 
placebo does not negatively influence metabolic health profile.
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Only few side effects of GH treatment in adults with PWS are reported, but studies 
are scarce and mainly uncontrolled or short term in a relatively small number of previ-
ously GH-untreated patients35, 59, 60. Our findings are in line with a study reporting a small 
increase in fasting glucose of +0.27 mmol/l and a trend towards an increase in fasting 
insulin of +20.2 pmol/l during GH treatment59. The results of our study indicate that GH 
treatment does not elicit pronounced adverse effect on glucose and insulin homeostasis.
The physiological phenomenon that GH treatment induces a minor increase in fasting 
insulin with minimal influences on glucose metabolism is well-known59, 61. Our findings 
show that the benefits of GH versus placebo outweigh the mildly unfavourable effects 
on glucose and insulin homeostasis. These effects of GH on carbohydrate metabolism 
are thus compensated, while the benefits on body composition remain. Furthermore, 
we found that GH versus placebo does not disturb blood pressure, lipid profile or com-
ponents of metabolic syndrome.
In conclusion, this cross-over study demonstrates no adverse effects of GH treatment on 
carbohydrate metabolism, blood pressure, lipid profile or the development of metabolic 
syndrome. Thus, GH-treated young adults with PWS who have attained AH benefit from con-
tinuation of GH treatment without safety concerns regarding their metabolic health profile.
8.6 coGNiTioN iN youNG adulTHood
We previously demonstrated that long-term GH treatment during childhood improves 
cognitive functioning62. We investigated in Chapter 7 whether this GH-induced improve-
ment would not be lost after cessation of GH treatment at attainment of adult height. 
Our results are reassuring, as there was no significant deterioration in TIQ, VIQ or PIQ 
after 1 year of placebo in young adults with PWS. Furthermore, there was no significant 
difference in cognitive functioning between placebo and GH treatment. This might 
suggest that GH treatment during childhood, when the brain develops and matures, 
induces long-lasting effects, which remain present, at least for 1 year after cessation of 
GH treatment. Alternatively, it might be that 1 year of cessation is too short to show a 
significant decrease in cognitive functioning.
Although there was no deterioration in TIQ, VIQ or PIQ during 1 year of placebo, we 
found that patients with a lower TIQ had more loss in TIQ points during placebo than 
during GH treatment, in particular VIQ decreased more in those with a lower VIQ. These 
findings resemble those during childhood, where children with a greater deficit had 
more benefit from GH treatment62.
Cognitive functioning influences daily functioning, but other aspects are relevant 
as well. In the old DSM-IV, IQ-score was an important diagnostic criterion, but this has 
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changed in the new DSM-V63. Now the diagnosis Intellectual Disability involves impair-
ments of general mental abilities that impact adaptive functioning in 3 domains. The 
domains Conceptual, Social and Practical determine how well an individual copes with 
everyday tasks, and the IQ-score gives support for the diagnosis. This is relevant for 
individuals with PWS, as some have a relatively normal IQ-score, but are not able to live 
independently or to make their own decisions regarding money and food.
In conclusion, our cross-over trial in young adults with PWS who were treated for many years 
with GH during childhood demonstrates that 1 year placebo versus 1 year of GH treatment 
after attainment of adult height did not deteriorate cognitive functioning. However, patients 
with a lower VIQ lost more VIQ points during placebo.
8.7 GeNeral coNcluSioNS aNd cliNical imPlicaTioNS
Since 2002, our longitudinal PWS studies evaluated the short and long-term effects of 
GH treatment in a large group of children with PWS. Over the last decade, GH treatment 
has considerably changed the phenotype of children with PWS and we, therefore, also 
assessed the effects of cessation versus continued GH treatment after attainment of 
adult height. In addition, other aspects of PWS, like hyperphagia, appetite-regulating 
hormones and effects of intranasally administered oxytocin have been investigated and 
are described in this thesis.
We showed that the switch from failure to thrive to excessive weight gain in PWS 
coincides with an increase in the AG/UAG ratio, as PWS patients without weight gain or 
hyperphagia had a similar AG/UAG ratio as age-matched healthy controls, while those 
with weight gain and/or hyperphagia had an elevated AG/UAG ratio. In general, PWS 
patients have higher AG levels but similar UAG levels compared to healthy controls, 
resulting in a significantly higher AG/UAG ratio in PWS patients than in healthy controls. 
Despite these elevated fasting AG/UAG ratios, the ghrelin system of young adults with 
PWS showed a physiological response with a strong decline of AG and UAG levels, and 
AG/UAG ratio after glucose intake. This suggests that the impaired satiety in PWS is not 
the result of an abnormal response of the orexigenic ghrelin to food intake.
Our randomized, double-blind, placebo-controlled, cross-over study demonstrated 
beneficial effects of intranasal oxytocin on social behaviour and food-related behaviour 
in children with PWS between 6 and 11 years of age. In contrast to the younger children 
with PWS, those older than 11 years of age had no benefit from oxytocin treatment. This 
lack of benefit in the older children might be explained by dose issues or development of 
an unresponsive oxytocin system. Although more research is warranted, this first oxyto-
cin trial in children with PWS demonstrated promising effects of a new treatment option.
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The improved body composition of young adults with PWS who were treated with 
GH during childhood and had attained AH deteriorated after cessation of GH treatment, 
while GH treatment maintained the improved FM and LBM. Compared to placebo, GH 
treatment did not affect carbohydrate parameters except for a slightly higher fasting 
glucose and insulin which remained within the normal ranges. Other components of 
metabolic health profile did not change. Cognitive functioning did not deteriorate dur-
ing one year of placebo in the total group, although patients with a lower VIQ lost more 
VIQ points during placebo than during GH administration. Taken together, this indicates 
that young adults with PWS who have attained adult height benefit from continuation 
of GH treatment without safety concerns. Additional studies are needed to confirm this 
on the longer term, as these patients are still young and received only 1 year of GH 
treatment during adulthood.
8.8 direcTioNS for furTHer reSearcH
In this thesis, we describe new perspectives of treatment, with promising treatments 
such as intranasal administration of oxytocin in younger children with PWS. We found 
encouraging effects on social and eating behaviour after 4 weeks of treatment, but 
further research is warranted to confirm our findings and to study the long-term ef-
fects. As both social and eating behaviour are quite subjective, more objective outcome 
measures such as brain imaging are preferable. Besides, the optimal dose and frequency 
of oxytocin administration should be investigated. Furthermore, it should be elucidated 
why children younger than 11 years of age showed promising effects, while the older 
ones did not benefit from oxytocin treatment.
Besides the elevated fasting AG/UAG ratios in PWS, we found that the switch to hyper-
phagia might coincide with an increase in AG/UAG ratio. This supports the hypothesis 
that ghrelin is involved in hyperphagia in PWS. This is the cause or the consequence of 
the switch in eating behaviour could not be elucidated. Further research should there-
fore focus on longitudinal observations identifying the phases of PWS in parallel with 
the changes in ghrelin levels.
The nutritional phases according to Miller et al.1 were used to score the feeding 
problems, but in practice, the clinical presentation of children with PWS has significantly 
changed in today’s population. The controlled hyperphagia makes it difficult to catego-
rize the child according the nutritional phases. Development of a better hyperphagia 
scale for today’s population is, therefore, warranted.
The crucial AG/UAG ratio is normal in the nutritional phases without weight gain and/
or hyperphagia, suggesting that UAG is sufficiently high to compensate for the elevated 
AG level. From phase 2a onwards, when weight gain and hyperphagia develop, AG/UAG 
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ratio increases. It might be that UAG levels are then too low to modulate the effects 
of elevated AG levels. Elaborating on this idea, it might be worthwhile to investigate 
whether a more physiological AG/UAG ratio could be achieved by increasing the plasma 
UAG or decreasing the plasma AG levels and/or bioactivity, and whether this normaliza-
tion of the AG/UAG ratio results in a reduction of the hyperphagia.
We are the first to demonstrate that the body composition of young adults with PWS 
who were treated during childhood and had attained adult height deteriorated dramati-
cally during 1 year of placebo, while 1 year of GH treatment maintained the improved 
body composition achieved during childhood. Ongoing monitoring of young adults with 
PWS receiving GH treatment is highly recommended as they are at risk to develop T2DM 
and CVD, although our study demonstrates reassuring findings regarding metabolic 
health profile. Additional studies are needed to confirm this on the longer term, as these 
patients are still young and received only 1 year of GH treatment during adulthood. Also, 
studies are needed to individualize treatment with GH in adults with PWS.
Further research regarding the GH dose titration for young adults with PWS is recom-
mended. We considered the approved GH dose for children with PWS too high and the 
adult GHD dose too low for young adults and therefore treated them with 0.67 mg/
m2/day, which resulted in high-normal IGF-I levels without side effects. It is, however, 
debatable whether IGF-I levels are appropriate for titrating the GH dose, as there is a 
disrupted correlation between serum IGF-I levels and IGF-bioactivity in PWS, although 
this disruption is more pronounced in younger children than in the older ones64.
Current treatments focus on the main signs and symptoms of PWS, such as obesity, 
hyperphagia or behavioural problems, but further research should also give attention 
to the underlying cause of these signs and symptoms on different levels. Genomic 
imprinting induces activated genes in the PWS region of the paternal chromosome only, 
while the intact genes on the maternal chromosome 15 are silenced. Reactivation of 
the maternally silenced genes or other treatments specifically targeting the molecular 
defect might solve all or some aspects of PWS. Besides, a dozen of genes are situated 
on the PWS region, but the contribution of most of these individual genes is poorly 
understood. Animal models have attempted to address these questions, but have not 
been able to fully recapitulate the human phenotypes.
Finally, more national collaboration in the form of a National Reference Center and on 
European level as European Reference Network (ERN) can support the pooling of exper-
tise and help to ensure that knowledge is shared across borders. This will contribute to 
improvements in clinical outcomes and the quality of life of patients living with a rare 
disease.
Rare diseases are rare, but rare disease patients are numerous (Orpha.net)
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PWS Oxytocin Study
Randomized, double-blinded, placebo-controlled 
cross-over trial  
4 weeks of oxytocin versus 4 weeks of placebo
n=25 children with PWS 
6 to 11 years
behavior and food-related 
behavior
and food-related behavior, 
and improvement of social 
behavior
60 11 14 Adult Height 25 years
11 to 14 years
behavior and 
eating behavior
Oxytocin is a promising treatment for PWS, 
but more research regarding dose and longer 
The switch to excessive weight gain in PWS 
seems to coincide with an increase in AG/UAG 
ratio, even prior to the start of hyperphagia
PWS Transition Study
Randomized, double-blinded, placebo-controlled
cross-over trial  
1 year of GH versus 1 year of placebo 
n= 27 young adults with PWS  
Body composition: 
Deteriorated during placebo with an increase in fat 
mass
Maintained during GH versus placebo with a lower 
fat mass and higher lean body mass
carbohydrate metabolism, blood pressure, lipid 
Cognitive functioning:
Did not deteriorate during placebo
Reassuring results, but do not exclude a 
deterioration on the long term
continuation of GH treatment without safety 
concerns
PWS Ghrelin Study
Observational study 
n=138 patients with PWS, aged 0 to 30 years, 
compared with 50 obese and 39 healthy controls
Fasting AG/UAG ratio:
Was higher in PWS patients than in healthy controls, 
due to higher AG levels and similar UAG levels in PWS
Was similar in PWS patients without weight gain or 
hyperphagia and age-matched healthy controls, 
but higher in PWS patients with weight gain and/or 
hyperphagia
Ghrelin response in OGTT
n=25 GH-treated + 10 GH-stop young adults with PWS
AG and UAG levels strongly declined after glucose 
intake, resulting in a lower AG/UAG ratio
The ghrelin system responded physiologically
GH treatment resulted in lower AG levels
The impaired satiety does not seem to result  
from an abnormal reponse of the ghrelin system 
to food intake
AH+2
figure 1. Overview of this thesis.
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Summary
In this thesis we provide a detailed description of the studies performed to improve 
knowledge about Prader-Willi syndrome (PWS) and to optimize care for patients and 
parents. This chapter summarizes the studies and their most important outcomes.
chapter 1
This chapter provides an introduction in PWS by discussing the genetic background, 
symptoms in different phases of life, GH treatment, and unresolved issues, such as fast-
ing and glucose-stimulated levels of the appetite-stimulating hormone ghrelin, effects 
of oxytocin treatment on social and eating behaviour, and effects of cessation versus 
continuation of GH treatment on body composition, metabolic health profile and cogni-
tion in young adults who were treated during childhood and had attained adult height. 
This chapter further describes the aims and outline of this thesis.
chapter 2
Prader-Willi syndrome is characterized by a switch from failure to thrive to excessive 
weight gain and hyperphagia in early childhood. The underlying mechanism of this 
switch is unknown, but the appetite-regulating hormone ghrelin might be involved. 
Acylated ghrelin (AG) is diabetogenic and stimulates appetite, while unacylated ghrelin 
(UAG) is known for its protective effects and is able to suppress AG. This suggests a crucial 
role for the ratio between AG and UAG. We, therefore, conducted an observational study 
in collaboration with PWS Centers in Toulouse and Lyon, France, and evaluated fasting 
AG and UAG serum levels and their associations with hyperphagia in a large group of 
138 patients with PWS from 0.2 to 29.4 years. We compared them with levels of 50 age-
matched obese subjects and 39 healthy controls. PWS patients had higher AG levels 
but similar UAG levels compared to healthy controls, resulting in a significantly higher 
AG/UAG ratio in PWS patients than in healthy controls. Obese controls had significantly 
lower AG and UAG levels than PWS patients, but also a high AG/UAG ratio. Remarkably, 
PWS patients without weight gain or hyperphagia had a similar AG/UAG ratio as age-
matched healthy controls, in contrast to those with weight gain and/or hyperphagia 
who had an elevated AG/UAG ratio.
We conclude that the switch to excessive weight gain in PWS seems to coincide with 
an increase in the AG/UAG ratio, even prior to the start of hyperphagia.
chapter 3
Prader-Willi syndrome is characterized by hyperphagia with impaired satiety. Fasted 
PWS patients have very high AG with normal UAG levels, resulting in an elevated AG/
UAG ratio, suggesting an intrinsic defect in the ghrelin regulation. Normally, food intake 
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induces satiety and a drop in AG and UAG levels, but it was unknown if these levels also 
decline in PWS. We, therefore, evaluated serum levels of AG, UAG and AG/UAG ratio be-
fore and after a glucose load during an oral glucose tolerance test (OGTT). These OGTTs 
were performed in 24 GH-treated and in 10 GH-stop young adults with PWS. In both 
groups, there was a sharp decline of AG levels and a decrease of UAG levels in the first 
30 minutes after the glucose load, which resulted in a lower AG/UAG ratio. GH-treated 
patients had significantly lower AG levels than GH-stop patients at baseline and during 
the OGTT.
We conclude that, even in the presence of very high fasting AG/UAG ratios, the ghrelin 
system of young adults with PWS shows a physiological response with a strong decline 
of AG and UAG levels after glucose intake. Our findings might suggest that the impaired 
satiety is not the result of an abnormal response of the orexigenic ghrelin to food intake. 
Continuation of GH treatment after attainment of adult height results in lower AG levels 
at baseline and during OGTT, suggesting a more favourable metabolic profile.
chapter 4
PWS is known for hyperphagia with impaired satiety and a specific behavioural pheno-
type with stubbornness, temper tantrums, manipulative and controlling behaviour and 
obsessive-compulsive features. PWS is associated with hypothalamic and oxytocinergic 
dysfunction. In humans without PWS, intranasal oxytocin administration had positive 
effects on social and eating behaviour. We, therefore, evaluated the effects of intranasal 
oxytocin compared to placebo administration on social behaviour and hyperphagia in 
a randomized, double-blind, placebo-controlled, cross-over study. Twenty-five children 
with PWS between 6 and 14 years of age received 4 weeks oxytocin and 4 weeks placebo 
twice daily. In the total group, no significant effects of oxytocin on social behaviour or 
hyperphagia were found, but in the 17 children younger than 11 years, parents reported 
significantly less anger, sadness, conflicts and food-related behaviour, and improvement 
of social behaviour during oxytocin treatment compared with placebo. In the 8 children 
older than 11 years, the items happiness, anger and sadness were negatively influenced 
by oxytocin treatment compared to placebo. There were no side effects or adverse 
events.
We conclude that intranasal oxytocin administration has promising effects on social 
and food-related behaviour in children with PWS younger than 11 years of age.
chapter 5
Patients with PWS have an abnormal body composition with an increased FM and 
decreased LBM. During childhood, GH treatment counteracts the natural course of in-
creasing obesity, but young adults have to stop GH treatment when they attain AH. The 
consequences of cessation of GH treatment were unknown, but it was conceivable that 
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it would deteriorate their improved clinical condition, while continuation might benefit 
them. We, therefore, investigated the effects of 1 year of GH versus 1 year of placebo on 
body composition measured by DXA in a 2-year, randomized, double-blind, placebo-
controlled cross-over study with stratification for gender and BMI. Twenty-seven young 
adults with PWS who were GH-treated for many years during childhood and had at-
tained AH participated and received GH treatment and placebo. During placebo, there 
was an increase of FM of +21.5%. Compared to placebo, GH treatment resulted in a lower 
FM and higher LBM, with changes of -17.3% and +3.5% respectively. Both FM% of the 
limbs and trunk were lower during GH versus placebo (change -17.3% and -15.6%). No 
GH-related adverse events occurred.
We conclude that GH-treated young adults with PWS who have attained AH, benefit 
from continuation of GH treatment. Cessation of GH treatment leads to a deterioration 
of body composition, while GH maintains the improved FM and LBM. This is very impor-
tant, because development towards morbid obesity is a major threat to these patients. 
Thus, it is likely that continued GH administration contributes to a better future health 
for these young adults.
chapter 6
Patients with PWS are severely at risk to develop morbid obesity, diabetes mellitus 
type 2 and cardiovascular disease, leading to high mortality. GH-treated young adults 
with PWS who have attained adult height benefit from continuation of GH treatment, 
because GH versus placebo maintains their improved body composition. It was, how-
ever, unknown whether GH affects metabolic health profile of this patient group. We, 
therefore, investigated the effects of 1 year of GH versus 1 year of placebo on metabolic 
health in a 2-year, randomized, double-blind, placebo-controlled cross-over study with 
stratification for gender and BMI. Twenty-seven young adults with PWS who were GH-
treated for many years during childhood and had attained AH received GH treatment 
and placebo. Compared to placebo, GH treatment resulted in similar glucose and insulin 
levels during oral glucose tolerance test. Only fasting glucose and insulin were slightly 
higher during GH versus placebo, although both remained within the normal ranges. 
Blood pressure and lipid profile were similar during GH versus placebo. At baseline (AH) 
and during GH, no patients had metabolic syndrome, while 1 developed metabolic 
syndrome during placebo.
We conclude that GH treatment has no adverse effects on carbohydrate metabolism, 
blood pressure, lipid profile or the development of metabolic syndrome in young adults 
with PWS. Thus, GH-treated young adults with PWS who have attained AH benefit from 
continuation of GH treatment without safety concerns regarding to metabolic health.
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chapter 7
Patients with PWS have a cognitive impairment. We have shown that GH treatment 
during childhood improves cognitive functioning, while GH-untreated children show a 
deterioration in IQ over time. The consequences of cessation of GH treatment on cogni-
tion at attainment of AH were unknown, but it could be that the GH-induced improved 
cognition would deteriorate. We, therefore, investigated the effects of 1 year of placebo 
versus 1 year of GH administration on cognition in a 2-year, randomized, double-blind, 
placebo-controlled cross-over study. Twenty-five young adults with PWS who were GH-
treated for many years during childhood and had attained AH received GH treatment 
and placebo. One year of placebo did not deteriorate TIQ, VIQ or PIQ compared to GH 
treatment. However, young adults with a lower TIQ had significantly more loss of TIQ 
points during placebo than during GH treatment, in particular those with a lower VIQ 
lost more VIQ during placebo. The effect of placebo versus GH on TIQ, VIQ and PIQ was 
not different for gender or genotype.
We conclude that 1 year of placebo did not deteriorate cognitive functioning in young 
adults with PWS who were treated for many years with GH during childhood and had 
attained AH. However, patients with lower cognitive functioning had more loss of IQ 
points during placebo versus GH administration. These results are reassuring, but do 
not exclude that cessation of GH treatment for many years could result in a gradual 
deterioration of cognitive functioning on the long term.
chapter 8
In the general discussion, we discuss our results in view of the current literature and 
present the clinical implications of our findings. In addition, we report our general con-
clusions and give suggestions for further research.
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SameNvaTTiNG
In dit proefschrift geven we een gedetailleerd overzicht van de verschillende studies die 
zijn uitgevoerd om de kennis over Prader-Willi syndroom (PWS) te vergroten en de zorg 
voor patiënten en ouders te verbeteren. Hier wordt een samenvatting gegeven van deze 
studies en de belangrijkste resultaten worden besproken.
Hoofdstuk 1
In dit hoofdstuk wordt achtergrondinformatie over PWS gegeven. De genetische achter-
grond, de karakteristieke kenmerken per levensfase en groeihormoon (GH) behandeling 
worden besproken. Daarna volgt een korte inleiding van de onderwerpen die onder-
zocht zijn in dit proefschrift, namelijk de nuchtere en glucose-gestimuleerde spiegels 
van het eetluststimulerende hormoon ghreline, de effecten van oxytocinebehandeling 
op sociaal- en eetgedrag, en de effecten van stoppen versus voortzetten van GH be-
handeling op de lichaamssamenstelling, het metabole gezondheidsprofiel en cognitief 
functioneren van uitgegroeide jongvolwassenen met PWS die tijdens kindertijd behan-
deld zijn met GH. Daarnaast geeft dit hoofdstuk een overzicht van de vraagstellingen in 
dit proefschrift.
Hoofdstuk 2
De verandering van ‘failure to thrive’ naar een overmatige gewichtstoename en hyperfa-
gie is een typisch kenmerk van PWS. Het onderliggende mechanisme van deze verande-
ring in de vroege kindertijd is onbekend, maar het eetlustregulerende hormoon ghreline 
zou betrokken kunnen zijn. Geacyleerd ghreline (AG) is diabetogeen en stimuleert de 
eetlust, terwijl ongeacyleerd ghreline (UAG) bekend staat om zijn beschermende ef-
fecten en de mogelijkheid om AG te onderdrukken. Dit suggereert een cruciale rol voor 
de verhouding tussen AG en UAG, oftewel de AG/UAG ratio. Samen met 2 andere PWS 
centra in Toulouse en Lyon (Frankrijk) hebben we nuchtere serum AG en UAG spiegels 
en hun associaties met hyperfagie onderzocht in een grote groep van 138 patiënten met 
PWS tussen 0.2 en 29.4 jaar. De spiegels werden vergeleken met die van 50 obese en 39 
gezonde controles met dezelfde leeftijd. Kinderen en jongeren met PWS hadden hogere 
nuchtere AG spiegels, maar gelijke UAG spiegels in vergelijking met gezonde controles, 
resulterend in een significant hogere AG/UAG ratio in PWS patiënten dan in gezonde 
controles. Obese controles hadden significant lagere AG en UAG spiegels dan PWS pa-
tiënten, maar eveneens een hogere AG/UAG ratio. Het was opmerkelijk dat de AG/UAG 
ratio van PWS patiënten zonder gewichtstoename of hyperfagie gelijk was aan die van 
gezonde controles, terwijl PWS patiënten met gewichtstoename en/of hyperfagie een 
verhoogde AG/UAG ratio hadden.
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Uit dit onderzoek concluderen we dat de verandering naar een overmatige ge-
wichtstoename in PWS samen lijkt te gaan met een toename in de AG/UAG ratio, zelfs 
voorafgaand aan het ontstaan van de hyperfagie.
Hoofdstuk 3
Het Prader-Willi syndroom wordt gekenmerkt door hyperfagie in combinatie met 
een onverzadigbare eetlust. PWS patiënten hebben erg hoge nuchtere AG spiegels 
met normale UAG spiegels, leidend tot een verhoogde AG/UAG ratio. Dit zou kunnen 
wijzen op een intrinsiek defect in de ghreline regulatie. Voedselinname leidt normaal 
gesproken tot een verzadigd gevoel en een daling van de AG en UAG spiegels, maar het 
was onbekend of deze spiegels ook omlaag gaan bij mensen met PWS. Daarom hebben 
we de serum spiegels van AG, UAG en AG/UAG ratio onderzocht voorafgaand aan en 
na inname van een gestandaardiseerde hoeveelheid glucose tijdens een orale glucose 
tolerantie test (OGTT). Deze OGTTs werden verricht bij 24 GH-behandelde en 10 met GH 
gestopte jongvolwassenen met PWS. In beide groepen werd in de eerste 30 minuten na 
de glucose inname een sterke afname van AG spiegels gezien. De UAG spiegels daalden 
minder sterk, waardoor de AG/UAG ratio lager werd. GH-behandelde patiënten hadden 
significant lagere AG spiegels dan de met GH gestopte patiënten, zowel voorafgaand 
aan als tijdens de OGTT.
We concluderen dat het ghreline systeem van jongvolwassenen met PWS na inname 
van glucose een fysiologische reactie laat zien met een sterke daling van AG en UAG 
spiegels, zelfs in de aanwezigheid van erg hoge nuchtere AG/UAG ratio’s. Onze bevindin-
gen zouden erop kunnen wijzen dat de onverzadigbare eetlust niet wordt veroorzaakt 
door een afwijkende reactie van het eetluststimulerende ghreline op voedselinname. 
Het continueren van GH behandeling nadat een jongvolwassene is uitgegroeid leidt 
tot lagere AG spiegels voorafgaand aan en tijdens een OGTT, wat wijst op een gunstiger 
metabool profiel.
Hoofdstuk 4
Karakteristieke symptomen die bij PWS passen zijn hyperfagie met een onverzadigbare 
eetlust en een specifiek gedragsfenotype met koppigheid, driftbuien, manipulatief en 
controlerend gedrag en obsessief-compulsieve kenmerken. PWS is geassocieerd met 
hypothalame en oxytocinerge stoornissen. Bij mensen zonder PWS had intranasale 
oxytocinebehandeling een positief effect op sociaal- en eetgedrag. Daarom hebben we 
middels een gerandomiseerde, dubbelblinde, placebogecontroleerde cross-over studie 
de effecten van intranasale oxytocine op sociaal gedrag en hyperfagie onderzocht. 
Vijfentwintig kinderen met PWS tussen 6 en 14 jaar kregen tweemaal daags neusspray 
toegediend, eerst 4 weken oxytocine en vervolgens 4 weken placebo of in de omge-
keerde volgorde. In de gehele groep werden geen significante effecten van oxytocine op 
Samenvatting 171
9
sociaal gedrag en hyperfagie gevonden, maar in de 17 kinderen die jonger waren dan 11 
jaar, werd tijdens de oxytocinebehandeling significant minder boosheid, verdriet, con-
flicten en voedselgerelateerd gedrag, en een verbetering van sociaal gedrag gevonden 
dan tijdens placebo. In de 8 kinderen ouder dan 11 jaar had oxytocinebehandeling een 
negatief effect op de items geluk, boosheid en verdriet. Er waren geen bijwerkingen of 
ongewenste gebeurtenissen.
We concluderen dat intranasale oxytocinebehandeling veelbelovende effecten heeft 
op sociaal- en voedselgerelateerd gedrag bij kinderen met PWS jonger dan 11 jaar. 
Toekomstig onderzoek moet uitwijzen of oudere kinderen gebaat zijn bij een lagere 
dosering oxytocine.
Hoofdstuk 5
Patiënten met PWS hebben een afwijkende lichaamssamenstelling met een toegeno-
men vetmassa en weinig spiermassa. Tijdens de kinderleeftijd gaat GH-behandeling het 
natuurlijk beloop van toenemende obesitas en een afwijkende lichaamssamenstelling 
tegen, maar jongvolwassenen moeten stoppen met deze behandeling op het moment 
dat ze uitgegroeid zijn. De consequenties van het stoppen van de GH-behandeling 
waren onbekend, maar het was voorstelbaar dat de verbeterde klinische conditie 
zou verslechteren, terwijl jongvolwassenen met PWS ze baat zouden kunnen hebben 
bij voortzetting van GH-behandeling. We hebben daarom de effecten van GH versus 
placebo op lichaamssamenstelling via DXA-scans onderzocht in een 2-jarige, gerando-
miseerde, dubbelblinde, placebogecontroleerde cross-over studie met stratificatie voor 
geslacht en BMI. Zevenentwintig uitgegroeide jongvolwassenen met PWS die tijdens de 
kinderleeftijd behandeld zijn met GH participeerden in de studie en werden behandeld 
met GH-behandeling en placebo, beiden gedurende 1 jaar. Tijdens placebo nam de vet-
massa toe met +21.5%. In vergelijking met placebo resulteerde GH-behandeling in een 
lagere vetmassa en hogere spiermassa, -17.3% en +3.5% respectievelijk. Zowel het vet-
percentage van de ledematen als van de romp waren lager tijdens GH-behandeling dan 
tijdens placebo (-17.3% en -15.6%, resp.). Er waren geen GH-gerelateerde bijwerkingen.
Uit dit onderzoek concluderen we dat uitgegroeide GH-behandelde jongvolwas-
senen met PWS baat hebben bij het voortzetten van GH-behandeling. Stoppen van 
GH-behandeling zorgt voor een verslechtering van de lichaamssamenstelling, terwijl 
voortzetten van GH de verbeterde vetmassa en spiermassa behoudt. Dit is van groot 
belang, aangezien de ontwikkeling van morbide obesitas een ernstige bedreiging is 
voor deze patiënten. Voortzetting van GH-behandeling zou bij kunnen dragen aan een 
betere en gezondere toekomst voor jongvolwassenen met PWS.
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Hoofdstuk 6
Patiënten met PWS lopen een ernstig risico op het ontwikkelen van morbide obesitas, 
diabetes mellitus type 2 en cardiovasculaire ziekten, wat zorgt voor een hoog risico op 
sterfte. Uitgegroeide GH-behandelde jongvolwassenen met PWS zouden baat kunnen 
hebben bij het voortzetten van GH-behandeling, aangezien placebo zorgt voor een 
toename van vetmassa, terwijl GH versus placebo de verbeterde lichaamssamenstel-
ling kan behouden. Het was echter onbekend of GH-behandeling het metabole 
gezondheidsprofiel van deze patiëntengroep beïnvloedt. We hebben daarom de ef-
fecten van GH versus placebo op het metabole gezondheidsprofiel onderzocht in een 
2-jarige, gerandomiseerde, dubbelblinde, placebogecontroleerde cross-over studie 
met stratificatie voor geslacht en BMI. Zevenentwintig uitgegroeide jongvolwassenen 
met PWS die tijdens de kinderleeftijd behandeld waren met GH participeerden in de 
studie en werden behandeld met GH-behandeling en placebo, beiden gedurende 1 
jaar. In vergelijking met placebo resulteerde GH-behandeling in vergelijkbare glucose 
en insuline spiegels tijdens een OGTT. Enkel het nuchtere glucose en insuline waren 
iets hoger tijdens GH dan tijdens placebo, hoewel beide in beide periodes binnen de 
normale grenzen bleven. Bloeddruk en lipiden waren gelijk tijdens GH-behandeling en 
placebo. Voorafgaand aan de studie en gedurende de GH-behandeling had geen van de 
patiënten metabool syndroom, terwijl 1 patiënt dit ontwikkelde tijdens placebo.
We concluderen dat GH-behandeling geen negatieve effecten heeft op het koolhy-
draatmetabolisme, de bloeddruk, het lipidenprofiel of op de ontwikkeling van metabool 
syndroom. Al met al hebben uitgegroeide GH-behandelde jongvolwassenen met PWS 
baat bij voorzetting van GH-behandeling zonder dat er ongerustheid hoeft te bestaan 
over de veiligheidsaspecten aangaande het metabole gezondheidsprofiel.
Hoofdstuk 7
Patiënten met PWS hebben een cognitieve beperking. Onze onderzoeksgroep heeft 
voorheen laten zien dat GH-behandeling tijdens de kinderleeftijd het cognitief functio-
neren verbetert, terwijl GH-onbehandelde kinderen achteruitgaan in IQ. De gevolgen van 
het stoppen met GH-behandeling op het moment dat jongeren uitgegroeid zijn waren 
onbekend, maar het was voorstelbaar dat de GH-geïnduceerde verbeterde cognitie zou 
verslechteren, terwijl jongvolwassenen met PWS baat zouden kunnen hebben bij voort-
zetting van GH-behandeling. We hebben daarom de effecten van placebo versus GH op 
het cognitief functioneren onderzocht in een 2-jarige, gerandomiseerde, dubbelblinde, 
placebogecontroleerde cross-over studie. Vijfentwintig uitgegroeide jongvolwassenen 
met PWS die tijdens de kinderleeftijd behandeld waren met GH participeerden in de 
studie en werden behandeld met GH-behandeling en placebo, beiden gedurende 1 
jaar. Eén jaar placebo gaf geen verslechtering van het totaal IQ (TIQ), verbaal IQ (VIQ) 
of performaal IQ (PIQ), en TIQ, VIQ of PIQ waren niet verschillend tijdens GH of placebo. 
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Jongvolwassenen met een lager TIQ verloren echter significant meer TIQ punten tijdens 
placebo versus GH-behandeling, met name jongvolwassenen met PWS met een lager 
VIQ verloren meer VIQ punten tijdens placebo. Het effect van placebo versus GH op TIQ, 
VIQ en PIQ was niet verschillend voor geslacht of genotype.
We concluderen dat 1 jaar placebo geen achteruitgang gaf van het cognitief functio-
neren van uitgegroeide jongvolwassenen met PWS die tijdens de kindertijd langdurig 
behandeld zijn met GH. Echter, patiënten met een lager VIQ verloren meer VIQ punten 
tijdens placebo versus GH behandeling.
Hoofdstuk 8
In de algemene discussie bespreken we onze resultaten in het kader van de huidige 
literatuur en presenteren de klinische consequenties van onze bevindingen. We geven 
onze algemene conclusies en suggesties voor verder onderzoek.
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liST of abbreviaTioNS
ACTH  corticotropin
AE  adverse event
AEBSF  4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride
AG  acylated ghrelin
AH  adult height
ASD  autism spectrum disorder
AUC  area under the curve
BMD  bone mineral density
BMI  body mass index
BP  breakpoint
BP  blood pressure
CRH  corticotropin-releasing hormone
CVD  cardiovascular disease
CV  coefficients of variation
CV  curriculum vitae
DNA  deoxyribonucleic acid
DXA  dual-energy X-ray absorptiometry
EMA  European Medicines Agency
FDA  Food and Drug Administration
FM  fat mass
FM%  fat mass percentage
FSH  follicle stimulating hormone
GH  growth hormone
GHRH  growth hormone-releasing hormone
GHSR  growth hormone secretagogue receptor
GLP-1  glucagon like peptide type 1
GnRH  gonadotropin-releasing hormone
GOAT  ghrelin O-acyltransferase
HDLc  high-density lipoprotein cholesterol
HOMA-IR homeostatic model assessment of insulin resistance
ICD  imprinting center defect
IGF-I  insulin-like growth factor type I
IGFBP-3  insulin-like growth factor binding protein 3
IGT  impaired glucose tolerance
IQ  intelligence quotient
IQR  interquartile range
LBM  lean body mass
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LDLc  low-density lipoprotein cholesterol
LH  luteinizing hormone
MD  medical doctor
MRI  magnetic resonance imaging
MS  metabolic syndrome
mUPD  maternal uniparental disomy
OGTT  oral glucose tolerance test
PIQ  performance IQ
PWS  Prader-Willi syndrome
RCT  randomized controlled trial
SAE  severe adverse event
SPSS  Statistical Package for Social Sciences
SDS  standard deviation score
T2DM  diabetes mellitus type 2
TC  total cholesterol
TG  triglyceride
TIQ  total IQ
TRH  thyrotropin-releasing hormone
TSH  thyrotropin
UAG  unacylated ghrelin
VIQ  verbal IQ
WC  waist circumference
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daNkWoord
Het is zover, mijn boekje is af! De afgelopen jaren heb ik met ontzettend veel plezier en 
enthousiasme gewerkt, maar promoveren doe je nooit alleen. De inspirerende betrok-
kenheid van velen heeft veel voor mij betekend en zonder hen was het niet gelukt. Ik 
wil iedereen daarvoor hartelijk bedanken. Een aantal mensen wil ik in het bijzonder 
noemen.
Allereerst wil ik alle kinderen en jongeren met PWS en hun ouders enorm bedanken 
voor hun inspanningen en enthousiasme voor onze studies. We zagen elkaar soms wel 
4 keer per jaar en ik heb velen in de afgelopen jaren zien groeien. Jullie zorgden voor 
afwisseling en brachten emotie, lach en verbazing. Wat waardeer ik jullie inzet, geduld 
en openheid. Jullie maken onderzoek naar het verbeteren van de kwaliteit van leven van 
kinderen en jongeren met PWS mogelijk.
Mijn promotor, prof. dr. A.C.S. Hokken-Koelega. Beste Anita, wat ben ik blij dat ik jouw 
promovenda mocht zijn! Je hebt me ongelooflijk veel geleerd en je grenzeloze vertrou-
wen heeft me laten groeien. Ik bewonder je passie voor het onderzoek, je gedrevenheid 
en ambitie, en je altijd vlotte, kritische en waardevolle commentaar. Ik ben onder de 
indruk van je warme hart voor mij, je promovendi en kinderen en jongeren met PWS. 
Mede hierdoor kijk ik met veel plezier terug naar de afgelopen jaren. Enorm bedankt!
Prof. dr. A.J. van der Lelij. Beste Aart Jan, bedankt dat u altijd laagdrempelig beschikbaar 
was voor overleg en voor de snelle, opbouwende commentaren op de manuscripten. 
Hartelijk dank voor uw bereidheid om plaats te nemen als secretaris in de kleine com-
missie.
Prof. dr. A. Vogels. Beste Annick, wat fijn dat u beschikbaar was voor overleg en advies. 
Hartelijk dank voor uw bereidheid om plaats te nemen in de kleine commissie.
Prof. dr. W. Kiess. I am very grateful and honored by your willingness to participate in my 
inner committee. Thank you for your interest and for travelling to Rotterdam.
Prof. dr. T. Stijnen. Beste Theo, hartelijk dank voor de laagdrempelige statistische hulp 
bij onze belangrijke studies en de prettige samenwerking. Bedankt voor de bereidheid 
plaats te nemen in mijn promotiecommissie.
Dr. A.A.E.M. van Alfen-van der Velden. Beste Janiëlle, ik waardeer je betrokkenheid bij 
de studies en je inzet voor kinderen met PWS. Samen zijn we nu Expertisecentrum PWS! 
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Bedankt voor de prettige samenwerking en dat je plaats wilt nemen in mijn promotie-
commissie.
Dr. L.C.G. de Graaff. Beste Laura, wat fijn dat we de jongvolwassenen met PWS nu met 
een gerust hart kunnen overdragen naar de volwassengeneeskunde. Mede dankzij jouw 
inzet is de zorg voor volwassenen met PWS in Nederland flink verbeterd en kunnen ook 
zij terecht in het Expertisecentrum PWS. Bedankt voor het plaatsnemen in mijn promo-
tiecommissie.
Alle kinderartsen van de samenwerkende centra. G.C.B. Bindels-de Heus, G. Bocca, 
D.A.J.P. Haring, J.J.G. Hoorweg-Nijman, E.C.A.M. Houdijk, P.E. Jira, L. Lunshof, R.J. Odink, 
W. Oostdijk, J. Rotteveel, E.J. Schroor, M. van Leeuwen, E. van Pinxteren-Nagler, V. van Tel-
lingen, H. van Wieringen, M.E.J. Wegdam-den Boer, N. Zwaveling-Soonawala en alle poli-
assistenten. Bedankt voor jullie gastvrijheid, betrokkenheid en inzet voor onze studies 
en voor kinderen met PWS. Ook dank aan andere betrokken artsen; K.P. Wolffenbuttel, 
K.F.M. Joosten, H. Bruggenwirth, M. Smits, T.C.J. Sas, B. Otten, K. Haasnoot, B. Bakker, R. 
Moonen, N. Stikkelbroeck en vele anderen.
Erica van den Akker, Annelies Brandsma, Sandra de Kort en Sabine Hannema, bedankt 
voor alle leerzame momenten tijdens de endobesprekingen. 
Philippe Collin, Sylvia Rasenberg, Jacqueline Heeren en José Veen. Bedankt dat jullie al-
tijd bereid waren om mee te denken en om advies te geven. Wat fijn dat jullie de ouders 
zo goed kunnen ondersteunen.
Martin en Patric, bedankt voor alles rondom de ghrelinbepalingen en de fijne samen-
werking. En Martin, ook voor de gezellige koffietjes.
Co-authors G. Diène, C. Molinas, S. Faye, M. Nicolino, D. Bernoux, S. Allas, M. Julien, T. 
Delale and M. Tauber, I would like to thank you for our collaboration on the ghrelin 
project. International Infant PWS group, M. Tauber, R. Nergardh, V. Beauloye, B. Hauffa 
and all their colleagues involved in the project, thank you for the kind collaboration.
Pfizer, en in het bijzonder Joli van der Lans en Joost van Middendorp, bedankt voor de 
prettige samenwerking en de onafhankelijke research grants voor de PWS-studies.
Prader-Willi Fonds, Ingeborg en Gertjan, jullie inzet voor kinderen en volwassenen met 
PWS is buitengewoon. Veel dank voor de financiële ondersteuning voor de oxytocine-
studie. Stichting PWS, bedankt voor de fijne samenwerking.
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Het belang van fijne collega’s om je heen mag niet worden onderschat. Ineke, Gladys, 
Connie, Sandra, Sunita, Trudie, José, Manouk, Elise, Sander, Akvile, Berber, Momoko en 
Rosadinde. Wat kon het tussendoor gezellig zijn met koffie en theetjes in koude en 
warme tijden, en lunches in het kopieerhok of liever nog in de zon op het balkon. Sunita, 
wat fijn dat je altijd bereid bent om te helpen. Ineke, we kunnen op de stichting niet 
zonder jou! Sander, onwijs fijn dat je altijd wilt meedenken en een oplossing hebt voor 
bijna elk computerprobleem. Manouk, wat bijzonder dat we de afgelopen tijd allebei 
zo hard gewerkt hebben om ons boekje af te maken. Roos, wat is mijn boekje mooi hè? 
Bedankt voor alles! Ik wens jullie allemaal een hele mooie toekomst en veel geluk.
Mijn voorgangers binnen het PWS-team, Dederieke, Roderick, Elbrich, Nienke en Sind-
die. Ik voel me vereerd dat ik jullie plekje heb mogen opvolgen. Bedankt voor jullie 
snelle en enthousiaste reacties bij vragen, de gezellige momenten in de PWS-wereld 
en het meedenken met manuscripten. Jullie hebben een stevige basis gelegd voor de 
studies en dat merken we nu nog. Ik waardeer jullie betrokkenheid en inzet, en wens 
jullie een prachtige carrière en veel geluk.
Het huidige PWS-team met Mariëlle, Stephany, Eva, Layla en Laura. Lieve Mariëlle, je 
bent voor zowel het hele PWS-team als voor vele kinderen en ouders onmisbaar. Mede 
door jou zijn de studies zo’n succes. Bedankt voor je toewijding, zorg, steun en onvoor-
waardelijk inzet. Stephany, wat fijn dat jij Nienke’s plek in nam. Bedankt dat je me op het 
juiste moment werk uit handen nam, zodat ik mijn proefschrift kon schrijven, en bovenal 
voor de fijne samenwerking. Eva, bedankt voor je interesse en alle gezelligheid. Layla en 
Laura, jullie zijn nu al zo betrokken, dat komt helemaal goed. Samen een prachtig team, 
wat fijn om te weten dat jullie het werk met zoveel toewijding voortzetten. Ik heb er alle 
vertrouwen in dat het nog veel moois gaat brengen.
Collega’s van de Endo, Annemieke, Elbrich, Florentien, Gerthe, Judith, Kirsten, Laura, 
Layla, Lidewij, Lin, Manouk, Nienke, Sinddie, Stephany en Yvonne. Lieve meiden, naast 
de vele inspirerende endobesprekingen en waardevolle adviezen, vooral veel gezellig-
heid zoals op borrels en congressen. Wat is het fijn om in zo’n mooie groep te mogen 
promoveren. Bedankt voor alles. Ik wens jullie veel geluk en succes in de toekomst.
Collega’s van het Sophia, jullie hebben gezorgd voor vele mooie herinneringen aan 
ski-reizen, borrels, barbecues en diners. Bedankt voor de gezelligheid. Laura, wat een 
eer dat ik naast je mocht staan, ik ben er van overtuigd dat je een prachtige toekomst 
tegemoet gaat. Suzanne, als je terug bent doen we snel weer een koffietje.
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Mijn geweldig lieve vrienden en vriendinnen, die ik enorm waardeer om wie ze zijn. 
Ieder zijn eigen uitdagingen, maar altijd betrokken en geïnteresseerd in mij. Jullie staan 
altijd voor mij klaar. Bedankt voor de vele gezellige drankjes, etentjes en uitjes. Wat fijn 
dat ik mezelf mag zijn bij jullie en dat we samen zo kunnen ontspannen en genieten.
Lieve Marieke, Martha, Sabine en Susanne, een vijf-eenheid sinds dag één van de ge-
neeskundestudie en al meer dan 12 jaar delen we lief en leed. Hopelijk blijft dat nog heel 
lang zo. Lieve Anne en Sawadi, wat voor ons drieën begon als onze eerste echte baan 
in Dordt, is uitgegroeid tot een bijzonder dierbare en hechte vriendschap, die ik enorm 
waardeer.
Lieve schoonfamilie, bedankt dat jullie mij zo snel in jullie familie hebben opgenomen. 
Ab en Richtje, dank voor alle interesse in mijn onderzoek, en voor de gezelligheid en 
betrokkenheid voor ons beiden.
Mijn paranimfen Nienke en Nine, wat ben ik blij dat jullie vandaag zo dicht bij mij staan. 
Lieve Nienke, jaren werkten we nauw en intensief samen, aan een half woord hadden 
we genoeg. Je enthousiasme en liefde voor de patiënten werkte aanstekelijk. Door de 
jaren heen ben ik je als veel meer dan zomaar een collega gaan beschouwen. En dan 
onze mannen die samen bier of whisky gaan proeven in Barcelona of Dublin terwijl 
wij bij een congres zitten. Bedankt voor al je support! Lieve Nine, als kind hebben we 
samen heel wat gekibbeld, maar ik kan me nu geen fijnere zus wensen. Jij en Simon zijn 
meestal druk in de weer, maar als het nodig is dan ben je er altijd. Nog even en dan ben 
je huisarts. Ik wens jullie samen alle geluk toe, ik ben zo trots op jou! Simon, wat fijn om 
jou als schone broer te hebben. Wat hebben we samen een heerlijk gezin.
Lieve papa en mama, ik hou zoveel van jullie, dat dat nooit in één dankwoord past. Jullie 
hebben Nine en mij een liefdevolle opvoeding gegeven vol met kansen. Jullie zullen me 
nooit tegenhouden en geven ons altijd onvoorwaardelijke steun en vertrouwen. Ik ben 
trots dat ik jullie dochter ben!
Lieve Reyer, bedankt voor je onvoorwaardelijke liefde, grenzeloze relativeringsvermo-
gen, en gewoon dat je er altijd bent. Ondanks dat het Denemarkenavontuur ons gemak-
kelijk af ging, ben ik toch blij dat je letterlijk weer dichter bij me bent, want samen met 
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renske jozefien kuppens was born on June 24th 1985 in Zeve-
naar, the Netherlands. She passed her secondary school exam 
(Atheneum) at the Liemers College in 2003. She discovered she 
wanted to study medicine and at the age of 19 years, she packed 
her belongings and moved to live in Utrecht, to start a life as a 
medical student at the Utrecht University Medical Center.
During her study, Renske got acquainted with multiple medi-
cal disciplines, among which she educated local clinical officers 
throughout Malawi, Africa. During this period, Renske’s love 
for travelling and seeing the world developed simultaneously with her enthusiasm for 
medicine. In 2010, Renske conducted a pediatric internship at the Erasmus MC-Sophia 
Children’s Hospital, which gave rise to her specific interest in pediatrics.
Renske obtained her medical degree in October 2010, after which she soon started 
working as a pediatric resident at the Albert Schweitzer hospital in Dordrecht. During 
her study, Renske left Utrecht to live together with her boyfriend Reyer in Rotterdam, 
from which Dordrecht had become an apparent choice. After a joyful and instructive 
period in Dordrecht, Renske decided that she wanted to increase her experience in 
scientific research before moving on to a medical specialization. In April 2012, Renske 
happily accepted a clinical research project at the Dutch Growth Research Foundation 
and the department of Pediatric Endocrinology of the Erasmus MC-Sophia Children’s 
Hospital, Rotterdam.
As a PhD fellow, Renske committed her research to Prader-Willi syndrome under su-
pervision of Prof. A.C.S. Hokken-Koelega. During her four years of performing scientific 
research, Renske has had the opportunity to concentrate on both the scientific and the 
humane aspects of medicine. This enlarged Renske’s commitment to the care and con-
sideration for the children as well as their parents. The result of four years of extensive 
research on several facets of Prader-Willi syndrome has resulted in this thesis bundled 
before you.
Although pediatrics in general, and children and young adults with Prader-Willi syn-
drome in particular, have obtained a special place in Renske’s heart, Renske decided that 
it was time to broaden her perspective. She will surely continue her medical career with 
the same care and consideration as she applied to this research.

 
